Curriculum Vitae - University of Kansas Medical Center

Faculty Curriculum Vitae: Bruce F. Kimler, Ph.D. compiled: 20 September 

2011 

A. Name Bruce Franklin Kimler, Ph.D. Department: Radiation Oncology 

B. Personal Data 

Office Address and Phone 

Home Address and Phone 

Department of Radiation Oncology 9210 West 111th Terrace 

University of Kansas Medical Center Overland Park, KS 66210-1703 

3901 Rainbow Boulevard 

Kansas City, KS 66160-7321 

913-588-4523 or 3660 913-345-2037 

913-588-3648 or 3663 (FAX) 913-205-6382 (mobile) 

e-mail: bkimler@kumc.edu 

Date of Birth September 23, 1948 

Place of Birth 

Current Citizenship 

St. Paul, MN 

U.S.A. 

Social Security No. 451-84-6090 

Professional Registration/Licensure 

Not Applicable 

C. Education 

Year Degree Institution 

1970 B.A. University of Texas at Austin 

1971 M.A. University of Texas at Austin 

Thesis Title: Effect of Inert Gases on the Radiation 

Sensitivity of Spores of Bacillus megaterium. 

1973 Ph.D. University of Texas at Austin 

Dissertation Title: Modification of the Water-Dependent 

Radiation Sensitivity of Bacterial Spores by Inert Gases. 

1


2011 

D. Post-Graduate Education 

Years Institution 

1973-75 Division of Biological and Medical Research, Argonne National Laboratory, 

Argonne, IL. 

1975-77 Laboratory of Experimental Radiation Oncology, Department of Radiation 

Therapy and Nuclear Medicine, Thomas Jefferson University Hospital, 

Philadelphia, PA. 

E. Academic Appointments (in reverse chronological order) 

Month and Year Position Institution 

1990- Member, Graduate Faculty Department of Pharmacology, Toxicology, 

and Therapeutics, University of Kansas 

Medical Center, Kansas City, KS 

1985- Professor Department of Radiation Oncology, 

(Primary Appointment) University of Kansas Medical Center, Kansas 

City, KS 

1984-97 Professor International Molecular Cytology Program of 

the Instituto de Investigaciones Citologicas 

de la Caja de Ahorros de Valencia, Valencia, 

Spain 

1984-5 Professor Department of Radiation Therapy, University 

of Kansas Medical Center, Kansas City, KS 

1980-84 Associate Professor Department of Radiation Therapy, University 


1977-84 Member, Graduate Faculty Department of Radiation Biophysics, 

University of Kansas, Lawrence, KS 

1977-80 Assistant Professor Department of Radiation Therapy, University 


F. Certification 

None 

2


2011 

G. Professional Societies and Affiliations 

Year Organization Offices Held 

1971 Radiation Research Society 1985-91 Member, Constitution and Bylaws 

Committee 

1986-90 Member, Commercial Exhibits 

Committee 


Committee for IXth International 

Congress of Radiation Research 

1991-94 Councillor-at-Large 

1994-95 Member, Selection Comm for Travel 

Awards to 10th ICCR 

1999- Editor, rrsNews Newsletter 

2001-09 Associate. Editor, Radiation 

Research 

2001-03 Member, Website Committee 

2001-03 Member, Committee on Electronic 

Publishing 

2003- Member, History Committee 

2006-09 Chair, Website Committee 

2007-08 Secretary-Treasurer-Elect 

2008-11 Secretary-Treasurer 

2011- Co-Chair, Constitution & Bylaws 

Committee 

2011- Member, Finance Committee 

2011- Member, Website Committee 

2011- Councillor, International Association 

for Radiation Research 

1971 Texas Association for Radiation Research 

1977 American Association for 1989-90 State Chairman, 

Cancer Research 

Science and Public Education 

Committee 

1991-2002 Chairman, State Legislative 

Committee 

2005-06 2006 Program Committee (Preclinical 

Prevention Studies: Biomarkers and 

Prevention Subcommittee of the 

Prevention Research Section) 

1977 Cell Kinetics Society 1978-79 Member, Membership Committee 

1979-80 Chairman, Membership Committee 

1980-81 Member, Nominations Committee 

1981-83 Secretary 

1982-83 Chairman, Constitution and Bylaws 

Committee 

1983-84 Member, Long Range Planning 

Committee 

1984-86 Councilor 

3


2011 

1984-85 Member, Editorial Journal Policy and 

Procedures Committee 

1986-87 Member, Program Committee 

1987-88 Chair, Membership Committee 

1988-89 Chair, Finance Committee 

1989-92 Ad Hoc Committee to Consider 

Amalgamation of the CKS and the 

International Cell Cycle Society 

1991-92 Vice-President and President-Elect 

Chairman, Program Committee 

1992-93 President 

1993-94 Past-President 

Chairman, Long- 

Range Planning Committee 

1995-97 Historian 

1978 American Society of 1985-89 Member, Radiation Biology 

Therapeutic Radiology 

Committee 

and Oncology 2000 Member, Annual Meeting Program 

Advisory Group 

2002-03 Member, Constitution and Bylaws 

Committee 

2003-04 Vice-Chair, Constitution and Bylaws 

Committee 

American Society of 2004-09 Chair, Constitution and Bylaws 

Radiation Oncology (ASTRO) 

Committee 

2009-12 Immediate past-Chair, Constitution 

and Bylaws Committee 

1979 Mid-America Radiation Research Society Founder, organizer, and host of first 

annual meeting 

1980 Organizer/host of second meeting 

1980 SouthWest Oncology Group 1983-2002 Member of Developmental 

Therapeutics, Radiation Therapy, 

Breast, Brain, & Flow Cytometry 

Committees 

1983-98 Organizer and Chairman of the semiannual 

Workshops on Pre-Clinical 

Therapeutics 

1992-99 Co-Chairman, Developmental 

Therapeutics Committee 

1980 Pediatric Oncology Group Member of Brain Tumor, Radiation 

Therapy, Tumor Biology Core, and 

Bone Marrow Transplantation 

Committees 

1982 International Society for Analytical Cytology 

1986 North American Hyperthermia Society Charter Member, Author of 

4


2011 

Constitution and Bylaws 

1986-90 Chairman, Constitution, and Bylaws 

Committee 


Committee 

1990- Parliamentarian 

1995-00 Member, Finance Committee 

2000-01 Member, Constitution and Bylaws 

Committee 

1986 Association de Cytometrie de Flux Charter Member 

Sociedad Iberica de Citometria 1993 Scientific Organizing Committee, 

Annual Meeting 

H. Honors and Awards (Include service on national and international professional 

committees, study sections, offices in professional societies, membership of editorial 

boards, positions as reviewer for scientific journals, examiner for board examinations, 

etc.) 

1970-73 Recipient, NIH Physiology and Biophysics Pre-Doctoral Training Grant 

1974, 1979 Recipient of Travel Awards to the International Congresses 

& 1983 of Radiation Research 

1982 Recipient of University of Kansas College of Health Sciences Faculty 

Research Award. 

1999 Research award from the Ladies Auxiliary to the Veterans of Foreign Wars 

Service on national and international professional committees, study sections, offices in 

professional societies, membership of editorial boards, positions as reviewer for scientific 

journals, etc.: 

1981 Reviewed five manuscripts for journals. 

Chaired session at Radiation Research Society meeting. 

Chaired session at American Society of Therapeutic Radiologists meeting 

Reviewed proposal for Veteran's Administration grant application. 


Consultant to the Nuclear Medicine Science Syllabus Subcommittee, The 

Society of Nuclear Medicine. 

1983 Reviewed fourteen manuscripts for journals. 

Chaired session at Cell Kinetics Society meeting. 

Consultant, Endotronics, Inc., Minneapolis, MN. 

1984 Reviewed eleven manuscripts for journals. 

Reviewed two research grant applications for the Medical Research 

Council of Canada. 

Member, NIH Experimental Therapeutics Ad Hoc Study Section. 

1985 Reviewed ten manuscripts for journals. 

Consultant, Department of Radiation Oncology, St. Jude Children's 

Research Hospital, Memphis, TN. 

Member, NIH Ad Hoc Pharmacology Study Section. 


Chaired session at American Society for Therapeutic Radiology and 

Oncology meeting. 


5


2011 

Wrote Constitution and Bylaws for the North America Hyperthermia 

Group. 

1987 Chaired platform session at Cell Kinetics Society meeting. 

Wrote Constitution and Bylaws for the International Association for 

Hyperthermic Oncology. 

Reviewed eight manuscripts for journals. 

Member, Cancer Fellowship Review Panel for Ladies Auxiliary - Veterans 

of Foreign Wars. 

Member, NIH Special Study Section for the Review of Shared 

Instrumentation Grant Proposals for the Division of Research 

Resources. 

1988 Member, American Cancer Society Scientific Advisory Committee on 

Clinical Investigations III - Prevention, Diagnosis, and Therapy. 

Reviewed seven manuscripts for journals. 




Member, four Special Review Sections for the Division of Research 

Resources of NIH: 1) Shared Instrumentation Grant applications; 2) 

Small Business Innovative Research Grant proposals. 

Reviewed grant application for the United Cancer Council. 

Ad Hoc Consultant for Marion Laboratories 



Consultant for Marion Laboratories. 

Reviewed four manuscripts for journals. 


Member, Technical Review Committee, Nebraska Cancer and Smoking 

Diseases Program. 



Member, Blue Valley School District Science Curriculum Development 

Committee. 

Planning Committee for Symposium on Innovations in Pediatric Brain 

Tumor Therapy. 

Ad Hoc Member, NIH Radiation Study Section. 

State Chairman, American Association for Cancer Research Committee 

on Science and Policy Education. 



Consultant for Marion Merrell Dow Inc. 



Reviewed seven manuscripts for journals. 

Grand Award Judge, Tulsa International Science and Engineering Fair. 

Member, NIGMS/NIH Program Project Review Committee Site Visit Team 

- University of Texas at San Antonio. 

Advisory Committee for Science Pioneers Meet-the-Mentor Program 

Organizing Committee for an International Workshop on Flow and Image 

Cytometry; Porto, Portugal; 18 Feb - 1 Mar 1991. 



6


2011 

Consultant for Marion Merrell Dow Inc. 

Reviewed five manuscripts for journals. 

Organizing Committee and Faculty Member for the International 

Workshop on Flow and Image Cytometry; Porto, Portugal; 18 Feb - 1 

Mar 1991. 

Chaired session at the Annual Meeting of the Cell Kinetics Society. 



Judge, Greater Kansas City Science and Engineering Fair. 

Chairman, Cancer Fellowship Review Panel for Ladies Auxiliary – 

Veterans of Foreign Wars. 

Advisory Committee for Science Pioneers Meet-the-Mentor Program 

Reviewed invited manuscript presented at symposium during IXth 

International Congress of Radiation Research. 

Reviewer for VA Research Advisory Group (RAG) Proposal. 

1992 Reviewed eleven manuscripts for journals. 

Reviewer for Arkansas Science and Technology Authority. 





Reviewer for American Cancer Society grant application. 

Ad hoc reviewer for Radiation Study Section, NIH. 

Invited speaker, workshop participant, and session moderator at second 

meeting of the Iberian Society of Cytometry. 

1993 Reviewed twenty manuscripts for journals. 



Member, NIH ad hoc Experimental Therapeutics Study Section. 

Scientific Organizing Committee, Third Annual Meeting of the Iberian 

Society of Cytometry; Porto, Portugal; Nov 1993. 

1994 Reviewed twenty manuscripts for journals 

American Cancer Society Advisory Committee for Personnel - C grants 

Reviewer, ASTRO Research Fellowship Applications 

Chair, Ad hoc teleconference review for Radiation Study Section, NIH 



Faculty, Course on Radiation and Chemotherapy Injury, Armed Forces 

Institute of Pathology. 

Member, Institutional Grant Review Committee, Nebraska Cancer and 

Smoking Diseases Program. 

Faculty, Course on Clinical Applications of Flow Cytometry. 

1995 Reviewed twenty-four manuscripts for journals 

American Cancer Society Scientific Advisory Committee - Cell Biology 

Chaired session at Cell Kinetics Society meeting. 





Ad hoc reviewer, Israel Science Foundation. 

Ad hoc reviewer - American Cancer Society Scientific Advisory 

Committee - Drug Development, Hematology and Oncology 

7


2011 

1996 Reviewed 17 manuscripts for journals 

American Cancer Society Scientific Advisory Committee - Personnel C 



Ad Hoc Reviewer, University of Nebraska Medical Center; Nebraska 

Cancer and Smoking Diseases Program. 

Ad Hoc Reviewer, NIH Special Emphasis Panel ZRG4. 

Panel Member, United States Army Medical Research and Materiel 

Command 1996 Breast Cancer Research Peer Review Committee, 

Clinical and Experimental Therapeutics #3. 


Ad hoc reviewer, Israel Science Foundation 



Member, Institutional Grant Review Committee, Nebraska Cancer and 

Smoking Diseases Program. 

1998 Reviewed twelve manuscripts for journals 

American Association for Cancer Research - Gertrude Elion Award 

Selection Committee. 




Reviewed Rapid Opportunity Grant application for American Cancer 

Society 



Subject Matter Expert for American Institute of Biological Sciences: Breast 

Cancer Research Program Knowledge Harvesting Phase 3: May 3, 

1999 through July 9, 1999. 

Scientist Reviewer (Radiological Sciences), Department of Defense, 

USAMRMC, 1999 Breast Cancer Research Program. 

Reviewer, Dutch Cancer Society grant application. 




Reviewer, Post-Doctoral Fellowship Grant Applications, Susan G. Komen 

Breast Cancer Foundation. 

2001 Editorial Board, Radiation Research - processed 19 manuscripts 

Reviewed 2 manuscripts for other journals 



Panel Member (Molecular Biology for Cancer Research), Department of 

Defense 2001 Peer-Reviewed Medical Research Program. 

Reviewer, Post-Doctoral Fellowship Grant Applications, Susan G. Komen 

Breast Cancer Foundation. 

2002 Editorial Board, Radiation Research 

Reviewed 4 manuscripts for journals 



Scientific Reviewer (Physical Imaging-2), Department of Defense 2002 

Breast Cancer Research Program. 

Member, Ad Hoc Review Panel for applications in response to RFA-CA- 

8


2011 

03-005, “Chemoprevention of Estrogen Receptor Negative Breast 

Cancer Pre-clinical Studies”. 

Chair, Susan G. Komen Breast Cancer Foundation Review Committee for 

Post-Doctoral Fellowship award applications. 


Reviewed nine manuscripts for other journals 

Book reviewer (2) for Doody’s Review Service 



Ad hoc reviewer for grant proposal, Goldman Philanthropic Partnerships 

Scientific Reviewer (Concept Awards), Department of Defense 2003 




Scientific Reviewer (Physical Imaging 1), Department of Defense 2003 



Manuscript reviewer for journals - 16 manuscripts 


Post-Doctoral Fellowship award applications (FY2004),. 

Scientific Reviewer (Concept Awards - Radiation Oncology Panel), 

Department of Defense 2004 Breast Cancer Research Program. 

Scientific Reviewer, NASA Radiation Biology Peer Review Panel 

External reviewer for grant application to the Associazione Italiana per La 

Ricerca Sul Cancro 






Post-Doctoral Fellowship award applications (FY2005). 

Member, Chemo/Dietary Prevention Study Section, NIH 

Member, Susan G. Komen Breast Cancer Foundation Advisory Council 

for Mission of Hope Conference,. 


Manuscript reviewer for journals (14) 



Member, Chemo/Dietary Prevention Study Section, NIH (Feb; Jun 

meetings). 

Member, Susan G. Komen Breast Cancer Foundation Advisory Council 

for Mission of Hope Conference. 

. Scientific Reviewer (Physical Imaging 1), Department of Defense 2005 


Scientific Reviewer, NASA Radiation Biology Peer Review Panel 



Member, Special Review Panel for applications submitted in response to 

RFA-AI-04-045, Centers for Medical Countermeasures Against 

Radiation. 



9


2011 

Book reviewer for Doody’s Review Service 




National Cancer Institute of Canada Review Panel E - Biophysics, 

Imaging and Radiobiology 






Member, American Board of Radiology Radiation Oncology (Radiation 

Biology) Item Writing Task Force 

Member, Potential Extramural Research review of applications received by 

the National Center for Chronic Disease Prevention and Health 

Promotion, Division for Heart Disease and Stroke Prevention, Centers 

for Disease Control and Prevention, in response to an RFA titled 

Determinants of Receiving Radiation Therapy after Breast Conserving 

Surgery Among Low-Income Women (2006-R-09). 

Member, Technical Evaluation Panel for applications in response to RFP 

DHHS-ORDC-DDA-O5-12, entitled "Medical Countermeasures to 

Mitigate and/or Treat Neutropenia Alone or in Combination with Co- 

Morbidities Associated with Acute Radiation Syndrome (ARS). 

Teleconference reviewer for Department of Defense 2006 Breast Cancer 

HBCU/MI Review Panel. 

Member, Sub-Group for Secondary review; Technical Evaluation Panel for 

RFP DHHS-ORDC-DDA-O5-12 (ARS). 

Ad hoc reviewer for Department of Defense 2006 Breast Cancer 

Research Program - predoctoral and postdoctoral training grants. 




Ad hoc reviewer, Cancer Research UK Translational Research in Clinical 

Trials 

Reviewer, National Cancer Institute of Canada Review Panel E - 

Biophysics, Imaging and Radiobiology 

Scientific Reviewer (Physical Imaging), Department of Defense 2007 


Working Group, Susan G. Komen for the Cure Research Grants Program, 



Member, Susan G. Komen for the Cure Imaging-Based Diagnosis and 

Prognosis Review Committee, 

Member, National Cancer Institute of Canada Review Panel E – 


Scientific Reviewer (Concept Awards - Physical Imaging), Department of 

Defense Breast Cancer Research Program. 



Chairman, NIH Special Emphasis Panel/Scientific Review Group 2008/05 

ZAI1 BDP-I (M3) for applications in response to RFA AI-07-038 

“Radiation Combined Injury: Radiation Exposure in Combination with 

10


2011 

Burn, Wound, Trauma or Infection”. 

Reviewer, NIH Special Emphasis Panel/Scientific Review Group 2008/05 

ZAI1 TP-I (M1) for applications in response to RFA AI-07-039 

“Mechanisms, Diagnosis, and Treatment of Radiation Injury from 

Nuclear Accident or Terrorist Attack”. 

Scientific Reviewer (Physical Imaging), Department of Defense 2008 




Scientific Reviewer (Concept Awards - Physical Imaging), Department of 

Defense Breast Cancer Research Program. 

Chairman, NCI panel to review proposals in Response to SBIR Topic 

#258 "Innovative Strategies to Protect Radiosensitive Organs and 

Structures During Radiation Therapy”. 



Scientific Reviewer (Training - Physical Imaging/Radiation Oncology), 

Department of Defense Breast Cancer Research Program. 

Member, NIH Chemo/Dietary Prevention Study Section (June, October). 

Member, NIH Special Emphasis Panel/Scientific Review Group; ZRG1 

OTC-N (95) S; ARRA-CR. 

Member, CDC Special Emphasis Panel/Scientific Review Group for 

Cancer Prevention and Control Research Network. 

Chair, NIH Special Emphasis Panel/Scientific Review Group for ARRA 

GO applications in response to RFA-AI-06-030. 

Member, Special Emphasis Panel/Scientific Review Group for ARRA GO 

applications to the NCI Molecular Target Discovery and 

Development Centers Pilot Program 

Member, Scientific Review Group for applications submitted in response 

to RFA-CA-09-011 "The Integrative Cancer Biology Program (ICBP): 

Centers for Cancer Systems Biology (CCSB)(U54). 


2010 Scientific Reviewer for Idea Expansion and Postdoctoral Award, Physical 

Imaging (IPD-PIM), Department of Defense Breast Cancer Research 

Program. 

Chair, NCI Technical Evaluation Panel for applications submitted in 

Response to SBIR Topic #258 "Innovative Devices to Protect 

Radiosensitive Organs and Structures During Radiation Therapy” 

Member, NCI Special Emphasis Panel/Scientific Review Group for 

applications submitted in response to RFA-GM-10-009: “Exceptional, 

Unconventional Research Enabling Knowledge Acceleration 

(EUREKA)(R01) 



Chair, NIAID Special Emphasis Panel for applications submitted in 

response to RFA-AI-09-036 for “Centers for Medical Countermeasures 

against Radiation (U19)” 

Member, NIAID Technical Evaluation Panel for applications submitted in 

response RFP-NIAID-DAIT-NIHAI2009079 "Radiation/Nuclear Medical 

Countermeasure Product Development Support Services”. 

Scientific Reviewer for Predoctopral and Postdoctoral Awards, Physical 

Imaging (TRN-PIM), Department of Defense Breast Cancer Research 

11


2011 

Program. 

Member, Arbitration Committee for the International Radiogenomics 

Consortium. 

Member, Organizing Committee for 14 th International Congress of 

Radiation Research; Warsaw, Poland 

Member, NIH Chemo/Dietary Prevention Study Section (October). 

Manuscript reviewer for: journals (6) 

2011 Scientific Reviewer for Idea Expansion and Postdoctoral Award, Physical 

Imaging (IPD-PIM), Department of Defense Breast Cancer Research 

Program. 

Ad Hoc Reviewer, National Cancer Institute of Canada Review Panel E - 


Member, NCI Special Emphasis Panel/Scientific Review Group for 

applications submitted in response to RFA-GM-11-003: “Exceptional, 

Unconventional Research Enabling Knowledge Acceleration 

(EUREKA)(R01) 



Scientific Reviewer for IDEA Awards, Detection, Diagnosis and Prognosis 

(IDEA-DDP), Department of Defense Breast Cancer Research 

Program. 

Manuscript reviewer for 

Cancer Epidemiology Biomarkers and Prevention (1) 

Cancer Prevention Research (7) 

Cancer Res (1) 

Breast Cancer Research and Treatment (2) 

European Journal of Cancer (2) 

Reproductive Biology (1) 

12


2011 

I. Research Activities 

1. Brief statement of areas of research interests: 

Development and utilization of biomarkers for prediction, prevention, and detection of 

breast cancer; and use in the conduct of Phase I and II clinical trials of potential 

chemopreventive agents. 

Analysis of clinical data for elucidation of prognostic and predictive factors related to 

clinical outcomes. 

The development of biological test systems by which the interactions of ionizing radiation 

and cancer therapeutic modalities can be tested. These studies assess at the 

experimental level the potential use of new combined modality therapies for cancer 

treatment. Clinical trials are then conducted to evaluate the efficacy of new cancer 

therapeutic approaches. 

The effect of ionizing radiation on the development of the mammalian nervous system. 

2. Current projects underway: 

Prediction, prevention, and detection of breast cancer. Clinical chemoprevention trials. 

Assessment of predictive and prognostic factors for improvement of cancer therapy. 

3. Grant support available: 

a) Previous grants (PI or Co-PI only): 

John W. and Effie E. Speas Memorial Trust: "Source Irradiator for Radiobiological 

Studies"; $93,636 for purchase of Cs-137 source irradiator; 3/1980. 

NIH/NCI CA29017: "Rat lung changes after radiotherapy-chemotherapy"; $175,268; 

1/1981-12/1983. 

NIH/NCI: U10 CA 32102; "SouthWest Oncology Group - Preclinical Therapeutics"; 

$2,000; 1/1984-12/1984. 

Alpha Therapeutics Corporation: "Pre-clinical evaluation of Fluosol as an adjuvant for the 

treatment of brain tumors"; $2,620; 10/1985-4/1986. 

Department of State: U.S.-Spain Joint Committee for Scientific and Technological 

Cooperation: "Flow Cytometry as a Preparative and Analytical Procedure to Study 

Protein Turnover in Highly Homogeneous Populations of Cells and Organelles"; 

$127,500; 6/1985-4/1989. 

NIH/NICHHD HD21666; "Developmental Effects of Fetal Ultrasound Exposure"; Co- 

PI; $235,375; 4/1986-9/1989. 

Comision Asesora de Investigacion Cientifica y Tecnica: Sabbatical grant to conduct 

research at the Instituto de Investigaciones Citologicas, Valencia, Spain. 

1,420,000 ptas for 7/1986-6/1987. 

University of Kansas Medical Center Shared Biomedical Equipment Fund: "Cesium-137 

Source Irradiator for Cell and Tissue Products"; $25,000 for purchase of irradiator; 

11/1988. 

Generalitat Valenciana Conselleria de Cultura, Educacio i Ciencia: A grant for travel to 

the Department of Biochemistry and Molecular Biology, University of Valencia, 

Valencia, Spain for the purpose of designing, organizing, and conducting graduate 

courses in Flow Cytometry. 750,000 ptas for 11/1990-10/1993. 

NIH/NINDS NS 16694-7,8,9: "Radiation-Induced Damage To Developing Brain"; 25%; 

$223,317 for 4/1989-11/1992. 

NIH/NINDS NS 16694-10,11,12: "Radiation-Induced Damage To Developing Brain"; 25%; 

$348,561 for 12/1992-11/1996. 

Dupont Pharmaceuticals, Inc.: “Development of Sestimibi as a Non-Invasive Biomarker 

13


2011 

for Breast Cancer Chemoprevention Trials”; 10%; $4,000 for pilot study, 

10/1998-3/1999. 

Dupont Pharmaceuticals, Inc.: “Development of Sestimibi as a Non-Invasive Biomarker 

for Breast Cancer Chemoprevention Trials”; 10%; $190,500 for Phase I study, 

5/1999-7/2001. 

NIH/NCI NO1-CN-65124-MAO; “Phase II Clinical Trial - Agent (TBN) in Breast 

Dysplasia with Biomarker Abnormalities”; 20%, Co-PI with CJ Fabian; $1,425,932 

total costs for 9/1996-9/2001. 

NIH/NCI NO1-CN-85035-MAO; “A Phase I NonRandomized Study of an Antiestrogen in 

Women with Newly-Diagnosed Breast Cancer - Workstatement #31”. 15%, Co-PI 

with CJ Fabian; $2,782,847 total costs for 10/1997-12/2003. 

Developmental Research Program Grant from University of Alabama-Birmingham 

SPORE in Breast Cancer: “Breast Density: Chemoprevention Trial Response 

Biomarker”. 5%, $50,000 total costs for 10/2002-9/2004. 

Developmental Research Program Grant from Kansas City Area Life Sciences Institute: 

KCALSI-03-04: “Improved Software for Assessment of Breast Density”. 5%, 

$25,000 total costs for 12/2003-11/2004. 

NIH/NCI UO1 CA77165: “Chemoprevention for Women at High Risk of Breast Cancer”; 

20%; Co-PI with CJ Fabian; $6,583,336 total costs for 9/1997-6/2005. 

NIH/NCI Subcontract from University of Alabama Birmingham 3 P50 CA089019-05 

(SPORE in Breast Cancer; PI=K Bland); “Biomarker Assessment Using qRT- 

PCR”; 10%, Co-PI with CJ Fabian. $68,027 direct costs for 9/2005 - 8/2006. 

Susan G. Komen Breast Cancer Foundation: BCTR0100732; “Prevalence of 

COX-2 Expression in Breast FNA and Modulation with Celecoxib”. Co-PI with CJ 

Fabian; $246,339 total costs for 10/2001-9/2005. 

NIH/NCI NO1-CN-15135-MAO; “Workstatement 76: A Study to Identify Biomarker 

Modulation by Cyclooxygenase-2 (COX-2) Inhibitors in Breast Tissue of 

Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) 

Breast Cancer ”. 18%, Co-PI with CJ Fabian; $2,993,736 total costs for 9/2001- 

6/2007. 

Novartis Pharmaceuticals Corporation: “Study of the Effect of Letrozole on Breast 

Biomarkers of High Risk Postmenopausal Women Receiving Hormone 

Replacement Therapy”. 10%, Co-PI with CJ Fabian; $906,892 total costs for 

4/2002-8/2006. 

Pharmacia & Upjohn Company: “Phase IB Study of Biomarker Modulation by Celecoxib 

in Newly-Diagnosed Breast Cancer”. 15%, Co-PI with CJ Fabian; $1,749,730 total 

costs for 7/2002-6/2006. 

Intergenetics, Inc: “Correlation of SNP Patterns in High Risk Postmenopausal Women on 

HRT”; 5%; Co-PI (PI=CJ Fabian). $132,811 direct costs for 4/1/2005 - 3/31/2009. 

NIH/NCI R21 CA117847-03: “Flaxseed Lignan for Breast Cancer Chemoprevention”. 5%, 

Co-PI (PI=CJ Fabian); $335,904 direct costs for 5/12/2005-4/30/2009. 

NIH/NCI P50 CA89019-AV-80P: Avon-NCI Progress for Patients Award Program via 

University of Alabama Birmingham SPORE in Breast Cancer; “QM-MSP, Ki-67, 

and Cytomorphology of RPFNA Specimens from High Risk Women”; 10% Co- 

Investigator (PI=CJ Fabian). $485,394 (total costs) for 7/1/2005-3/31/2008. 

Hearst Foundation, Inc.: Trans Illumination Breast Spectroscopy. $100,000 for 6/1/2006 - 

5/31/2009. PI. 

Avon Foundation Breast Cancer Crusade: “Mechanisms of Pregnancy Protection of 

Human Breast Cancer”; 10%, Co-PI (PI=CJ Fabian). $394,998 total costs for 

11/1/2006 - 2/28/2011 (collaborative project with Baylor College of Medicine; PI, D 

Medina). 

NIH/NCI 1R21CA121106: “Breast Cancer Risk Biomarkers and Energy Balance”; 

14


2011 

5% Co-Investigator (PI=CJ Fabian). $220,000 direct costs for 12/1/2006- 

3/31/2010. 

Oncimmune, LLC (via Kansas Business Authority): “Validation Study of Oncimmune Test 

for Breast Cancer Detection”; 15% PI. $102,041 direct costs for 1/15/2007- 

12/31/2009. 

Breast Cancer Research Foundation: “Biomarkers of Response to Prevention Strategies 

for Postmenopausal Women”; 10%, Co-PI (PI=CJ Fabian); $ 333,295 direct costs 

for 10/1/2008-9/2010. 

b) Current grants: 

NIH/NCI N01 CN35153: (University of Wisconsin Chemoprevention Consortium): “Phase 

II Study of Acolbifene in Women at High Risk for Breast Cancer”; 10% Co-PI (PI: 

CJ Fabian); $608,782 total costs 2/2/2006-9/29/2011. 

NIH/NIEHS T32 ES007079-26A2: “Training Program in Environmental Toxicology”; 2% 

Co-I (PI=C Klaassen). $267,186 Annual direct costs; 7/1/2006 - 6/30/2011. 

Novartis Pharmaceuticals Corporation CFEM345DUS45: "Breast Cancer Prevention by 

Letrozole in High Risk Women”; Co-PI (PI=CJ Fabian). $544,590 total costs 

10/1/2006-12/31/2012. 

NIH/NCI RO1 CA122577-03: “Breast Cancer Prevention by Letrozole in High Risk 

Women”; 20% Co-Investigator (PI=CJ Fabian); $1,313,701 direct costs for 

9/20/2007-7/31/2012. 

Novartis Pharmaceuticals Corporation CFEM345DUS61T: A Randomized Trial to 

Evaluate the Benefit of High Dose Vitamin D3 on Aromatase inhibitor Letrozole- 

Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).”; Co-PI 

(PI=QJ Khan). $398,000 total costs 10/2008-12/31/2011. 

American Cancer Society IRG-09-062-01: Institutional Research Grant; no specific effort; 

PI; $90,000 annually for 1/1/2009-12/31/2011. 

Susan G. Komen for the Cure® Promise Grant KG101039: “Flaxseed Lignan as a 

Prevention Strategy for Pre-Menopausal Women at High Risk for Development of 

Breast Cancer”; 20% Co-I (PI=CJ Fabian). $4,500,047 funded ($3,600,038 

direct costs) for 9/22/2010-9/21/2015. 

Kansas Bioscience Authority - Collaborative Cancer Research Initiative: “Omega 3 Fatty 

Acids for Prevention of Breast Cancer in Premenopausal Women”; 8% Co-I 

(PI=CJ Fabian). $227,250 direct ($249,975 total) costs for 6/2010-5/2021. 

Breast Cancer Research Foundation: “Biomarkers of Response to Omega-3 Fatty Acids 

Used as Prevention in Postmenopausal Women”; 8%, Co-I (PI=CJ Fabian); 

$185,833 direct costs awarded for 10/1/2010-9/30/2011. 

Breast Cancer Research Foundation: “Exploration of miRNA as a Biomarker of Response 

to Prevention Strategies involving Omega-3 Fatty Acids”; 10%, Co-I (PI=CJ 

Fabian); $187,500 direct costs awarded for 10/1/2011-9/30/2012. 

c) Pending proposals: 

15

Faculty Curriculum Vitae: Bruce F. Kimler, Ph.D. compiled: 20 September 2011 

J. Clinical Activities 

Participate in writing, coordinating, and conducting clinical research protocols 

Attend radiation therapy treatment planning conferences 

Advise clinical faculty on biological aspects of radiation therapy 

K. Teaching Activities 

Courses: Please include the year, title of course, number of registrants, length of 

course, and category of students. Give sufficient details to indicate time 

involved. 

Jun-Aug 1978 Advisor - Medical Student Summer Research Project: Terence 

McDonald 

Jan-May 1979 Radiation Biology course for Nuclear Medicine Technologists. 

Jan-May 1980 Radiation Biophysics 923: Radiobiological Bases for Radiation Therapy. 

1978 - 1980 Graduate Advisor - Doctoral Research: Sheri D. Henderson 

1980 - 1984 Graduate Advisor - Master's Program: Richard W. Glover; Michael F. 

Scanlan 

24 Mar 1980 Final Doctoral Dissertation Defense (Chairman): Sheri D. Henderson 

Jun-Aug 1980 Advisor - Medical Student Summer Research Project: Richard E. 

Barnes 

Jan-May 1981 Radiation Biology course for Radiation Therapy, Diagnostic Radiology, 

and Nuclear Medicine Technologists. Radiation Biophysics 709: Basic 

Radiation Biology. 

12 Mar 1981 Final Doctoral Dissertation Defense: Carol M. Beach 

12 Mar 1981 Final Doctoral Dissertation Defense: Michael I. Riley 

13 Mar 1981 Comprehensive Exam for Doctoral Candidancy: Darwin Zellmer 

23 Mar 1981 Radiation Biology lecture to Gynecologic Oncology Conference for 

residents and fellows in Department of Gynecology and Obstetrics 

Sep 81-May 82 Radiation Biology for Residents in Radiation Therapy 

10 Sep 1981 Radiation Biology lecture to graduate students in Nuclear 

Pharmacology; Pharmacology 725. 

Jan-May 1982 Radiation Biology for Radiation Therapy Technology Students 

Jun-Aug 1982 Advisor - Medical Student Summer Research Project: Rita Mies 

Sep 82-Jun 83 Radiation Biology for Residents in Radiation Therapy 


17 Sep 1983 Final Master's Thesis Defense (Chairman): Richard W. Glover 

8-22 Dec 1983 Radiation Biology to Orthopedic Surgery Residents 

Sep 83-Jun 84 Radiation Biology for Residents in Radiation Therapy 


21-22 Feb 1984 Pediatric Oncology Outreach Series, Great Bend, KS 

Jun-Aug 1984 

Advisor - Medical Student Summer Research Project: Deepak Ahuja, 

Richard Rethorst, Michael J. Wulzer 

5-6 Jun 1984 Pediatric Oncology Outreach Series, Garden City, KS 

28 Aug 1986 Pediatric Oncology Outreach Series, Arkansas City, KS 

Sep 84-May 85 Radiation Biology for Residents in Radiation Therapy 

12 Nov 1984 Lecture on Carcinogenesis by Ionizing and Non-ionizing Radiation. 

Community Health 850 (Cancer Epidemiology). 

17 Dec 1984 Final Doctoral Dissertation Defense: Darwin L. Zellmar 

Jan-Jun 1985 Radiation Biology for Radiation Therapy Technology students 

28 Feb 1985 Pediatric Oncology Outreach Series, Chanute, KS 

16


28 May 1985 Pediatric Oncology Outreach Series, Atchison, KS 

27 Jun 1985 Pediatric Oncology Outreach Series, Manhattan, KS 

25 Jul 1985 Pediatric Oncology Outreach Series, Topeka, KS 

22 Aug 1985 Pediatric Oncology Outreach Series, Leavenworth, KS 

Dec 85-May 86 Radiation Biology for Radiation Therapy Residents 

Jan-May 1986 Radiation Biology for Radiation Therapy Technology students 

Jun-Aug 1986 Advisor - Medical Student Summer Research Project: Stacy Holstrum, 

Michael Spradlin 

Aug 86- Jun 87 Radiation Biology for Radiation Therapy Residents 

28 Aug 1986 Pediatric Oncology Outreach Series, Topeka, KS 

28 Oct 1986 Lecture on Carcinogenesis by Ionizing and Non-ionizing Radiation. 

Community Health 850 (Cancer Epidemiology). 


Jun-Aug 1987 Advisor - Medical Student Summer Research Project: Michael C. 

Morgan 


Jul 87-Jun 88 

Jun-Aug 1988 

Radiation Biology for Radiation Oncology Residents 

Advisor - Medical Student Summer Research Project: Ashwin 

Gollerkeri, John Nyugen 

1 Dec 1988 Pediatric Oncology Outreach Series, Topeka, KS 

8 Dec 1988 Pediatric Oncology Outreach Series, Leavenworth, KS 

20 Dec 1988 Pediatric Oncology Outreach Series, Ottawa, KS 

Jun-Aug 1989 Advisor - Medical Student Summer Research Project: Kevin Nasseri, 

Mark Matthes 

Jul 88-Jun 89 Radiation Biology for Radiation Oncology Residents 



Jun-Aug 1990 Advisor - Medical Student Summer Research Project: Robert M. Ford, 

David Grosser, Daniel Kloster, Genon Wicina, Paul Zuercher 

Sep 90-Jun 91 Radiation Biology for Radiation Oncology Residents 


Jun-Aug 1991 Advisor - Medical Student Summer Research Project: 

Edward C. Chen, Daniel S. Mitchell, Christopher K. Screiber, 

Stanley Bowling, John Gatti, Samuel Lehman 

Jun-Aug 1991 RADO 910 Research in Radiation Oncology: Edward C. Chen, Daniel 

S. Mitchell, Christopher K. Screiber, John Gatti. 



Jun-Aug 1992 RADO 910 Research in Radiation Oncology: John F. Brandt, Steven R. 

Hays, Terry M. Welsh, Doug W. Wimer. 



Jun-Aug 1993 Advisor - Medical Student Summer Research Project: Darin M. 

Brummett, Michael J. Connor, Robert A. Epp 


Feb 94-Jun 94 Radiation Biology for Radiation Therapy Technology students 


Jun-Aug 1995 Advisor - Medical Student Summer Research Project: Carmen D. 

Chase, Sean M. Herrington 


Jun-Aug 1996 Advisor - Medical Student Summer Research Project: Daniel C. Buckles 

Aug 96-Jun 97 Radiation Biology for Radiation Oncology Residents 

17


Jun-Jul 1997 PHCL939 - PTOX939 - P&) 939 Carcinogenesis and Cancer Biology 

Course. Lectures on Radon, Radiation, and Cancer; .Cancer Genetics 


10 Apr 1998 Final Doctoral Dissertation Defense: Patricia A. Jamerson 


Mar 1999 Thesis Defense: Jennifer R. Klemp (Masters of Public Health) 



Jun-Jul 2001 PHCL939 - PTOX939 Carcinogenesis and Cancer Biology Course. 

Lecture on Radon, Radiation, and Cancer. 


9 Nov 2001 PTOX 918 Toxicology: Lecture on Radiation Toxicology and 

Carcinogenesis 

29 Jan 2002 Guest lecture, PRVM 810, Clinical Trial Methodology 


17 Sep 2002 Guest lecture, PRVM 850, Cancer Epidemiology 

4 Feb 2003 Guest lecture, PRVM 810, Clinical Trial Methodology 


7 Nov 2003 PTOX 918 Toxicology - Lecture on Radiation Toxicology 

17 Dec 2003 Thesis Defense: Carolyn Chamberlain (Masters of Public Health) 







26 Oct 2005 PTOX 918 Toxicology - Lecture on Radiation Toxicology 


14 Mar 2006 Lecture, “Radon, Radiation, and Cancer”, PHCL 939, Carcinogenesis 

and Cancer Biology. 



20 Nov 2006 Thesis Defense: Julie R. Anderson (Master's of Science in Clinical 

Research; Department of Preventive Medicine and Public Health) 

27 Mar 2007 Lecture, “Radon, Radiation, and Cancer”; PHCL 939, Carcinogenesis 

and Cancer Biology. 


Jul 08-Jun 09 Radiation Biology for Radiation Oncology Resident 

27 Mar 2009 Lecture, “Radon, Radiation, and Cancer”; PHCL 939, Carcinogenesis 

and Cancer Biology 

Jul 09-May 10 Radiation Biology for Radiation Oncology Residents 


18 Oct 2010 Guest lecture, PRVM 850, Cancer Epidemiology 


25 Apr 2011 Lecture, “Radon, Radiation, and Cancer”; PHCL 939, Carcinogenesis 

and Cancer Biology 


Aug – Dec 2011 PRVM 872; Grant Writing 

18


L. Doctoral and Master's theses directed and post-doctorals supervised 

Master's degree program supervised 

Xuelin Li 

Shelly L. Peterson 

Doctoral degree program supervised 

Michael J. Wulser 

Master's degree conferred: 

Richard W. Glover 

Michael F. Scanlan 

Department of Pharmacology, Toxicology, 

and Therapeutics, KUMC 

Department of Pyschology, University of 

Missouri - Kansas City 

Department of Pharmacology, Toxicology, 

and Therapeutics, KUMC 

Department of Radiation Biophysics, 

University of Kansas, Lawrence 


University of Kansas, Lawrence 

Ph.D. degree conferred 

Sheri D. Henderson 


University of Kansas, Lawrence - 1980 

Patricia A. Jamerson School of Nursing, KUMC - 1999 

Post-doctoral fellows supervised: 

Sheri D. Henderson, Ph.D. 1980-82 

Gabriella Vidal-Pergola, M.D. 1990-91 

Changnian Liu, Ph.D. 1990-92 

Rosa M. Guasch, Ph.D. 1994 

MS Thesis Defense Committees 

Shengqi Li Department of Dietetics and Nutrition – 4 

June 2010 

PhD Dissertation Defense Committees 

Jennifer R. Klemp Department of Psychology (KU-Lawrence) - 

18 May 2007 

Alison Ting 

Department of Molecular and Integrative 

Physiology - 5 Mar 2009 

(Graduate Studies representative) 

Cheryl Spittler School Nursing - 13 April 2011 

(Graduate Studies representative) 

19


M. Administration (List department committees, KUMC, VAMC, and University committees 

on which you serve or have served in the past. Describe any other administrative 

responsibility you carry.) 

1977-present Director, Radiation Biology Laboratory 

1977-79 Member, School of Allied Health Research Development Committee 

1979-85 Member, Department of Radiation Therapy Education Program Committee 

1981-85 Member, Faculty Assembly Animal Care Committee 

1982 Member, Research Week Planning Committee 

1982-84 Member, University of Kansas Cancer Center 

Member, Operations Advisory Committee 

Member, Research Advisory Committee 

Basic Science Coordinator 

Chairman, Basic Science Task Force 

1983 Research Week Planning Committees 

Member, Program Development Committee 

Member, Awards Committee 

Chairman, Tours Committee 

1983-84 Chairman, Faculty Assembly Animal Care Committee 

1984 Member, Ad Hoc Committee for the Animal Care Facility 

1984 Member, Ad Hoc Committee to Evaluate the Radiation Biophysics Program 

1984 Chairman, Research Award Selection Committee 

1984 Member, Research Day Planning Committee 

1984-87 Member, School of Medicine Faculty Research Committee 

1984-88 Member, Research and Development Committee, Veteran's Administration 

Hospital, Kansas City, MO. 

1984-85 Member, LCME Steering Committee 

Chairman, Subcommittee for Research 

1985 Judge for the Student Research Forum 

1985-present Member, Department of Radiation Oncology Education Program Committee 

1985-86 Member, Kansas University Multidisciplinary Cancer Committee 

Co-Chairperson and Member, Research Subcommittee 

1986-87 Member, Faculty Assembly Animal Care Committee 

1986-87 Chairman, Faculty Assembly Animal Care Committee 

1986-87 Chairman, Medical Faculty Research Committee 

1986-87 Member, Faculty Assembly Research Committee 

1986-96 Member, Advisory Committee for the International Agreement between the 

University of Kansas Medical Center and the Institute for Cytological 

Investigations, Valencia, Spain. 

1986-89 Member, University of Kansas Cancer Center Research Review Committee 


1987-88 Chairman, Faculty Assembly Faculty Concerns and Policies Committee 

1987-88 Member, Faculty Assembly Steering Committee and Council 

1987-93 Faculty Advisor for Medical Students 

1987-88 Budget and Finance Sub-Committee, Five-Year Plan Committee 


1988 Chairman, Task Force for Master's Degree Program in Biometry and Data 

Management 

1989 Chairman, Faculty Ad Hoc Grievance Committee 

1989-91 Chairman, Flow Cytometry Users Group 

1989-90 Acting Director, Flow Cytometry Facility 

20


1990-99 Director, Research Flow Cytometry Facility 

1992-5 Delegate to the School of Medicine Faculty Council 

1992-5 Member, Histology Advisory Committee, Mental Retardation Research 

Center 

1993-99 Co-Leader, Risk Factors in Development, Mental Retardation Research 

Center 

1993-99 Member, Internal Scientific Advisory Committee, Mental Retardation 

Research Center 

1993-96 Member, Faculty Assembly Resources and Facilities Planning Committee 

1993-94 Chairman, Faculty Assembly Resources and Facilities Planning Committee 

1993-94 Member, Faculty Assembly Council 

1994-97 Member, Graduate Travel Committee 

1994-97 Representative, School of Medicine Space Allocation Advisory Committee 

1994-95 Vice-Chair, School of Medicine Space Allocation Advisory Committee 

1995-97 Member, Cancer Center Clinical Investigations Support Services Review 

and Monitoring Committee 

1995-97 Member, School of Medicine Space Allocation Advisory Committee 

1995-96 Member, Primary Care Task Force 

1996-99 Member, Kansas Cancer Institute Internal Advisory Committee 

1996-99 Member, Kansas Cancer Institute Program Directors Committee 

1996-98 Faculty Assembly Election Committee 

1998-99 Task Force, School of Medicine 2005 Strategic Planning Initiative0 

2000-2011 Chair, Department of Radiation Oncology Promotions and Tenure 

Committee 

2002-03 Member, School of Medicine Promotion and Tenure Committee 

2003-06 Chair (KC Campus), School of Medicine Promotion and Tenure Committee 

2003-present Member, Tissue and Serum Repository Advisory Committee, Kansas 

Masonic Cancer Research Institute 

2004 Member, School of Medicine Promotions and Tenure Task Force 

2004-05 Chair, School of Medicine Promotion and Tenure Committee 

2004-29 Member, Protocol Review and Monitoring Committee, Kansas Masonic 

Cancer Research Institute. 

2004-05 Member, LCME Working Committee on Faculty Personnel Policies and 

Governance. 

2004-05 Search Committee for Director of Drug Development, Kansas Masonic 

Cancer Research Institute. 

2005-06 Search Committee for Chair, Department of Gynecology-Obstetrics. 

2006 Chair, School of Medicine Faculty Appeals Committee 

2006 Chair, Search Committee for Program Leader in Cell Biology, Kansas 

Masonic Cancer Research Institute 

2007-08 Member, Ad Hoc Committee to revise the Faculty Bylaws for the School of 

Medicine. 

2008-present Member, Clinical Research Advisory Committee 

2008-present Chair, American Cancer Society Institutional Research Grant Review 

Committee 

2008-09 Member, Chancellor's Rewards and Recognition Task Force 

2009-present Member, Biostatistics/Informatics Shared Resource (B/ISR) Advisory 

Committee, Kansas University Cancer Center 

2009-10 Co-Chair, Protocol Review and Monitoring Committee, University of Kansas 

Cancer Center. 

2010-11 Chair, Protocol Review and Monitoring Committees, University of Kansas 


21


2011-present Member, Engaging Scholarship with Public Service Work Group; Strategic 

Planning Process. 

2011-present Member, Department of Radiation Oncology Promotions and Tenure 

Committee 

2011-present Co-Chair, Protocol Review and Monitoring Committee, University of Kansas 


22


N. Physical Facilities Available 

Building and Room 

Square Feet 

1. Office Westwood Medical 100 

Pavilion; 1102-007 

Wescoe G022 260 

2. Laboratory Wescoe G018 94 

23


O. Full Length Papers in Scientific Journals 

1) Manuscripts published: 

1. Tallentire A, Hayes JR, Kimler BF, Powers EL: H 2 O and D 2 O sorption studies on spores of 

Bacillus megaterium. Radiat Res 57:300-305, 1974. PMID: 10874944 

2. Iwasaki T, Tallentire A, Kimler BF, Powers EL: The influence of added H 2 O and D 2 O on 

anoxic radiation sensitivity in bacterial spores. Radiat Res 57:306-310, 1974. PMID: 

10874945 

3. Han A, Sinclair WK, Kimler BF: The effect of N-ethylmaleimide on the response to X-rays 

of synchronized HeLa cells. Radiat Res 65:337-350, 1976. PMID: 1250954 

4. Kimler BF, Leeper DB: The effect of Adriamycin and radiation on G 2 progression. Cancer 

Res 36:3212-3216, 1976. PMID: 975085 

5. Schneiderman MH, Kimler BF, Kirschner AS, Hofer KG, Leeper DB: 125 I-UdR-induced 

division delay. Biophys J 17:199-202, 1977. PMID: 836938 

6. Kimler BF, Sinclair WK, Elkind MM: N-ethylmaleimide sensitization of X-irradiated hypoxic 

Chinese hamster cells. Radiat Res 71:204-213, 1977. PMID: 560026 

7. Snyder MH, Kimler BF, Leeper DB: The effect of caffeine on radiation-induced division 

delay. Int J Radiat Biol 32:281-284, 1977. PMID: 303628 

8. Kimler BF, Leeper DB: The effect of hydroxyurea on radiation-induced division delay in 

CHO cells. Radiat Res 72:265-276, 1977. PMID: 335430 

9. Kimler BF, Schneiderman MH, Leeper DB: Induction of concentration-dependent blockade 

in the G 2 phase of the cell cycle by cancer chemotherapeutic agents. Cancer Res 38:809- 

814, 1978. PMID: 75061 

10. Schneiderman MH, Kimler BF, Leeper DB, Dewey WC: Hydroxyurea retards the 

progression of G 2 cells. Exp Cell Res 115:465-467, 1978. PMID: 689106 

11. Kimler BF, Leeper DB: Effect of Adriamycin and radiation on G 2 cell survival. Int J Radiat 

Oncol Biol Phys 5:1297-1300, 1979. PMID: 528280 

12. Kimler BF: Effect of bleomycin and irradiation on G 2 progression. Int J Radiat Oncol Biol 

Phys 5: 1523-1526, 1979. PMID: 94055 

13. Kimler BF, McDonald T, Cheng CC, Podrebarac EG, Mansfield CM: Development and 

testing of new hypoxic cell radiosensitizers. Radiol 133:515-517, 1979. PMID: 493545 

14. Kimler BF: Effect of dihydroxyanthraquinone and radiation on G 2 progression. Cancer Res 

40:42-46, 1980. PMID: 7349902 

15. Mansfield CM, Kimler BF, Cheng CC, Abrahams IL, Podrebarac EG, Wittek PJ, Reddy EK: 

The search for new hypoxic cell radiosensitizers. J Nat Med Assoc 72:765-769, 1980. 

PMID: 7401185 

16. Kimler BF, Oliver LM: Rationale for fractionated radiotherapy. Radiologic Technology 

51:809-814, 1980. PMID: 7413963 

17. Kimler BF, Leeper DB, Schneiderman MH: Radiation-induced division delay in Chinese 

hamster ovary fibroblasts and carcinoma cells: dose-effect and ploidy. Radiat Res 85:270- 

280, 1981. PMID: 7193334 

18. Pierce GE, Kimler BF, Thomas JH, Watts LW, Kinnaman ML: Fractionated sublethal total 

body irradiation and donor bone marrow infusion for induction of specific allograft 

tolerance. Transplantation Proc 13:446-451, 1981. PMID: 7022871 

19. Henderson SD, Kimler BF, Morantz RA: Radiation therapy of 9L rat brain tumors. Int J 

Radiat Oncol Biol Phys 7:497-502, 1981. PMID: 7251420 

20. Kimler BF, Hacker MP: Combination of dihydroxyanthraquinone and radiation on L1210 

murine leukemia. Cancer Clin Trials 4:173-176, 1981. PMID: 7249253 

21. Kimler BF, Vats TS, Morantz RA, Henderson SD: Response of the 9L rat brain tumor to 

combination treatment with radiation and bleomycin. Int J Radiat Oncol Biol Phys 7:1069- 

1074, 1981. PMID: 6170619 

24


22. Kimler BF, Leeper DB, Snyder MH, Rowley R, Schneiderman MH: Modification of 

radiation-induced division delay by caffeine analogs and dibutyryl cyclic AMP. Int J Radiat 

Biol 41:47-58, 1982. PMID: 6277814 

23. Vats TS, Kimler BF, Morantz RA, Henderson SD. Combination chemotherapy for the 9L 

rat brain tumor model system. Cancer Treat Rep 66:575-579, 1982. PMID: 6174232 

24. Kimler BF, Henderson SD: Cyclic responses of cultured 9L cells to radiation. Radiat Res 

91:155-168, 1982. PMID: 7100394 

25. Kimler BF, Henderson SD, Mansfield CM, Svoboda DJ, Cheng CC: Effect of 

Dihydroxyanthraquinone (NSC 279836) and thoracic irradiation on long-term survival of 

rats. Cancer Res 42:2656-2659, 1982. PMID: 7083157 

26. Kimler BF, Cheng CC: Comparison of the effects of dihydroxyanthraquinone and 

Adriamycin on the survival of cultured Chinese hamster cells. Cancer Res 42:3631-3636, 

1982. PMID: 7105035 

27. Kimler BF: Interaction of razoxane and radiation on cultured Chinese hamster cells. Int J 


28. Kimler BF: Interaction of hyperthermia and radiation on the induction of division delay in 

CHO cells. Natl Cancer Inst Monogr 61:119-121, 1982. 

29. Henderson SD, Kimler BF, Scanlan MF: Interaction of hyperthermia and radiation on the 

survival of synchronous 9L cells. Radiat Res 92:146-159, 1982. PMID: 7134380 

30. Kimler BF: Effect of dihydroxyanthraquinone (DHAQ) and radiation on the survival of 

cultured Chinese hamster ovary cells. Radiat Res 93:406-415, 1983. PMID: 6681675 

31. Kimler BF, Cheng CC, Barnes RE, Barnes ML: Correlation of the structure of aminosubstituted 

anthraquinones to cytotoxicity of cultured Chinese hamster cells. 

Investigational New Drugs 1:213-218, 1983. PMID: 6687221 

32. Morantz RA, Kimler BF, Vats TS, Henderson SD: Bleomycin and brain tumors: a review. J 

Neuro-oncology 1:249-255, 1983. PMID: 6206209 

33. Kimler BF, Park CH, Yakar D, Mies R: Lack of recovery from radiation-induced sublethal 

damage in human hematopoietic cells. Br J Cancer 49 (Suppl VI):221-225, 1984. PMID: 

6582910 

34. Kimler BF, Reddy EK, Henderson SD, Glover RW, Scanlan MF: Effect of 

dihydroxyanthraquinone on the response of a rat solid tumor to radiation therapy. Am J 

Clin Oncol 7:141-144, 1984. PMID: 6702717 

35. Mansfield CM, Kimler BF, Henderson SD, Vats TS, Svoboda DJ: Angiotensin-I-converting 

enzyme in cancer patients. J Clin Oncol 2:452-456, 1984. PMID: 6327925 

36. Feaster GR, Kimler BF, Henderson SD, Mansfield CM: A simple plethysmograph for 

measuring respiration rates in rats with lung damage. Rev Sci Instrum 55:1058-1060, 

1984. 

37. Kimler BF, Cox, GG, Reddy, EK: Interaction of radiation, dihydroxyanthraquinone, and 

adriamycin on the induction of acute lethality in mice. Int J Radiat Oncol Biol Phys 

10:1459-1463, 1984. PMID: 6381433 

38. Kimler BF, Mansfield CM, Svoboda DJ, Cox GG: Ultrastructural evidence of cardiac 

damage resulting from thoracic irradiation and anthracyclines in the rat. Int J Radiat Oncol 

Biol Phys 10:1465-1469, 1984. PMID: 6469769 

39. Kimler BF, Cheng CC: Modification of radiation and dihydroxyanthraquinone-induced cell 

lethality by cysteamine and N-ethylmaleimide. Int J Radiat Oncol Biol Phys 10:1683-1686, 

1984. PMID: 6480454 

40. Mansfield CM, Kimler BF, Henderson SD, Vats TS, Svoboda DJ: Development of normal 

tissue damage in the rat subsequent to thoracic irradiation and prior treatment with cancer 

chemotherapeutic agents. Am J Clin Oncol 7:425-430, 1984. PMID: 6209980 

41. Giri PGS, Kimler BF, Giri UP, Cox GG, Reddy EK: Comparison of single, fractionated, and 

hyperfractionated irradiation on the development of normal tissue damage in rat lung. Int J 


25


42. Kimler BF, Park CH, Yakar D, Mies R: Radiation response of human hematopoietic cells 

(normal and leukemic) assayed by in vitro colony formation. Int J Radiat Oncol Biol Phys 

11:809-816, 1985. PMID: 3980276 

43. Park CH, Kimler BF, Smith TK: Comparison of the supervital DNA dyes Hoescht 33342 

and DAPI for flow cytometry and clonogenicity studies of human leukemic marrow cells. 

Exp Hematol 13:1039-1043, 1985. PMID: 4054243 

44. Park CH, Kimler BF: Cellular basis for growth promotion of human leukemic cells by L- 

ascorbic acid. J Nutrition, Growth, and Cancer 3:131-134, 1986. 

45. Giri PGS, Kimler BF, Giri UP, Cox GG: Hyperfractionation of thoracic irradiation protects 

against long-term pulmonary fibrosis in rats. Br J Cancer 53 (Suppl VII):324-326, 1986. 

PMID: 3459530 

46. Kimler BF, Giri PGS, Giri UP, Cox GG: Effect of single dose, fractionated, and 

hyperfractionated trunk irradiation on weight gain, respiration frequency, and survival in 

rats. Br J Cancer 53 (Suppl VII):360-362, 1986. 

47. Reddy EK, Kimler BF, Cytacki EP, Evans RG: Hyperthermia in cancer therapy. Kansas 

Medicine 87:163-168, 1986. PMID: 3525959 

48. Kimler BF, Rethorst R Cox GG: Interaction of anthracyclines and radiation in the fetal 

mouse heart organ culture system. Investigational New Drugs 4:127-133, 1986. PMID: 

3733373 

49. Saving KL, Kimler BF, Vats TS: Intraperitoneal bleomycin for ventriculoperitoneal spread 

of a hypothalamic astrocytoma. Cancer Drug Delivery 3:205-210, 1986. PMID: 2430685 

50. Park CH, Kimler BF, Smith TK: Clonogenic assay combined with flow cytometric cell 

sorting for cell-cycle analysis of human leukemic colony-forming cells. Anticancer Res 

7:129-132, 1987. PMID: 3551785 

51. Norton S, Kimler BF: Correlation of behavior with brain damage after in utero exposure to 

toxic agents. Neurotoxicol Teratol 9:145-150, 1987. PMID: 3657750 

52. Hart RM, Kimler BF, Evans RG, Park CH: Radiotherapeutic management of 

medulloblastoma in a pediatric patient with ataxia telangiectasia. Int J Radiat Oncol Biol 

Phys 13:1237-1240, 1987. PMID: 3610711 

53. Henderson SD, Kimler BF, Barnes ML: Comparison of cancer chemotherapeutic agents in 

asynchronous and synchronous 9L cells. Investigational New Drugs 5:145-154, 1987. 

PMID: 3654148 

54. Park CH, Kimler BF: Cyclic AMP modulation of leukemic cell growth in acute 

nonlymphocytic leukemia. J Nutrition Growth Cancer 4:141-146, 1987. 

55. Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS: Effects of spirogermanium and 

radiation therapy in the 9L rat brain tumor model. NCI Monogr 6: 115-118, 1988. PMID: 

3352753 

56. Martin DF, Kimler BF, Evans RG, Morantz RA, Vats TS: Potentiation of brain tumor 

therapy by Fluosol and oxygen. NCI Monogr 6:119-122, 1988. PMID: 3127732 

57. O'Connor JE, Vargas JL, Kimler BF, Hernandez-Yago J, Grisolia S: Use of Rhodamine 

123 to investigate alterations in mitochondrial activity in isolated mouse liver mitochondria. 

Biochem Biophys Res Comm 151:568-573, 1988. PMID: 3348796 

58. Lindsley HB, Jamieson, TW, DeSmet AA, Kimler BF, Kremer MA, Hassanein KM: Total 

lymphoid irradiation for treatment of experimental collagen-induced arthritis in rats. J 

Rheumatol 15:742-744, 1988. PMID: 3262749 

59. Norton S, Kimler BF: Comparison of functional and morphological deficits in the rat after 

gestational exposure to ionizing radiation. Neurotoxicol Teratol 10:363-371, 1988. PMID: 

3226380 

60. O'Connor JE, Kimler BF, Morgan MC, Tempas KJ: A flow cytometric assay for intracellular 

non-protein thiols using Mercury Orange. Cytometry 9:529-532, 1988. PMID: 3208619 

61. Kimler BF, Norton S: Behavioral changes and structural defects in rats irradiated in utero. 

Int J Radiat Oncol Biol Phys 15:1171-1177, 1988. PMID: 3182350 

26


62. Wesselius LJ, Kimler BF: Alveolar macrophage proliferation in situ following thoracic 

irradiation of rats. Am Rev Respir Dis 139:221-225, 1989. PMID: 2912342 

63. Papdopoulos D, Kimler BF, Estes NC, Durham FJ: Growth delay effect of combined 

interstitial hyperthermia and brachytherapy in a rat solid tumor model. Anti-Cancer Res 

9:45-48, 1989. PMID: 2705755 

64. O'Connor JE, Kimler BF, Vargas JL: Flow cytometric analysis of the effects of high protein 

diet on isolated rat liver mitochondria. Cell Tissue Kinet 21:331-338, 1988. PMID: 3245955 

65. Wesselius LJ, Floreani AF, Kimler BF, Papasian CJ, Dixon ALY: Effect of corticosteroid 

treatment on cell recovery by lung lavage in acute radiation-induced lung injury. Radiat 

Res 120:313-322, 1989. PMID: 2616742 

66. Norton S, Kimler BF, Cytacki EP, Rosenthal SJ: Acute response of fetal rat telencephalon 

to ultrasound exposure in utero. Experimental Neurology 107:154-163, 1990. PMID: 

2406162 

67. Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS: Combination therapy with 

intracranial bleomycin and radiation in the 9L rat brain tumor model. Int J Radiat Oncol Biol 

Phys 18:1115-1121, 1990. PMID: 1693363 

68. Rao JS, Baker JB, Morantz RA, Kimler BF, Evans RG: Serpin inhibitors or urokinase and 

thrombin in normal rat brain and the 9L brain tumor: Evidence for elevated expression of 

protease nexin I-like inhibitor and a novel SDS-activated tumor antithrombin. Cancer Res 

50:5039-5044, 1990. PMID: 2116223 

69. Miller PJ, Hassanein RS, Giri PGS, Kimler BF, O'Boynick PL, Evans RG: Univariate and 

multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose 

and other prognostic factors. Int J Radiat Oncol Biol Phys 19:275-280, 1990. PMID: 

2168352 

70. Evans RG, Kimler BF, Morantz RA, Vats TS, Liston V, Lowe N: A Phase I-II study of the 

use of Fluosol-DA 20% as an adjuvant to radiation therapy in the treatment of primary high 

grade brain tumors. Int J Radiat Oncol Biol Phys 19:415-420, 1990. PMID: 2168356 

71. Norton S, Kimler BF: Early effects of low doses of ionizing radiation on the fetal cerebral 

cortex in rats. Radiat Res 124:235-241, 1990. PMID: 2247604 

72. Smalley SR, Kimler BF, Evans RG: 5-Fluorouracil modulation of radiosensitivity in cultured 

human carcinoma cells. Int J Radiat Oncol Biol Phys 20:207-211, 1991. PMID: 1991680 

73. Norton S, Kimler BF, Cytacki EP, Rosenthal SJ: Prenatal and postnatal consequences in 

the brain and behavior of rats exposed to ultrasound in utero. J Ultrasound Med 10:69-75, 

1991. PMID: 2020052 

74. Norton S, Kimler BF, Mullenix PJ: Progressive behavioral changes in rats after exposure 

to low levels of ionizing radiation in utero. Neurotoxicol Teratol 13:181-188, 1991. PMID: 

2046638 

75. McMillan JH, Cox, GG, Kimler BF, Spicer JS, Batnitzky S: Mn[III] Uroporphyrin I: a novel 

metalloporphyrin contrast agent for magnetic resonance imaging. Magnetic Resonance 

Imaging 9:553-558, 1991. PMID: 1779726 

76. Nasseri KK, Kimler BF, Hassanein RS, Gemer LS: Factors influencing the survival of 

patients with cervical carcinoma. Kansas Med 92:217-221, 1991. PMID: 1942719 

77. Park CH, Kimler BF: Growth modulation of human leukemic, preleukemic, and myeloma 

progenitor cells by L-ascorbic acid. Am J Clin Nutrition 54:1241S-1246S, 1991. PMID: 

1962577 

78. Park CH, Kimler BF, Bodensteiner D, Lynch SR, Hassanein RS: In vitro growth modulation 

by L-ascorbic acid of colony-forming cells from bone marrow of patients with 

myelodysplastic syndromes. Cancer Res 52:4458-4466, 1992. PMID: 1643638 

79. Smalley SR, Kimler BF, Evans RG, Dalziel WC: Mammalian cell heterogeneity to 

modulation of radiosensitivity by 5-fluorouracil. Int J Radiat Oncol Biol Phys 24:519-525, 

1992. PMID: 1399739 

80. Kimler BF, Liu C, Evans RG, Morantz RA: Intracerebral chemotherapy in the 9L rat brain 

27


tumor model. J Neuro-Oncol 14:191-200, 1992. PMID: 1281224 

81. Liu C, Kimler BF, Evans RG, Morantz RA: Immune adjuvants to chemotherapy or 

radiotherapy in the 9L rat brain tumor model. J Neuro-Oncol 15:113-123, 1993. PMID: 

8509816 

82. Vidal-Pergola GM, Kimler BF, Norton S: Effect of in utero irradiation on the postnatal 

development, behavior, and brain structure of rats: dose fractionation with a 6-h interval. 

Radiat Res 134:369-374, 1993. PMID: 8316631 

83. Kimler BF, Liu C, Evans RG, Morantz RA: Combination of aziridinylbenzoquinone and cisplatinum 

with radiation therapy in the 9L rat brain tumor model. Int J Radiat Oncol Biol 

Phys 26:445-450, 1993. PMID: 8514542 

84. Storm HS, Kimler BF, Norton S, Oh S: Reduction in radiation-induced toxicity by dietary 

squalene. Lipids 28:555-559, 1993. PMID: 8355581 

85. Evans RG, Kimler BF, Morantz RA, Batnitzky S: Lack of complications in long-term 

survivors after treatment with fluosol and oxygen as an adjuvant to radiation therapy for 

high-grade malignant brain tumors. Int J Radiat Oncol Biol Phys 26:649-652, 1993. PMID: 

8330996 

86. Kimler BF, Liu C, Evans RG, Morantz RA: Effect of pentobarbital on normal brain 

protection and on the response of 9L rat brain tumor to radiation therapy. J Neurosurg 

79:577-583, 1993. PMID: 8410227 

87. O'Brien-Ladner A, Nelson ME, Kimler BF, Wesselius LJ: Release of Interleukin-1" by 

human alveolar macrophages following in vitro irradiation. Radiat Res 136:37-41, 1993. 

PMID: 8210336 

88. Hays SR, Li X, Kimler BF: Is there an adaptive response to radiation in the developing 

fetal rat cortex? Radiat Res136:293-296, 1993. PMID: 8248488 

89. Fabian CJ, Zalles C, Kamel S, McKittrick R, Moore WP, Zeiger S, Simon C, Kimler BF, 

Cramer A, Garcia F, Jewell WR: Biomarker and cytologic abnormalities in women at high 

and low risk for breast cancer. J Cell Biochem 17G(Suppl):153-160, 1993. PMID: 

7911861 

90. Kimler BF, Vidal-Pergola GM, Peterson SL, Li X, Norton S: Effect of in utero irradiation on 

postnatal development, behavior, and brain structure in rats: dose fractionation with a 3- 

hour interval. NeuroToxicology 15:183-190, 1994. PMID: 8090357 

91 Park CH, Kimler BF: Tumor cell-selective flow cytometric analysis for DNA content and 

cytokeratin expression of clinical tumor specimens by "cross-gating". Anticancer Res 

14:29-36, 1994. PMID: 7513144 

92. Fabian CJ, Zalles C, Kamel S, Kimler BF, McKittrick R, Tranin AS, Zeiger S, Moore WP, 

Hassanein RS, Simon C, Johnson N, Vergara G, Jewell WR, Lin F, Bhatia P, Chin T: 

Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast 

aspirates of women at high and low risk for breast cancer. Breast Cancer Res Treat 

30:263-274, 1994. PMID: 7981444 

93. Kimler BF: The 9L rat brain tumor model for pre-clinical investigation of radiationchemotherapy 

interactions. J Neuro-Oncology 20:103-109, 1994. PMID: 7528789 

94. Fabian CJ, Kimler BF, McKittrick R, Park CH, Lin F, Jewell WR, Krishnan L, Osborne CK, 

Martino S, Hutchins LF, Long LA, Green S: Recruitment with high physiologic doses of 

estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with 

locally advanced breast cancer -- A Southwest Oncology Group study. Cancer Res 

54:5357-5362, 1994. PMID: 7923165 

95. Pinson DM, Havu N, Hurwitz A, Sztern M, Looney GA, Kimler BF, Mattsson H: Druginduced 

hypergastrinemia: absence of effects on colonic carcinoma. 

Gastroenterology108:1068-1074, 1995. PMID: 7698573 

96. Fabian CJ, Kamel S, Kimler BF, McKittrick R: Potential use of biomarkers in breast cancer 

risk assessment and chemoprevention trials. The Breast Journal 1:236-242, 1995. 

97. Hurwitz A, Sztern M, Looney GA, Bauer KD, Pinson DM, Kimler BF: Effects of 

28


Omeprazole on cell kinetics of carcinogen-induced colon tumors in rats. Cell Prolif 28:525- 

531, 1995. PMID: 7488672 

98. Sancho-Tello M, Marcinkiewicz JL, Justice WM, Kimler BF, Terranova PF, Hunter VJ: 

Degradation of tumor necrosis factor-" bioactivity by a human ovarian epithelial carcinoma 

cell line in vitro. Am J Obstet Gynecol 173:1470-1477, 1995. PMID: 7503187 

99. Zalles C, Kimler BF, Kamel S, McKittrick R, Fabian CJ: Cytology patterns in random 

aspirates from women at high and low risk for breast cancer. The Breast Journal 1:343- 

349, 1995. 

100. Ruiz-Cerdá JL, Hernández M, Gomis F, Vera CD, Kimler BF, O´Connor JE, Jiménez-Cruz 

F: Value of DNA ploidy and nuclear morphometry for prediction of disease progression in 

renal cell carcinoma. J Urology 155:459-465, 1996. PMID: 8558635 

101. Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SPG, Kimler BF: Retrospective DNA 

ploidy analysis by image and flow cytometry in head and neck cancer. Laryngoscope 

106:1306-1313, 1996. PMID: 8849806 

102. Fabian CJ, Kamel S, Zalles CM, Kimler BF: Identification of a chemoprevention cohort 

from a population of women at high risk for breast cancer. J Cell Biochem 25S:112-122, 

1996. PMID: 9027607 

103. Li Y, Looney GA, Kimler BF, Hurwitz A: Opiate effects on 5-fluorouracil disposition in 

mice. Cancer Chemother Pharmacol 39:273-277, 1997. PMID: 8996532 

104. Fabian CJ, Kamel S, Zalles C, Kimler BF: Biomarkers predictive of short interval cancer 

development in high risk women. The Breast J 3(Suppl):42-48, 1997. 

105. Fabian CJ, Kimler BF: Chemoprevention of breast cancer. The Breast J 3:220-226, 1997. 

106. Kimler BF: Prenatal irradiation: a major concern for the developing brain. Int J Radiat Biol 

73:423-434, 1998. PMID: 9587081 

107. Kimler BF, Cox GG, Wulser MJ, Zhao WW, Norton S, Terranova PF: Ovulatory delay 

alters postnatal growth, behavior, and brain structure in rats. Dev Brain Res 107:49-55, 

1998. PMID: 9602055 

108. Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF: Breast cytology and 

biomarkers obtained by random fine needle aspiration: Use in risk assessment and early 

chemoprevention trials. J Cell Biochem Suppl 28:101-110,1997. PMID: 9589354 

109. Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken SW, Ward JH: Models for early 

chemoprevention trials in breast cancer. Hematology/Oncology Clinics of North America 

12:993-1017, 1998. PMID: 9888018 

110. Rider V, Kimler BF, Justice WM: Progesterone-growth factor interactions in uterine stromal 

cells. Biol Reproduction 59:464-469, 1998. PMID: 9716541 

111. Kamel S, Zeiger S, Zalles C, Tawfik O, Simon C, Kimler BF, Fabian CF: p53 

immunopositivity and gene mutation in a group of women at high risk for breast cancer. 

Breast J 4:396-404, 1998. 

112. Liu J, Kimler BF, Liu Y, Klaassen CD: Metallothionein-I transgenic mice are not protected 

from radiation. Toxicology Letters 104:183-187, 1999. PMID: 10079052 

113. Ruiz-Cerda J-L, Hernandez M, Sempere A, O’Connor JE, Kimler BF, Jiménez-Cruz F: 

Intratumoral heterogeneity of DNA content in renal cell carcinoma and its prognostic 

significance. Cancer 86:664-671, 1999. PMID: 10440695 

114. Jones SR, Kimler BF, Justice WM, Rider V: Progesterone-growth factor interactions 

regulate G1 progression in normal rat uterine stromal cells. Endocrinology 141:637-648, 

2000. PMID: 10650945 

115. Kimler BF, Fabian CJ,. Wallace DD: Breast cancer chemoprevention trials using the fine 

needle aspiration model. J Cell Biochem Suppl 34:7-12, 2000. PMID: 10762008 

116. Klemp J, Brady D, Frank TS, Kimler BF, Fabian CJ: Incidence of BRCA1/2 germ line 

alterations in a high risk cohort participating in a phase II chemoprevention trial. Eu J 

Cancer 36:1209-1214, 2000. PMID: 10882858 

117. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, Mayo MS: Short-term 

29


breast cancer prediction by random periareolar fine needle aspiration cytology and the 

Gail risk model. J Natl Cancer Inst 92:1217-1227, 2000. PMID: 11734584 

118. Mayo MS, Kimler BF, Fabian CJ: Evaluation of models for the prediction of breast cancer 

development in women at high risk of breast cancer. J Applied Res 1:37-44, 2001. 

119. Fabian CJ, Kimler BF: Chemoprevention for high risk women: Tamoxifen and beyond. 

Breast J 7:311-320, 2001. PMID: 11906441 

120. Fabian CJ, Kimler BF: Beyond tamoxifen: new endpoints for breast cancer 

chemoprevention, new drugs for breast cancer prevention. Ann N Y Acad Sci 952:44-59, 

2001. PMID: 11795443 

121. Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, 

Modrell C, Praeger M, McGinness M,. Mehta R, Fruehauf JP: Factors associated with 

success of the extreme drug resistance assay in primary breast cancer specimens. Breast 

Cancer Res Treatment 71:95-102, 2002. PMID: 11881914 

122. Fabian CJ, Kimler BF: Chemoprevention of breast cancer: implications for 

postmenopausal women. Drugs and Aging 19:43-78, 2002. PMID: 11929326 

123. Fabian CJ, Kimler BF: Breast cancer chemoprevention: current challenges and a look 

towards the future. Clin Breast Cancer 3:113-124, 2002. PMID: 12123535 

124. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CHJ, Ferraro JA, Zalles CM, Stanton 

AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA: A phase II breast cancer 

chemoprevention trial of oral "-Difluoromethylornithine: breast tissue, imaging, and serum 

and urine biomarkers. Clinical Cancer Res 8:3105-3117, 2002. PMID: 12374678 

125. Hurwitz A, Ruhl CE, Kimler BF, Topp EM, Mayo MS: Gastric function in the elderly: 

effects on absorption of ketoconazole. J Clin Pharmacol 43:996-1002, 2003. PMID: 

12971032 

126. Jamerson PA, Wulser MJ, Kimler BF: Neurobehavioral effects in rat pups whose sires 

were exposed to alcohol. Dev Brain Res 149:103-111, 2004. PMID: 15063090 

127. Park S, Han SS, Park CH, Hahm ER, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park 

K, Riordan HD, Kimler BF, Kim K, Lee JH: L-ascorbic acid induces apoptosis in acute 

myeloid leukemia cells via hydrogen peroxide-mediated mechanisms. Int J Biochem Cell 

Biol 36:2180-2195, 2004. PMID: 15313465 

128. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy 

JA, Albain KS, Hyams D, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, 

Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D: Breast cancer 

chemoprevention Phase I evaluation of biomarker modulation by arzoxifene, a third 

generation selective estrogen receptor modulator. Clin Cancer Res 10:5403-5417, 2004. 

PMID: 15328178 

129. Han S-S, Lee SJ, Park HK, Kim K, Kim WS, Jung CW, Lee MH, Park K, Lee J, Yang J-H, 

Yoon S-S, Riordan NH, Riordan HD, Kimler BF, Park CH, Park S: L-Ascorbic acid 

represses constitutive activation of NF-6 B and COX-2 expression in human acute myeloid 

leukemia, HL-60. J Cellular Biochem 93:257-270, 2004. PMID: 15368354 

130. Sharma P, Klemp JR, Simonsen M, Welsko CM, Zalles CM, Kimler BF, Fabian CJ: Failure 

of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic 

atypia in random periareolar fine needle aspiration specimens. Breast Cancer Res 

Treatment 87:59-64, 2004. PMID: 15377851 

131. Park S, Lee SJ, Park HK, Kim K, Kim WS, Lee MH, Park K, Lee J, Riordan HD, Kimler BF, 

Park CH: Activation of Raf1 and the ERK pathway in response to L-ascorbic acid in acute 

myeloid leukemia cells. Cell Signal 17:111-119, 2005. PMID: 15451031 

132. Han S-S, Kim K, Hahm E-R, Park CH, Kimler BF, Lee SJ, Lee S-H, Kim WS, Jung CW, 

Park K, Kim J, Yoon S-S, Park S: Arsenic trioxide represses constitutive activation of NFkB 

and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 

94:695-707, 2005. PMID: 15547942 

30


133. Fabian CJ, Kimler BF: Selective estrogen receptor modulators for primary prevention of 

breast cancer. J Clin Oncol 23:1644-1655, 2005. PMID: 15755972 

134. Khan QJ, Kimler BF, Clark J, Metheny T, Zalles CM, Fabian CJ: Ki-67 Expression in 

benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer 

Epidemiol Biomarkers Prevention 14:786-789, 2005. PMID: 15824144 

135. Bean GR, Scott S, Yee L, Ratliff-Daniel B, Troch MM, Seo P, Bowie ML, Marcom PK, 

Slade J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker, JC Jr, Wilke LG, 

Seewaldt VL: Retinoic acid receptor-$2 promoter methylation in random periareolar fine 

needle aspiration. Cancer Epidemiol Biomarkers Prevention 14:790-798, 2005. PMID: 

15824145 

136. Fabian CJ, Kimler BF, Mayo MS, Khan S: Breast tissue sampling for risk assessment and 

prevention. Endocrine-Related Cancer 12:185-213, 2005. PMID: 15947097 

137. Zalles CM, Kimler BF, Simonsen, M, Clark JL, Metheny T, Fabian CJ: Comparison of 

cytomorphology in specimens obtained by random periareolar fine needle aspiration and 

ductal lavage from women at high risk for development of breast cancer. Breast Cancer 

Res Treat 97:191-197, 2006. PMID: 16322885 

138. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, 

Thomas P, Connor C, Jewell W, Fabian CF: Comparison of immunohistochemistry by 

automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the 

evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 48:258- 

267, 2006. PMID: 16430472 

139. Rider V, Lia, X, Peterson G, Dawson J, Kimler BF, Abdou NI: Differential expression of 

estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 33:1093- 

1101, 2006. PMID: 16755656 

140. Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, Zalles CM, Fabian CJ: Estrogen 

receptor expression in benign breast ductal cells obtained from random periareolar fine 

needle aspiration correlates with menopausal status and cytomorphology index score. 

Breast Cancer Res Treat 100:71-76, 2006. PMID: 16791479 

141. Petroff BK, Clark JL, Metheny T, Xue Q, Kimler BF, Fabian CJ: Optimization of estrogen 

receptor analysis by immunocytochemistry in random periareolar fine-needle aspiration 

samples of breast tissue processed as thin layer preparations. Applied Immunohistochem 

Molec Morph 14:360-364, 2006. PMID: 16932030 

142. Fabian CJ, Kimler BF: Mammographic density: use in risk assessment and as a biomarker 

in prevention trials. J Nutr 136:2705S-2708S, 2006. PMID: 16988158 

143. Bean GR, Kimler BF, Seewaldt VL. Long-term raloxifene in a woman at high risk for breast 

cancer. N Engl J Med 355:1620-1622, 2006. PMID: 17035661 

144. Petroff BK, Phillips TA, Kimler BF, Fabian CJ. Detection of biomarker gene expression by 

real-time polymerase chain reaction using amplified ribonucleic acids from formalin-fixed 

random periareolar fine needle aspirates of human breast tissue. Anal Quant Cytol Histol. 

28:297-302, 2006. PMID: 17067012 

145. Ting A, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of 

simultaneous breast and ovarian cancer progression. Carcinogenesis 28:130-135, 2007. 

PMID: 16891317 

146. Li X, Rider V, Kimler BF, Abdou NI. Estrogen does not regulate CD154 mRNA stability in 

SLE T cells. Lupus 15:852-857, 2006. PMID: 17211990 

147. Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, Wilke LG, 

Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt 

VL. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict 

cytological atypia or correlate with surrogate end points of breast cancer risk. Cancer 

Epidemiol Biomarkers Prevention 16:50-56, 2007. PMID: 17220331 

148. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny 

T, Petroff BK: Reduction in proliferation with six months of letrozole in women on hormone 

31


replacement therapy. Breast Cancer Res Treat 106:75-84, 2007. PMID: 17221152 

149. Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF, Holzbeierlein J: Prognostic 

significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 

expression in renal cell carcinoma. Arch Pathol Lab Med 131:261-7, 2007. PMID: 

17284111 

150. Tawfik OW, Kimler BF, Davis M, Stasik C, Lai S-M, Mayo MS, Fan F, Donahue JK, 

Damjanov I, Thomas P, Connor C, Jewell WR, Smith H, Fabian CJ: Grading of invasive 

ductal carcinoma of the breast: advantages of using automated proliferation index instead 

of manual mitotic count. Virchows Archiv 450:627-636, 2007. PMID: 17458558 

151. Bartels PH, Fabian CJ, Kimler BF, Ranger Moore J, Frank D, Yozwiak M, Alberts D: 

Karyometry of breast epithelial cells acquired by random periareolar fine needle aspiration 

of women at high risk for breast cancer. Anal Quant Cytol Histol 29:63-70, 2007. PMID: 

17484269 

152. Goldenberg VK, Seewaldt VL, Scott S, Bean GR, Broadwater G, Fabian C, Kimler B, 

Zalles C, Lipkus IM: Atypia in random periareolar fine needle aspiration affects the 

decision of high-risk women to take tamoxifen for breast cancer chemoprevention. Cancer 

Epidemiol Biomarkers Prev 16:1032-1034, 2007. PMID: 17507634 

153. Khan QJ, Kimler BF, O'Dea A, Zalles CM, Sharma P, Fabian CJ: Mammographic density 

does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained 

by random periareolar fine needle aspiration from women at high risk of breast cancer. 

Breast Cancer Research 9:R35, 2007. PMID: 17537236; PMC1929099 

154. Fabian CJ, Kimler BF: Use of biomarkers in breast cancer risk assessment and 

prevention. J Steroid Biochem Molec Bio 106:31-39, 2007. PMID: 17596932 

155. Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie 

C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, 

Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL. Morphologically 

normal-appearing mammary epithelial cells obtained from high-risk women exhibit 

methylation silencing of INK4a/ARF. Clin Cancer Res 13:6834-41, 2007. PMID: 

18006786 

156. Abdou NI, Rider V, Greenwell C, Li X, Kimler BF: Fulvestrant (Faslodex), an estrogen 

selective receptor downregulator, in therapy of women with systemic lupus erythematosus. 

Clinical, serologic, bone density, and T cell activation marker studies: a double-blind 

placebo-controlled trial. J Rheumatol 35:797-803, 2008. PMID: 18381791 

157. Gorjestani S, Rider V, Kimler BF, Greenwell C, Abdou NI: Extracellular signal regulated 

kinase 1//2 signaling in SLE T cells is influenced by estrogen and disease activity. Lupus 

17:548-554, 2008. PMID: 18539708 

158. Kubicek G, Reddy EK, Kimler BF, Al-Kasspooles M, Baranda J, Wang F, Krishnan L, 

Jewell WR: Anal cancer: The KUMC experience. Kansas J Med. 1: 27-37, 2008. 

159. Kubicek GJ, Krishnan L, Kimler BF, Al-kasspooles M, Reddy EK, Wang F, Jewell WR: 

Adjuvant radiation for malignant melanoma: The KUMC experience. Kansas J Med 

Volume 2, Issue 1, 2008 (http://hdl.handle.net/2271/544). 

160. Ting A, Kimler BF, Fabian CJ, Petroff BK: Tamoxifen prevents premalignant changes of 

breast but not ovarian cancer in rats at high risk for both diseases. Cancer Prevention Res 

1:546-553, 2008. PMID: 19139004; PMC2748942 

161. Frank DH, Kimler BF, Fabian CJ, Ranger-Moore J, Yozwiak M, Bartels HG, Alberts DS, 

Bartels PH: Digital image analysis of breast epithelial cells collected by random periareolar 

fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone 

replacement and the aromatase inhibitor, letrozole, for six months. Breast Cancer Res 

Treat 115:661-668, 2009. PMID: 19125322 

162. Stevens E, Kimler BF, Davis MK, Fan F, Thomas P, Wang X-Y, Damjanov I, Tawfik OW: A 

newly proposed semi-automated method of grading invasive lobular carcinomas. Ann Clin 

Lab Sci 39:25-31, 2009. PMID: 19201737 

32


163. Krishnan L, Jewell WR, Connor C, Tawfik OW, Alvarez-Farinetti A, Wang F, Reddy EK, 

Thatikonda S, Krishnan EC, Kimler BF: Breast conservation therapy with tumor bed 

brachytherapy alone in Stage I breast cancer: Results of a Phase II trial. Kansas J Med 2; 

33-40, 2009 (http://hdl.handle.net/2271/566). 

164. Fabian CJ, Kimler BF: Is chemoprevention practical? Current Breast Cancer Reports. 

1:48-53, 2009. 

165. Park CH*, Kimler BF*, Yi SY, Park SH, Kim K, Jung CW, Kim SH, Lee ER, Rha M, Kim S, 

Park HK, Lee SJ, Park HK, Lee MH, Yoon SS, Min YH, Kim BS, Kim J-A, Kim WS*: 

Depletion of L-ascorbic acid alternating with its supplementation in the treatment of 

patients with acute myeloid leukemia or myelodysplastic syndromes. European J 

Haematology 83:108-118, 2009. *These authors contributed equally PMID: 19284416 

166. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O'Dea AP, Klemp JR, Fabian CF: 

Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and 

fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer 

Res Treat 119:111-118, 2009. PMID: 19655244 

167. Walters E, Rider V, Abdou NI, Greenwell C, Svojanovsky S, Smith P, Kimler BF: Estradiol 

targets T cell signaling pathways in human systemic lupus. Clin Immunol 133:428-436, 

2009. PMID: 19793680; PMC2783703 

168. Khan QJ, Kimler BF, Fabian CJ: The relationship between vitamin D and breast cancer 

incidence and natural history. Curr Oncol Rep 12:136-142, 2010. PMID: 20425599 

169. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Petroff BK, Khan QJ, Sharma P, Setchell 

KDR, Zhao X, Phillips TA, Metheny T, Hughes JR, Yeh H-W, Johnson KA: Reduction in 

Ki-67 in benign breast tissue of high risk women with the lignan secoisolariciresinol 

diglycoside (SDG). Cancer Prev Res 3:1342-1350, 2010. PMID: 20724470; PMC2955777 

170. Kubicek GJ, Kimler BF, Wang F, Reddy EK, Girod DA, Williamson S: Chemotherapy in 

head and neck cancer: clinical predictors of tolerance and outcomes. Am J Clin Oncol. 

2010 Sep 24 [Epub ahead of print]. PMID: 20881477 

171. Tawfik O, Davis K, Kimler BF, Davis MK, Hull S, Hamidpour S, Fan F, Khan QJ, O'Dea 

AP, Connor C, Lai S-M, Patricia Thomas P: Clinicopathological characteristics of "triplenegative" 

invasive mammary carcinomas in African-American and Caucasian women: a 

comparative study. Ann Clin Lab Sci 40:315-323, 2010. PMID: 20947804 

172. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik OW: Prognostic significance of Bcl-2 in 

invasive mammary carcinomas: a comparative cllnicopathological study between:triplenegative” 

and non “triple-negative” tumors. Human Pathol 2011 Jul 19 [Epub ahead of 

print]. PMID: 21777944 

173. Stasik CJ, Davis M, Kimler BF, Fan F, Damjanov I, Thomas P, Tawfik OW: Grading ductal 

carcinoma in situ of the breast using an automated proliferation index. Ann Clin Lab Sci 

41: 122-130, 2011. 

2) Manuscripts accepted or in press: 

1. 

3) Manuscripts submitted but not yet accepted: 

1. O’Dea AP, Dusing R, Fabian CJ, Khan QJ, Kimler BF, Roling S, Sharma P: Integrated 

FDG-PET/CT for initial staging of asymptomatic patients with early stage breast cancer. 

2. Rider V, Johannenson E, Walters E, Abdou NI, Greenwell C, Kimler BF: Estradiol 

differentially regulates Foxp3 in human SLE T cells. 

3. Schafer G, Kimler BF, McGregor DH, Fan F, Tawfik OW: Variables impacting lymph node 

recovery in colectomy resection specimens removed for colorectal adenocarcinoma. 

33


4) Other publications 

1. Fabian CJ, Kimler BF: Breast cancer risk prediction: should nipple aspiration fluid cytology 

be incorporated into clinical practice? (Editorial) J Natl Cancer Inst 93:1762-1763, 2001. 

2. Fabian CJ, Kimler BF, Mayo MS: Ductal lavage for early detection - what doesn't come out 

in the wash. (Editorial) J Natl Cancer Inst 96:1488-1489, 2004. 

3. Fabian CJ, Kimler BF: COX-2 inhibitors for breast cancer prevention: a current 

understanding. American Society of Clinical Oncology 2005 Educational Book, 41 st 

Annual Meeting. pp139-144, 2005. 

4. Rockwell S, Kimler BF, Moulder JE: Publishing negative results: the problem of publication 

bias. (Editorial) Radiat Res 165: 623-625, 2006. 

34


P. Books and Book Chapters 

1) Books 

2) Book Chapters 

1. Kimler BF: Effect of razoxane and radiation on G 2 progression. In Radiation Sensitizers: 

Their Use in the Clinical Management of Cancer (Brady LW, ed). Masson Publishing 

U.S.A., Inc.: New York. pp 334-336, 1980. 

2. Henderson SD, Kimler BF: Hypoxic radiosensitization of 9L cells in vitro by misonidazole. 

In Radiation Sensitizers: Their Use in the Clinical Management of Cancer (Brady, LW, ed). 

Masson Publishing U.S.A., Inc.: New York. pp 455-457, 1980. 

3. Reddy EK, Kimler BF, Henderson SD, Morantz RA: Combination of misonidazole and 

radiation therapy in a rat brain tumor (9L) system. In Radiation Sensitizers: Their Use in 

the Clinical Management of Cancer (Brady LW, ed). Masson Publishing U.S.A., Inc.: New 

York. pp 457-460, 1980. 

4. Kimler, BF: Radiation Biology. Chapter 4 in Nuclear Medicine Science Syllabus (Benedetto 

AR, ed). The Society of Nuclear Medicine: New York, NY. pp 65-71, 1982. 

5. Evans RG, Kimler BF, Morantz RA, Vats TS, Liston V, Lowe NL: Perfluorochemical 

emulsion and oxygen with concomitant radiation therapy in primary high grade brain 

tumors. In Concomitant Continuous Infusion Chemotherapy and Radiation (Rotman M, 

Rosenthal CJ, eds). Springer-Verlag: Berlin, Heidelberg. pp 97-100, 1991. 

6. Kimler BF: Radiation therapy of brain tumors: basic principles. In Brain Tumors: A 

Comprehensive Text (Morantz RA, Walsh JW, eds). Marcel Dekker, Inc.: New York. pp 

613-642, 1993. 

7. Fabian CJ, Kimler BF, Mayo MS, Grizzle WE, Masood, S, Ursin G: Clinical approaches to 

discovering and testing new breast cancer prevention drugs. In Cancer Chemoprevention, 

Vol. 2; Strategies for Cancer Chemoprevention (Kelloff GJ, Hawk ET, Sigman CC, eds). 

Humana Press: Totowa, New Jersey. pp 213-237, 2005. 

35


Q. Published Abstracts 

1. Kimler BF, Powers EL: Effect of inert gases on the radiation sensitivity of Bacillus 

megaterium spores. Radiat Res 51:489, 1972. 

2. Kimler BF, Powers EL: Effect of water structure on the radiation sensitivity of Bacillus 

megaterium spores. Radiat Res 55:549, 1973. 

3. Kimler BF, Powers EL: Dosimetry considerations in the radiation biology of bacterial 

spores. Radiat Res 59:284, 1974. 

4. Sinclair WK, Han A, Kimler BF: The effect of N-ethylmaleimide on the response to X-rays 

of synchronized HeLa cells. Radiat Res 62:551, 1975. 

5. Kimler BF, Sinclair WK, Elkind MM: Sensitization of aerobic and hypoxic Chinese hamster 

cells to X-irradiation by N-ethylmaleimide. Radiat Res 62:568, 1975. 

6. Kimler BF: The effect of Adriamycin on cell cycle progression. Proc Amer Assoc Cancer 

Res 17:74, 1976. 

7. Schneiderman MH, Kimler BF, Leeper DB: Hydroxyurea effects on G 2 progression: 

comparison with other drugs and radiation. Radiat Res 67: 584, 1976. 

8. Kimler BF, Schneiderman MH, Leeper DB: The effect of hydroxyurea on radiation-induced 

division delay. Radiat Res 67:584, 1976. 

9. Leeper DB, Kimler BF, Schneiderman MH: Concentration dependence of drug transition 

points in G 2 . Radiat Res 67:585, 1976. 

10. Kimler BF, Schneiderman MH: Screening of cancer chemotherapeutic agents with the 

mitotic selection procedure. Proc Amer Assoc Cancer Res 18:11, 1977. 

11. Schneiderman MH, Kimler BF, Leeper DB, Hofer KG, Kirschner AS: 125 I-UdR-induced 

division delay. Radiat Res 70:692, 1977. 

12. Kimler BF, Snyder MH, Leeper DB: The effect of caffeine on irradiated CHO cells. Radiat 

Res 70:696, 1977. 

13. Kimler BF, Snyder MH, Leeper DB: Modification of radiation-induced division delay by 

caffeine, dibutyryl c-AMP, and theophylline. Radiat Res 74:519 1978. 

14. Kimler BF, Schneiderman MH, Leeper DB: Concentration-dependent blockade in the G 2 

phase by cancer chemotherapeutic agents. Cell Tissue Kinetics 11:679, 1978. 

15. Vats TS, Morantz RA, Kimler BF, Henderson SD, Tilzer S: Therapeutic effectiveness of 

intracerebral bleomycin and radiation therapy in rat brain tumor. Proc Amer Assoc Cancer 

Res 20:285, 1979. 

16. Kimler BF: Interaction of radiation and DHAQ: effect on G 2 progression. Cell Tissue 

Kinetics 12:665, 1979. 

17. Henderson SD, Morantz RA, Kimler BF: The effect of X-irradiation and adjuvant therapy 

on a rat brain tumor. Abstracts of the VIth International Congress of Radiation Research, 

p. 96, 1979. 

18. Reddy EK, Kimler BF, Henderson SD: Comparison of the cytotoxic and radiosensitizing 

properties of misonidazole using rat tumor model systems. Abstracts of VIth International 

Congress of Radiation Research, p. 114, 1979. 

19. Kimler BF: Modification of radiation-induced division delay and cell lethality in mammalian 

cells by cancer chemotherapeutic agents. Abstracts of the VIth International Congress of 

Radiation Research, p. 289, 1979. 

20. Morantz RA, Vats TS, Henderson SD, Kimler BF, Tilzer S: An evaluation of systemic and 

intratumor bleomycin in a brain tumor model. Proc Amer Assoc Neurological Surgeons, 

1980. 

21. Morantz RA, Vats TS, Henderson SD, Kimler BF, Tilzer S: An evaluation of systemic and 

intratumor bleomycin. Proc International Symposium of Brain Tumor Therapy 

(Multidisciplinary Aspects of Brain Tumor Therapy), 1980. 

22. Kimler BF, Cheng CC, Hacker MP, Henderson SD, Mansfield CM: 

Dihydroxyanthraquinone: a new cancer chemotherapeutic agent with radiation-potentiating 

36


properties. Fed Proc 39:1736, 1980. 

23. Vats TS, Morantz RA, Henderson SD, Kimler BF: Combination chemotherapy of an 

experimental brain tumor. Proc Amer Assoc Cancer Res. 21:258, 1980. 

24. Kimler BF: Interaction of radiation and DHAQ: effect on cell survival. Radiat Res 83:372, 

1980. 

25. Henderson SD, Kimler BF: Response of cultured 9L cells to bleomycin and X-rays. Radiat 

Res 83:371, 1980. 

26. Kimler BF: Mechanism of action of razoxane-induced division delay. Cell Tissue Kinetics 

13:665, 1980. 

27. Kimler BF: Radiation-induced division delay in several cultured mammalian cell lines. Cell 

Tissue Kinetics 13:666, 1980. 

28. Henderson SD, Kimler BF: Survival responses of synchronous 9L cells to radiation and 

cancer chemotherapeutic agents. Cell Tissue Kinetics 13:666, 1980. 

29. Vats TS, Kimler BF, Morantz RA, Henderson SD, Tilzer S: Combined modality treatment 

of an experimental rat brain tumor model. Pediatric Res 14:542, 1980. 

30. Kimler BF, Henderson SD, Vats TS, Morantz RA: Optimization of therapy in a rat brain 

tumor (9L) system. Int J Radiat Oncol Biol Phys 6:1369-1370, 1980. 

31. Mansfield CM, Kimler BF, Vats TS, Svoboda DJ, Henderson SD: Assessment of normal 

rat lung damage following radiotherapy-chemotherapy. Int J Radiat Oncol Biol Phys 

6:1400, 1980. 

32. Kimler BF: Comparison of Dihydroxyanthraquinone and Adriamycin: interaction with 

radiation in cultured mammalian cells. Int J Radiat Oncol Biol Phys 6:1400-1401, 1980. 

33. Reddy EK, Kimler BF, Henderson SD, Glover RW, Scanlan MF: Effect of 

dihydroxyanthraquinone on the response of Walker 256 carcinoma to radiation. Int J 

Radiat Oncol Biol Phys 7 (suppl 1):97-98, 1981. 

34. Mansfield CM, Kimler BF, Svoboda DJ, Vats TS, Henderson SD: Development of normal 

tissue damage in rats subsequent to chest irradiation following treatment with drugs. Int J 

Radiat Oncol Biol Phys 7 (suppl 1):103-104, 1981. 

35. Henderson SD, Kimler BF, Vats TS, Morantz RA: Intracerebral bleomycin therapy of 9L rat 

brain tumors. Proc Amer Assoc Cancer Res 22:253, 1981. 

36. Kimler BF, Henderson SD: Cyclic responses of cultured 9L cells to radiation. Radiat Res 

87:399, 1981. 

37. Henderson SD, Kimler BF, Scanlan MF: Interaction of cytotoxic agents on the survival of 

synchronous 9L cells. Radiat Res 87:399, 1981. 

38. Mansfield CM, Kimler BF, Henderson SD, Svoboda DJ, Vats TS: Normal tissue tolerance 

to combined modality therapy. Abstracts of the XVth International Congress of Radiology, 

p 53, 1981. 

39. Morantz RA, Vats TS, Kimler BF, Henderson SD: Brain tumor chemotherapy with intratumor 

bleomycin. Proceedings of the 7th International Congress of Neurological Surgery, 

1981. 

40. Mansfield CM, Kimler BF, Henderson SD, Svoboda DJ, Vats TS: Interaction of radiation 

and bleomycin on the development of pulmonary fibrosis in rats. Int J Radiat Oncol Biol 

Phys 7:1263-1264, 1981. 

41. Kimler BF: Interaction of razoxane and radiation in cultured Chinese hamster cells. Int J 

Radiat Oncol Biol Phys 7:1291, 1981. 

42. Kimler BF, Henderson SD, Vats TS, Morantz RA: Potentiation of radiation therapy by 

combination chemotherapy in the 9L rat brain tumor. Int J Radiat Oncol Biol Phys 7:1292, 

1981. 

43. Henderson SD, McDonald RD, Kimler BF, Mansfield CM, Vats TS, Svoboda DJ: 

Development of an angiotensin-I-converting enzyme assay as a predictor of pulmonary 

fibrosis. Int J Radiat Oncol Biol Phys 7:1294-1295, 1981. 

44. Kimler BF, Cheng CC, Barnes RE, Barnes ML: Effect of amino-substituted anthraquinones 

37


on cell cycle kinetics and survival. Cell Tissue Kinetics 15:104-105, 1982. 

45. Kimler BF, Henderson SD, Mansfield CM, Svoboda DJ, Cheng CC: Interaction of 

Dihydroxyanthraquinone (DHAQ, NSC 279836) and radiation on the induction of toxicity in 

rats. Proc Amer Assoc Cancer Res 23:172, 1982. 

46. Henderson SD, McDonald RD, Kimler BF, Mansfield CM, Vats TS, Svoboda DJ: 

Correlation of angiotensin-I-converting enzyme (ACE) levels with the development of 

normal tissue damage in the rat lung. Proc Amer Assoc Cancer Res 23:194, 1982. 

47. Leeper DB, Kimler BF: 45 o -hyperthermia-induced division delay: sensitivity, recovery 

kinetics, and thermotolerance. Radiat Res 91:282, 1982. 

48. Henderson SD, Kimler BF, Mansfield CM, Svoboda DJ: Late effects of radiation and 

bleomycin on normal rat lung structure. Radiat Res 91:309, 1982. 

49. Henderson SD, Kimler BF, Scanlan MF: Effect of hyperthermia and radiation in the 9L cell 

cycle. Radiat Res 91:313-314, 1982. 

50. Mansfield CM, Kimler BF, Henderson SD, Vats TS: Angiotensin-I-converting enzyme 

levels in the serum of lung cancer patients. Radiat Res 91:343-344, 1982. 

51. Kimler BF: Interaction of radiation and amino-substituted anthraquinones on the survival of 

cultured Chinese hamster cells. Radiat Res 91:346-347, 1982. 


enzyme levels in the serum of cancer patients. Proceedings of the 13th International 

Cancer Congress, p 210, 1982. 

53. Mansfield CM, Kimler BF, Henderson SD, Vats TS, Svoboda DJ: Effects of radiation and 

bleomycin on normal rat lung structure and function. Proceedings of the 13th International 

Cancer Congress, p 378, 1982. 

54. Feaster GR, Kimler BF, Mansfield CM, Henderson SD: A simple plethysmograph for small 

animal respiration studies. Proceedings of the 35th Annual Conference on Engineering in 

Biology and Medicine; vol 24, p 137, 1982. 

55. Mansfield CM, Kimler BF, Henderson SD, Vats TS, Svoboda DJ: Interaction of radiation 

and bleomycin on normal rat lung structure and function. Int J Radiat Oncol Biol Phys 8 

(suppl 1):71, 1982. 

56. Yakar D, Kimler BF, Park CH: Radiation response of human hemopoietic cells (normal and 

leukemic) assayed by in vitro colony formation. Int J Radiat Oncol Biol Phys 8 (suppl 1):72, 

1982. 

57. Kimler BF, Mansfield CM, Svoboda DJ, Henderson SD: Comparison of the effects of 

Dihydroxyanthraquinone (DHAQ, NSC 279836) and Adriamycin on the enhancement of 

radiation-induced toxicity in rats. Int J Radiat Oncol Biol Phys 8 (suppl 1):99, 1982. 

58. Kimler BF, Czapansky DK, Cheng CC: Correlation between chemical structure of aminosubstituted 

anthraquinones and in vitro biological activity. Cell Tissue Kinetics 15:674, 

1982. 

59. Park CH, Kimler BF, Smith TK: Primary cloning of acute non-lymphocyti leukemia cells 

following flow cytometric cell sorting based on DNA content. Proc Am Assoc Cancer Res 

24:310, 1983. 

60. Fabian CJ, Kimler BF, Park CH, Goodwin JW, Stephens RL: Kinetic analysis of human 

breast cancer tissue to monitor efficacy of estrogen stimulation and cytotoxic 

chemotherapy. Proc Am Assoc Cancer Res 24:171, 1983. 

61. Kimler BF, Park CH, Yakar D, Mies RM: Radiation response of human hematopoietic cells 

grown in agar culture. Radiat Res 94:622, 1983. 

62. Mansfield CM, Kimler BF, Feaster GR: Pulmonary function measurements in rats after 

thoracic irradiation. Radiat Res 94:651, 1983. 

63. Kimler BF: Mechanisms of the interaction between amino-substituted anthraquinones and 

ionizing radiation for the induction of mammalian cell lethality. Proceedings of the 

International Congress of Radiation Research; Amsterdam, The Netherlands; 3-7 Jul 

38


1983. 

64. Henderson SD, Kimler BF: Interaction of razoxane (ICRF 187) and radiation on the 

survival of 9L rat brain tumor cells. Proceedings of the International Congress of Radiation 

Research; Amsterdam, The Netherlands; 3-7 Jul 1983. 

65. Kimler BF, Park CH, Yakar D, Mies RM: Do human hematopoietic cells (normal and 

leukemic) demonstrate accumulation of and recovery from radiation-induced sublethal 

damage? Abstracts of the 11th L.H. Gray Conference: Cellular Repair of Radiation 

Damage, Mechanisms and Modifying Agents; Glasgow, Scotland; 18-22 July 1983. 

66. Kimler BF: Enhancement of radiation-induced lethality by amino-substituted 

anthraquinones in cultured Chinese hamster cells. Abstracts of the 11th L.H. Gray 

Conference: Cellular Repair of Radiation Damage, Mechanisms and Modifying Agents; 

Glasgow, Scotland; 18-22 July 1983. 

67. Kimler BF: Modification of the interaction between radiation and dihydroxyanthraquinone 

to produce cytotoxicity in cultured Chinese hamster cells. Int J Radiat Oncol Biol Phys 

9:119, 1983. 


enzyme levels in the serum of lung cancer patients. Int J Radiat Oncol Biol Phys 9:144, 

1983. 

69. Giri PGS, Kimler BF, Giri UP, Reddy EK, Mansfield CM, Cox GG: The effect of 

fractionated thoracic irradiation on the development of normal tissue damage in rats. Int J 

Radiat Oncol Biol Phys 9:168, 1983. 

70. Mansfield CM, Kimler BF, Svoboda DJ, Vats TS, Cox GG: Normal tissue damage in rats 

produced by thoracic irradiation and cancer chemotherapeutic agents that may potentiate 

lung damage. Int J Radiat Oncol Biol Phys 9:171, 1983. 

71. Kimler BF, Feaster GR, Mansfield CM, Cox GG: Plethysmographic measurements of 

normal tissue damage in rats following sublethal thoracic irradiation. Int J Radiat Oncol 

Biol Phys 9:183, 1983. 

72. Park CH, Kimler BF, Smith TK: Superiority of DAPI over Hoescht 33342 for viable cell 

sorting. Cell Tissue Kinet 16:606, 1983. 

73. Kimler BF, Fabian C, Park CH: Stimulation of ER+ breast cancer cells prior to 

administration of cell-cycle-specific chemotherapy. Cell Tissue Kinet 16:609, 1983. 

74. Jamieson TW, DeSmet AA, Kimler BF, Cremer MA, Lindsley HB: Total lymphoid 

irradiation intervention in experimental collagen-induced arthritis. Abstracts of the Central 

Society for Clinical Research; Chicago, IL; Nov 1983. 

75. Kimler BF, Hacker MP, Cox GG: Protection against dihydroxyanthraquinone-induced 

acute toxicity in mice by Adriamycin. Proc Am Assoc Cancer Res 25:316, 1984. 

76. Kimler BF: EFfect of sulfhydryls on potentiation of radiation-induced cell lethality by 

substituted anthraquinones. Abstracts of the Thirty-Second Annual Meeting of the 

Radiation Research Society, p 117, 1984. 

77. Kimler BF, Giri PGS, Giri UP, Cox GG: Potentiation of radiation-induced normal lung 

tissue damage in rats by cancer chemotherapeutic agents. Int J Radiat Oncol Biol Phys 10 

(Suppl 2):147, 1984. 

78. Kimler BF, Jamieson TW, DeSmet AA, Lindsley HB: Total lymphoid irradiation for 

treatment of experimental collagen-induced arthritis in rats. Int J Radiat Oncol Biol Phys 10 

(Suppl 2):148, 1984. 

79. Morantz RA, Vats TS, Kimler BF: Intraneoplastic chemotherapy of primary brain tumors. 

Annual Meeting of the American Association of Neurological Surgeons. Atlanta, GA; 21-25 

Apr 1985. 

80. Kimler BF, Rethorst RD, Cox GG: Investigation of the interaction of radiation and 

cardiotoxic anticancer agents using a fetal mouse heart organ culture system. Abstracts of 

the Thirty-Third Annual Meeting of the Radiation Research Society, p 108, 1985. 

81. Norton S, Kimler BF, Chapman AL, Terranova PF: Long-term consequences of low-level 

39


irradiation of rats in utero. Abstracts of the 33rd Annual Meeting of the Radiation Research 

Society, p 126, 1985. 

82. Giri SPG, Kimler BF, Giri UP, Cox GG, Reddy EK. The effects of single and fractionated 

irradiation of the trunk in rats. Abstracts of the 33rd Annual Meeting of the Radiation 

Research Society, p 127, 1985. 

83. Kimler BF, Rethorst RD, Cox GG: Cardiotoxic effects of radiation and anthraquinones 

investigated in a fetal mouse heart organ culture system. Proceedings of the Seventh 

Annual Pediatric Oncology/Hematology Symposium; Kansas City, MO; 11 April 1985. 

84. Park CH, Kimler BF: Requirement of L-ascorbic acid (LAA) for the growth of colonyforming 

cells (CFC) from leukemic and preleukemic marrows. Proc Amer Assoc Cancer 

Res 26:366, 1985. 

85. Dean RD, Spicer J, Kimler BF: An investigation of boosting dose by interstitial injection of 

Tc-99m-labelled albumin microspheres. Abstracts of the annual meeting of the American 

Association of Physicists in Medicine; Seattle, WA; August 1985. 


against long-term pulmonary fibrosis in rats. 12th L.H. Gray Conference: Assays of 

Normal-tissue Injury and Their Cellular Interpretations; Manchester, U.K.; 2-5 Sep 1985. 



rats. Abstracts for the 12th L.H. Gray Conference: Assays of Normal-tissue Injury and 

Their Cellular Interpretations; Manchester, U.K.; 2-5 Sep 1985. 

88. Kimler BF, Dean, RD, Spicer J: Investigation of the feasibility of intracranial injection of Tc- 

99m-labelled albumin microspheres for localized treatment of brain tumors. Int J Radiat 

Oncol Biol Phys 11 (Suppl 1):165, 1985. 

89. Kimler BF, Giri PGS, Giri UP, Cox GG, Vats TS: Functional damage induced in rats by 

thoracic irradiation and cancer chemotherapeutic agents. Abstracts of the Conference on 

Chemical Modifiers of Cancer Treatment; 20-24 Oct 1985. 

90. Giri SPG, Kimler BF, Giri UP, Cox GG, Vats TS: Potentiation of radiation-induced 

pulmonary fibrosis in rats by cancer chemotherapeutic agents. Abstract of the Conference 

on Chemical Modifiers of Cancer Treatment; 20-24 Oct 1985. 

91. Kimler BF, Held KD: Effect of modification of sulfhydryl levels on the interaction between 

radiation and substituted anthraquinones to produce mammalian cell lethality. Abstracts of 

the Conference on Chemical Modifiers of Cancer Treatment; 20-24 Oct 1985. 

92. Kimler BF, Held KD: Modification of anthraquinone-induced mammalian cell lethality by 

agents that alter sulfhydryl levels. Abstracts of the Conference on Chemical Modifiers of 

Cancer Treatment; 20-24 Oct 1985. 

93. Wulser MJ, Kimler BF: Mitochondrial activity in cultured mammalian cells treated with 

various cytotoxic agents. Cell Tissue Kinet 20:251, 1987. 

94. Kimler BF, Giri PGS, Giri UP, Cox GG: Functional damage induced in rats by various 

schedules of trunk irradiation. Abstracts of the 34th Annual Meeting of the Radiation 

Research Society; p 96, 1986. 

95. Wulser MJ, Kimler BF, Evans RG: Effect of various cytotoxic agents on mitochondrial 

activity in cultured mammalian cells. Abstracts of the 34th annual meeting of the Radiation 

Research Society; p 152, 1986. 

96. O'Connor JE, Kimler BF, Vargas JL, Hernandez-Yago J, Grisolia S: Analisis y aislamiento 

por citometria de flujo de mitocondrias de higado de rata, en funcion de su estado 

energetico, mediante tincion fluorescente con rhodamina 123. Abstracts of the 4th Annual 

Meeting of the Sociedad Espanola de Histoquimica; 24-26 April 1986. 


radiation in the 9L rat brain tumor model. Abstracts of the Conference on Interaction of 

Radiation Therapy and Chemotherapy; Williamsburg, VA; 28 Sep - 1 Oct, 1986. 

98. Martin DF, Kimler BF, Evans RG, Morantz RA, Vats TS: Potentiation of brain tumor 

40


therapy by Fluosol and oxygen. Abstracts of the Conference on Interaction of Radiation 

Therapy and Chemotherapy; Williamsburg, VA; 28 Sep-1 Oct, 1986. 

99. Hart RM, Evans RG, Kimler BF, Park CH: Radiotherapeutic management of 

medulloblastoma in a pediatric patient with ataxia telangiectasia. Int J Radiat Oncol Biol 

Phys 12 (Suppl 1):46, 1986. 

100. Kimler BF, Wulser MJ: Attempts to utilize a new DNA-specific fluorescent dye, LL585, for 

cell cycle analysis. Biology of the Cell 58:11a, 1986. 

101. O'Connor JE, Vargas JL, Kimler BF, Hernandez-Yago J, Grisolia S: Isolated mitochondria 

and flow cytometry. I. Study on the mechanism of Rhodamine-123 uptake by isolated 

mitochondria. Biology of the Cell 58:14a, 1986. 

102. O'Connor JE, Kimler BF, Vargas JL, Zaragoza R, Hernandez-Yago J, Grisolia S: Isolated 

mitochondria and flow cytometry. II. Effect of a long-term high-protein diet on rat liver 

mitochondria. Biology of the Cell 58:14a, 1986. 

103. Kimler BF, Norton S: Anatomic defects and behavioral abnormalities in rats irradiated in 

utero. Abstracts of the 35th Annual Meeting of the Radiation Research Society, p 78, 

1987. 

104. Martin DF, Kimler BF, Evans RG, Morantz RA, Vats TS: Effect of Fluosol and carbogen on 

rat brain tumor therapy. Abstracts of the 35th Annual Meeting of the Radiation Research 

Society, p 101, 1987. 

105. Wulser MJ, Kimler BF, Evans RG: Radioprotective properties of a DNA-specific 

fluorescent dye. Abstracts of the 35th Annual Meeting of the Radiation Research Society, 

p 122, 1987. 

106. O'Connor JE, Kimler BF, Vargas JL, Hernandez-Yago J, Grisolia S: Flow cytometric 

analysis of mammalian mitochondria using Rhodamine-123. Cell Tissue Kinetics 20:635, 

1987. 

107. Wulser MJ, Kimler BF: Problems with LL585, a new DNA-specific fluorescent dye, for 

mammalian cell analysis. Cell Tissue Kinetics 20:636, 1987. 

108. Kimler BF, Park CH, Evans RG: The human bone marrow colony assay as a predictor of 

response. Abstracts of the Conference on Prediction of Tumor Treatment Response, p C- 

22; Banff, Canada; 21-24 Apr 1987. 

109. Kimler BF, Norton S: Correlation of behavioral changes and structural defects in rats 

irradiated in utero. Radiation Research - Proceedings of the 8th International Congress of 

Radiation Research, Vol 1:197, 1987. 

110. Martin DF, Kimler BF, Evans RG, Morantz RA, Vats TS: Use of Fluosol and carbogen as 

an adjuvant to rat brain tumor therapy. Radiation Research - Proceedings of the 8th 

International Congress of Radiation Research, Vol 1:298, 1987. 

111. Kimler BF, Norton S: Effects of in utero exposure to ionizing radiation on subsequent 

growth and development in the rat. Int J Radiat Oncol Biol Phys 13(Suppl I):157, 1987. 

112. O'Connor JE, Morgan MC, Kimler BF: A new flow cytometric method for determination of 

glutathione using mercury orange and visible laser. Biology of the Cell 61:13a, 1987. 

113. Norton S, Kotkoskie L, Kimler BF: A model system for reversible and irreversible reponses 

of the developing central nervous system to toxic agents. Toxicologist 8:245, 1988. 

114. Kimler BF, Wulser MJ, Cox GG: Effect of thiol manipulation on toxicity and therapeutic 

efficacy of combinations of substituted anthraquinones in the murine L1210 leukemia 

model. Abstracts of the Conference on Chemical Modifiers of Cancer Treatment; Paris, 

France; 21-25 Mar 1988. 

115. Durham FJ, Kimler BF, Estes NC, Snyder J: Alteration of cell cycle kinetics by nutritional 

manipulation in the rat mammary AC33 tumor model. Cell Tissue Kinet 21:60, 1988. 

116. Estes NC, Kimler BF, Durham FJ: Effect of nutritional manipulation and hyperthermia on 

proliferation of rat mammary AC33 tumor cells. Abstracts of the 8th Annual Meeting of the 

North American Hyperthermia Group; p 12, 1988. 

117. Kimler BF, Norton S, Cytacki EP, Rosenthal SJ: Comparison of the effects produced by in 

41


utero exposure to ionizing radiation versus ultrasound. Abstracts of the Annual Meeting of 

the Radiation Research Society; p 132, 1988. 

118. Martin DF, Kimler BF, Evans RG, Morantz RA, Vats TS: Interaction of radiation and 

intracranial bleomycin in the 9L rat brain tumor model. Abstracts of the Annual Meeting of 

the Radiation Research Society; p 159, 1988. 

119. Estes NC, Snyder J, Durham FJ, Kimler BF: A model for nutritional manipulation of cell 

cycle kinetics of rat mammary AC33 tumor cells. Proc Am Soc Clin Oncol 7:282, 1988. 

120. Park CH, Kimler BF, Bodensteiner D, Lynch SR: The clinical implication and prognostic 

value of in vitro L-ascorbic acid (LAA) sensitivity of clonogenic cells in myelodysplastic 

syndrome (MDS). Proc Am Assoc Cancer Res 29:211, 1988. 

121. Fabian C, Park C, Jewell W, Kimler B, Lin F, Martino S, Osborne CK: Increase in 

proliferation fraction in breast cancer in vivo following estradiol vaginal suppositories as 

demonstrated by serial biopsies and flow cytometry. Proc Am Assoc Cancer Res 29:236, 

1988. 

122. Wesselius LJ, Kimler BF: Increased proliferative rate of alveolar macrophages (AM) 

following radiation injury. Am Rev Respir Dis 137:40, 1988. 

123. Floreani A, Wesselius L, Kimler BF: The effects of corticosteroids on BAL cells and 

respiratory rate in rats after thoracic irradiation. Am Rev Respir Dis 137:525, 1988. 

124. Park CH, Kimler BF, Bodensteiner D: Divergent effects of growth factors on leukemic 

progenitor cells: self-renewal vs differentiation. Exptl Hematol 16:509, 1988. 

125. Evans RG, Kimler BF, Morantz RA, Vats TS, O'Kell V, Lowe N: A Phase I-II study of the 


grade brain tumors. Abstracts of the 7th annual meeting of the European Society for 

Therapeutic Radiology and Oncology, p 336, 1988. 

126. Evans RG, Kimler BF, Martin DF, Morantz RA, Vats TS: Combination of radiation therapy 

and intracranial bleomycin in the 9L rat brain tumor model. Abstracts of the 7th annual 

meeting of the European Society for Therapeutic Radiology and Oncology, p 148, 1988. 

127. Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS: Combination of radiation therapy 

and intracranial bleomycin in the 9L rat brain tumor model. Int J Radiat Oncol Biol Phys 

15(Suppl I):150-151, 1988. 

128. Floreani AF, Kimler BF, Wesselius LJ: Effect of corticosteroid treatment on the 

development of pulmonary changes subsequent to thoracic irradiation in the rat. Int J 

Radiat Oncol Biol Phys 15(Suppl I):251, 1988. 

129. O'Connor JE, Gollerkeri A, Kimler BF: Flow cytometric analysis of cytotoxic effects of 

ammonia on murine neuroblastoma. Basic Appl Histochem 32:379, 1988. 

130. Rosenthal SJ, Cytacki E, Kimler BF, Norton S: Fetal damage following ultrasound 

exposure of the pregnant rat. Abstracts of the Fifth Meeting of the World Federation for 

Ultrasound in Medicine and Biology; Washington, DC; 17-21 Oct 1988. 

131. McMillan JH, Cox GG, Batnitzky S, Spicer S, Kimler BF, Khan J: Metalloporphyrin as MR 

contrast agent. Radiology 169 (Suppl):426, 1988. 

132. Kimler BF, Norton S, Cytacki EP, Rosenthal SJ: Are the effects of fetal rat ultrasound 

exposure on brain development due to heating? Abstracts of 9th Annual Meeting of the 

North American Hyperthermia Group; p 69; Seattle, WA; 18-23 Mar 1989. 

133. Kimler BF, McMillan JH, Cox GG, Batnitzky S: Magnetic resonance imaging of rat brain 

tumors using a novel metalloporphyrin contrast agent. Abstracts of the 37th Annual 

Meeting of the Radiation Research Society; p 129; Seattle, WA; 18-23 Mar 1989. 

134. Evans RG, Kimler BF: Development of an animal tumor model for intra-operative radiation 

therapy. Abstracts of the 37th Annual Meeting of the Radiation Research Society; p 181; 

Seattle, WA; 18-23 Mar 1989. 

135. McMillan JH, Cox GG, Batnitzky S, Spicer JS, Kimler BF, Khan JZ: Manganese 

uroporphyrin I as MRI contrast agent. Abstracts of the 27th Annual Meeting of the 

American Society of Neuroradiology; p E32; Orlando, FL; 19-24 Mar 1989. 

42


136. O'Connor JE, Kimler BF, Gollerkeri A: Metabolic effects of ammonia on cultured murine 

neuroblastoma cells. Cell Tissue Kinet 22:87, 1989. 

137. Estes NC, Kimler BF, Peterson S, Durham FJ: The effects of nutritional variation on 

hyperthermia-induced tumor cell proliferation. Cell Tissue Kinet 22:87, 1989. 

138. Morantz RA, Evans RG, Kimler BF, Vats TS, Lowe N: A Phase I-II study of the use of 

Fluosol as an adjuvant to radiation therapy in the treatment of high grade brain tumors. 

Abstracts of the annual meeting of the American Association of Neurological Surgeons; p 

374; Washington, D.C.; 2-6 Apr 1988. 

139. Evans RG, Kimler BF, Morantz RA, Vats TS, Liston V, Lowe NL: A phase I-II study of the 

use of Fluosol-DA 20% and oxygen with concomitant radiation therapy in the treatment of 

primary high-grade brain tumors. Abstracts of the Second Conference on the Clinical 

Applications of Concomitant Infusion Chemotherapy and Radiation; New York, NY; 6-8 

Apr 1989. 

140. Evans RG, Kimler BF, Martin DF, Morantz RA, Vats TS: Combination of infusional 

intracranial Bleomycin and radiation therapy in an experimental brain tumor model. 

Abstracts of the Second Conference on the Clinical Applications of Concomitant Infusion 

Chemotherapy and Radiation; New York, NY; 6-8 Apr 1989. 

141. McMillan JH, Cox GG, Batnitzky S, Spicer JS, Kimler BF, Khan JZ: Manganese 

uroporphyrin I as MRI contrast agent. Abstracts of the 89th Annual Meeting of the 

American Roentgen Ray Society; p 275; New Orleans, LA; 7-12 May 1989. 

142. Evans RG, Kimler BF, Morantz RA, Vats TS, Gemer LS, O'Kell V, Lowe N: A Phase I-II 

study of the use of Fluosol-DA 20% as an adjuvant to radiation therapy in the treatment of 

primary high-grade brain tumors. Int J Radiat Oncol Biol Phys 17 (Suppl 1):175-176, 1989. 

143. Gemer, LS, Kane SA, Gilles C, Kimler BF, Smalley SR, Hassanein R: Radiation-induced 

vascular changes: a canine model for intraoperative radiation therapy. Int J Radiat Oncol 

Biol Phys 17 (Suppl 1):245-246, 1989. 

144. Evans RG, Kimler BF, Estes NC, Gemer LS, Smalley SR, Price DM: Interaction of intraoperative 

radiation therapy and cis-platinum in an intra-abdominal rat tumor model. 

Abstracts of the Third International Conference on the Interaction of Radiation Therapy 

and Systemic Chemotherapy. Asilomar, CA; 9-12 Mar 1990 (abstract 1-16). 

145. Smalley SR, Kimler BF, Evans RG: Modulation of the radiosensitivity of cultured human 

carcinoma cells by treatment with 5-fluorouracil. Abstracts of the Third International 

Conference on the Interaction of Radiation Therapy and Systemic Chemotherapy. 

Asilomar, CA; 9-12 Mar 1990 (Abstract 1-3). 

146. Kimler BF, Norton S, Chrzanowski S: Acute morphological effects of ionizing radiation in 

the developing fetal rat brain. Abstracts of the 38th annual meeting of the Radiation 

Research Society; New Orleans, LA; 6-12 Apr 1990 (Abstract Cy-22). 

147. O'Connor JE, Matthes M, Costell M, Kimler BF: Effect of oral administration of carnitine on 

spermatogenesis in aging mice. Cell Tissue Kinet 23:359, 1990. 

148. O'Connor JE, Costell M, Kimler BF, Petit P: Flow cytometric analysis of ammonia 

cytotoxicity. Reunion International de Citometria; Salamanca, Spain; 20-22 Jun 1990; pp 

32-39. 

149. Costell M, O'Connor JE, Matthes M, Kimler BF: Carnitine stimulates spermatogenesis in 

aging mice, as shown by flow cytometric analysis of DNA in testis. Reunion International 

de Citometria; Salamanca, Spain; 20-22 Jun 1990; p 107. 

150. Giri SPG, Kimler BF, Giri UP, Cox GG: Effect of fractionation on radiation-induced normal 

lung damage in rats. Abstracts of the 15th International Cancer Congress; Hamburg, 

Germany; 16-22 Aug 1990. J Cancer Res Clin Oncol, 1990. 

151. Park CH, Kimler BF: Growth modulation of human leukemic and preleukemic progenitor 

cells by L-ascorbic acid. Abstracts of the Symposium on "Ascorbic Acid: Biological 

Functions and Relationship to Cancer"; Washington, D.C.; 10-12 Sep 1990; pp 55-56. 

152. Smalley SR, Kimler BF, Evans RG, Dalziel WC: Effect of 5-FU on mammalian cell 

43


radiosensitivity. Abstract presented at the Annual Meeting of the European Society of 

Therapeutic Radiology and Oncology; Montecantini Terme, Italy; 12-15 Sep 1990. 

153. Kimler BF, Evans RG, Smalley SR, Gemer LS, Peterson SL: A rat intra-abdominal tumor 

model for investigation of intra-operative radiation therapy. Int J Radiat Oncol Biol Phys 

19(Suppl 1):158, 1990. 

154. Smalley SR, Kimler BF, Evans RG, Dalziel WC: Mammalian cell heterogeneity to 

modulation of radiosensitivity by 5-fluorouracil. Int J Radiat Oncol Biol Phys 19(Suppl 

1):184, 1990. 

155. Kimler BF, O'Connor JE: Cytometric analysis of metabolic alterations in mammalian cells. 

Proceedings of the International Workshop on Flow and Image Cytometry; Porto, Portugal; 

18 Feb-1 Mar 1991. 

156. Kimler BF, Vidal-Pergola GM, Norton S: Effect of ionizing radiation on cell cycle kinetics in 

the fetal cerebral cortex of rats. Cell Prolif 24: 421, 1991. 

157. O'Brien-Ladner AR, Kimler BF, Wesselius LJ: Human alveolar macrophages release 

interleukin-1" in response to in vitro irradiation. Respiratory Disease 143:A391, 1991. 

158. Fabian CJ, Tranin A, McKittrick R, Zollas C, Zeiger S, Hassanein R, Lin F, Kimler BF: 

Incidence of overexpression of ER, EGFR, and ploidy abnormalities in a high risk group for 

breast cancer. Proc Am Soc Clin Oncol 10:61, 1991. 

159. Kimler BF, Vidal-Pergola GM, Norton S: Recovery from sublethal radiation damage in the 

fetal cerebral cortex of rats: acute morphological effects. Radiation Research - A Twentieth 

Century Perspective. Chapman JD, Dewey WC, Whitmore GF, eds. Proceedings of the 

IXth International Congress of Radiation Research; Toronto, Canada; 7-12 Jul 1991. p 

186. 

160. Vidal-Pergola GM, Kimler BF, Norton S: Recovery from sublethal radiation damage in the 

fetal cerebral cortex of rats: postnatal behavior and brain structure. Radiation Research - A 

Twentieth Century Perspective. Chapman JD, Dewey WC, Whitmore GF, eds. 

Proceedings of the IXth International Congress of Radiation Research; Toronto, Canada; 

7-12 Jul 1991. p 186. 

161. Kimler BF, Evans RG, Morantz RA, Batnitzky S: Lack of long-term complications 

subsequent to the use of Fluosol and oxygen as adjuvant to radiation therapy for highgrade 

malignant brain tumors. J Neuro-Oncol 12:265, 1992. 

162. Fabian CJ, Tranin A, Zeiger S, Zalles C, Kamel S, McKittrick R, Hassanein R, Kimler BF, 

Vergara G: Correlation of aneuploidy, atypical hyperplasia, and overexpressed ER and 

EGFR in random breast aspirates with breast cancer risk estimates based on personal 

and family history in a high risk population. Breast Cancer Res Treatment 19:210, 1991. 

163. Kimler BF, Liu C, Evans RG, Morantz RA: Intra-cranial chemotherapy plus radiation 

therapy in the 9L rat brain tumor model. Abstracts of the 40th annual meeting of the 

Radiation Research Society; Salt Lake City, UT; 14-19 Mar 1992; p 98. 

164. Fabian CJ, McKittrick R, Zalles C, Kamel S, Tranin A, Zeiger S, Lin F, Kimler BF: Cell 

cycle kinetics in breast aspirates of women at high risk for breast cancer. Cell Prolif 

25:387, 1992. 

165. Kimler BF, Dalziel WC, Mitchell DS, Smalley SR, Evans RG: Possible mechanisms for the 

enhancement of radiation-induced cell kill by 5-Fluorouracil in V79 cells. Cell Prolif 25:370, 

1992. 

166. Li, X, Vidal-Pergola GM, Kimler BF: Cellular effects of radiation in the cerebral cortex of 

rats on gestational days 14-16. Cell Prolif 25:385, 1992. 

167. Park CH, Kimler BF: Biomodulation of in vitro colony formation from malignant 

hematopoeitic progenitor cells. Cell Prolif 25:369, 1992. 

168. Liu C, Kimler BF, Evans RG, Morantz: Intracerebral chemotherapy in the 9L rat brain 

tumor model. Proc Am Assoc Cancer Res 33:444, 1992. 

169. Liu C, Kimler BF, Evans RG, Morantz: Immune adjuvants plus chemotherapy or 

radiotherapy in the 9L rat brain tumor model. Proc Am Assoc Cancer Res 33:331, 1992. 

44


170. Park CH, Kimler BF, Estrov Z, Deisseroth AB, Williams DE, Gillis S: Enhancement by c-kit 

ligand of leukemic colony formation in acute myelogenous leukemia. Proc Am Assoc 

Cancer Res 33:81, 1992. 

171. Kamel S, Zeiger S, McKittrick R, Tranin A, Zalles C, Kimler BF, Lin F, Fabian CJ: 

Overexpression of p53 protein in breast aspirates of women at high risk for breast cancer. 

Proc Am Assoc Cancer Res 33:263, 1992. 

172. Kimler BF, Vidal-Pergola GM, Peterson SL, Li X, Norton S: Effect of in utero radiation dose 

fractionation on rat postnatal development, behavior, and brain structure: 3 hour interval. 

NeuroToxicology 13:876, 1992. 

173. Evans RG, Kimler BF, Morantz RA, Batnitzky S: Lack of complications in long-term 

survivors after treatment with Fluosol and oxygen as an adjuvant to radiation therapy for 

high-grade malignant brain tumors. Int J Radiat Oncol Biol Phys 24(Suppl 1):143-144, 

1992. 

174. Smalley SR, Kimler BF, Dalziel WC, Mitchell DS, Evans RG: 5-Fluorouracil enhances 

radiation-induced killing of V-79 cells by a variety of mechanisms. Int J Radiat Oncol Biol 

Phys 24(Suppl 1):307-308, 1992. 

175. Kimler BF: Cytometry for breast cancer: prognosis, therapy, prediction. Abstracts of the 

Meeting of the Sociedad Iberica de Citometria Valencia, Spain; 19-21 Nov 1992. 

176. Kimler BF: Cytometric evaluation of cellular drug resistance. Abstracts of the Meeting of 

the Sociedad Iberica de Citometria Valencia, Spain; 19-21 Nov 1992. 

177. Sancho-Tello, M, Terranova PF, Justice WM, Kimler BF: Evaluación por citometría de flujo 

de la regulación de TNF" sobre el crecimiento de células de carcinoma ovárico humano. 

Abstracts of the Meeting of the Sociedad Iberica de Citometria Valencia, Spain; 19-21 Nov 

1992. 

178. Kamel S, McKittrick R, Zalles C, Kimler BF, Lin F, Fabian CJ: An immunocytochemical 

study of p53 protein in breast aspirates of women at high risk for breast cancer: correlation 

with other molecular and cytologic abnormalities. Breast Cancer Res Treatment 23:131, 

1992. 


fractionation on rat postnatal development, behavior, and brain structure: time course of 

recovery. Abstracts of the Annual Meeting of the Radiation Research Society; Dallas, TX; 

19-25 Mar 1993; p 172. 

180. Fabian C, Kamel S, McKittrick R, Zalles C, Chin T, Kimler B: Prevalence of abnormal 

biomarkers in fine needle aspirates in a high risk population: Potential for use in risk 

prediction. Proc Am Assoc Cancer Res 34:261, 1993. 

181. Kimler BF, Hurwitz A, Peterson SL, Li Y: Paradoxical reversal of therapeutic efficacy of 5- 

fluorouracil by morphine in rodent models of colon cancer in the liver. Proc Am Assoc 

Cancer Res 34:391, 1993. 

182. Sancho-Tello, M, Kimler BF, Hunter VJ, Terranova PF: Progressively enhanced 

degradation of bioactive tumor necrosis factor-" by human ovarian epithelial carcinoma 

cells during cytostasis in vitro. Proc Am Assoc Cancer Res 34:441, 1993. 

183. Kimler BF, Fabian CJ, Kamel S, McKittrick R, Zalles C: Prediction of breast cancer risk 

based on cytologic characteristic of cells from random breast aspirates. Cell Proliferation 

26:369, 1993. 

184. Sancho-Tello M, Terranova PF, Justice WM, Kimler BF: Tumor necrosis factor-" inhibits 

growth of human ovarian epithelial carcinoma cells in vitro. Cell Proliferation 26:379, 1993. 

185. Kimler BF: Introduction to flow cytometry. Abstracts of the Third Annual Meeting of the 

Iberian Society of Cytometry; 15-18 Nov 1993; Porto, Portugal. 

186. Kimler BF, Fabian CJ, McKittrick R: Flow cytometric verification of cell cycle recruitment 

by estradiol in women with locally advanced breast cancer. Abstracts of the Third Annual 

Meeting of the Iberian Society of Cytometry; 15-18 Nov 1993; Porto, Portugal. 

45


187. Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SPG, Kimler BF: Retrospective 

ploidy analysis by image and flow cytometry in head and neck cancer. Abstracts of the 

Third Annual Meeting of the Iberian Society of Cytometry; 15-18 Nov 1993; Porto, 

Portugal. 

188. Hunter V, Sancho-Tello M, Kimler BF, Terranova PF: Alteration of the tumor necrosis 

factor-" (TNF) bioactive to immunoactive ratio by human ovarian epithelial carcinoma cells 

in vitro. Presented at the Annual Meeting of the Society of Gynecologic Oncologists, 6-9 

Feb 1994. 

189. Kimler BF: Correlations between radiation-induced acute cellular changes in the 

developing rat cerebral cortex. Cell Prolif 27:416, 1994. 

190. Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SPG, Kimler BF: Comparative 

retrospective DNA ploidy analysis by image and flow cytometry in head and neck cancer. 

Cell Prolif 27:426, 1994. 

191. Fabian C, Zalles C, Kamel S, McKittrick R, Kimler B, Zeiger S, Simon C, Moore B: 

Correlation of breast tissue biomarkers with hyperplasia and dysplasia in fine needle 

aspirates (FNA's) of women at high and low risk for breast cancer. Proc Am Assoc 

Cancer Res 35:286, 1994. 

192. Kimler BF: Analysis of radiation therapy - chemotherapy interactions in the 9L rat brain 

tumor model. Proc Am Assoc Cancer Res 35:647, 1994. 

193. Park CH, Kimler BF, Cobos E, Keung Y-K, Morgan D, Oberleas D, Pelley J, Park MH, 

Kang WK, Yoon SS, Kim DW: Growth modulation by L-ascorbic acid of leukemic 

progenitor cells in acute myeloid leukemia and myelodysplastic syndromes. Symposium 

on Therapeutic Potential of Biological Antioxidants; Tiburon, CA; 29 Sep - 1 Oct 1994; 

Abstract No. 26. 

194. Maidment BW, Gorman P, Schrieber K, Brown R, Portnoy JM, Kimler BF: Collection of 

airborne biological organisms using the aqueous spinning vortex collector (SpinCon®) and 

analysis by flow cytometry using laser light scatter and fluorescence. Scientific 

Conference on Chemical and Biological Defense Research. Aberdeen Proving Ground, 

MD; 15-18 Nov 1994. 

195. Wulser MJ, Kimler BF: Cell death and dead cell removal in the irradiated fetal rat brain. 

Cell Prolif 28:293, 1995. 

196. Kimler BF, Sztern MI, Looney GA, Pinson DM, Bauer KD, Hurwitz A: Hypergastrinemia 

due to omeprazole does not alter cell kinetics of carcinogen-induced colon tumors in rats. 

Cell Prolif 28:300, 1995. 

197. Kimler BF, Park CH: Correlation between plating efficiency and radiosensitivity of human 

normal hematopoietic but not leukemic progenitor cells grown in an agar clonogenic 

assay. Annual Meeting of the Radiation Research Society; San Jose, CA; 1-6 Apr 1995. 

198. McKittrick R, Fabian C, Kamel S, Simon C, Kimler B, Zeiger S, Zalles C, Chiga M: 

Dysplasia and other biomarker abnormalities as potential surrogate biomarkers in breast 

chemoprevention trials. Proc Am Assoc Clin Oncol 14:166, 1995. 

199. Liu YP, Liu J, Kimler BF, Palmiter RD, Klaassen CD: Metallothionen-I transgenic mice are 

not protected from radiation or cisplatin. International Congress of Toxicology - VII; 2-6 Jul 

1995; Abstract 102-P-5. 

200. Kimler BF, Cox GG, Wulser MJ, Peterson SL, Norton S: Dose fractionation of in utero 

irradiation: effect on rat postnatal development, behavior, and brain structure. 

Proceedings of the Tenth International Congress of Radiation Research; Vol 1:414, 1995. 

201. Fabian CJ, Kamel S, Kimler BF, Bacus JW: Identification of a chemoprevention cohort 

from a high risk for breast cancer population. Abstracts of the Conference on Prospects 

for Chemoprevention in Cohorts with Cancer Risk Markers; Easton, MD; 5-7 Oct 1995. 

202. Kimler BF, Kamel S, McKittrick R, Zalles C, Zeiger S, Simon C, Fabian CJ: Potential 

biomarkers for prediction of breast cancer risk. Abstracts of The Lovelace Institutes 

Symposium on Mechanisms and Prevention of Environmentally Caused Cancers; Santa 

46


Fe, NM; 21-25 Oct 1995. 

203. Kamel S, Kimler BF, Zeiger S, McKittrick R, Zalles C, Simon C, Fabian CJ: p53 protein 

overexpression predicts premalignant changes in the breast. Abstracts of The Lovelace 

Institutes Symposium on Mechanisms and Prevention of Environmentally Caused 

Cancers; Santa Fe, NM; 21-25 Oct 1995. 

204. Kimler BF, Kamel S, McKittrick R, Zalles C, Simon C, Fabian CJ: Prediction of 

development of breast cancer. Cell Prolif 29:204,1996. 

205. O'Connor JE, Kimler BF, Costell M, Viña J: Ammonia cytotoxicity involves mitochondrial 

disfunction, impairment of lipid metabolism and oxidative stress. Abstracts of the 

Congress of the International Society of Analytical Cytology; Rimini, Italy; 13-18 Apr 1996; 

abstract SIII8. 

206. Kimler BF, Wulser WJ: Production and removal of radiation-induced damaged cells in the 

fetal rat brain. Annual Meeting of the Radiation Research Society; Chicago, IL; 14-17 Apr 

1996. 

207. Kamel S, Zeiger S, Zalles C, McKittrick R, Kimler BF, Simon C, Fabian CJ: p53 Protein 

overexpression is associated with premalignant cytologic changes in the breast. Proc Am 

Assoc Cancer Res 37:214, 1996. 

208. Kimler BF, Cox GG, Wulser MJ, Peterson SL, Norton S: Postnatal development and 

behavioral effects of prenatal irradiation. Abstracts of the 17th European Winter 

Conference on Brain Research; ARC 2000, France; 8-15 Mar 1997. 

209. Kimler BF, Morantz RA, Kepes JJ, Evans RG: Long-term survival following radiation 

therapy plus Fluosol and oxygen for high-grade brain tumors. Abstracts of the 45 th Annual 

Meeting of the Radiation Research Society, p 154, 1997. 

210. Fabian CJ, Zalles C, Kamel S, Kimler BF: Short term development of breast cancer is 

predicted by fine needle aspiration cytology and cellular biomarkers. Proc Am Soc Clin 

Oncol 16:129a, 1997. 

211. Smalley S, Lew D, Thompson I, Sarosdy M, Stephens R, Noble M, Kimler B: Protracted 

venous infusion (PVI) 5-FU and radiation as definitive therapy for stage C prostate cancer 

- a Southwest Oncology Group phase II study. Proc Am Soc Clin Oncol 16:343a, 1997. 

212. Kimler BF: Prenatal irradiation: a major concern for the developing brain. Abstracts of the 

Annual Meeting of the Association for Radiation Research and the 28 th Annual Meeting of 

the European Society for Radiation Research; Oxford, England; 24-26 Sep 1997. 

213. Kimler BF, Fabian CJ, Zalles CM, Kamel S: Selection of surrogate biomarkers for breast 

cancer chemoprevention trials. Abstracts of the Workshop on Cancer Chemoprevention in 

the Era of Genetic Diagnosis; Haifa, Israel; 22-24 June 1998. 

214. Kimler BF, Fabian CJ: Models for phase I/II breast cancer chemoprevention trials. 

Abstracts of the Workshop on Cancer Chemoprevention in the Era of Genetic Diagnosis; 

Haifa, Israel; 22-24 June 1998. 

215. Ellis R, Fabian CJ, Kimler BF, Fruehauf JP: Correlation between extreme drug 

resistance and clinical response in primary breast cancer. Proc Am Soc Clin Oncol 

18:210a, 1999. 

216. Park CH, Kim WS, Lee MH, Yoon S-S, Koh WS, Park MH, Lee H, Park C, Lee SJ, Kang 

WK, Park K, Hong S-I, Chung M-H, Kimler BF: Suppression of disease progression in 

acute myeloid leukemia by in vivo manipulation of L-ascorbic acid. Exptl Hematol 

27(Suppl. 1):75, 1999. 

217. Kimler BF: Radiation-induced cellular changes in the fetal rat brain. International 

Congress of Radiation Research; Dublin, Ireland; 18-23 July 1999. 

218. Park CH, Kim WS, Park C, Lee MH, Boo YC, Yoon S-S, Park MH, Lee H, Lee SJ, Riordan 

NH, Rubin D, Kimler BF: Clinical disease suppression and reduction in acute myeloid 

leukemia and solid tumors by very high dose of L-ascorbic acid : a new concept and in 

search of molecular targets. Clin Cancer Res 5(Suppl):3784S, 1999. 

219. Zalles CM, Masood S, Kimler BF, Fabian CJ: Application of the Masood scoring system to 

random fine needle aspirate specimens from women at high risk for breast cancer. 5 th 

47


Annual Multidiscipliinary Symposium on Breast Disease; Rome, Italy; 13-16 Feb 2000. 

220. Fabian CF, Kimler BF, Brady D, Zalles CM, Zeiger S, Kitchen J, Engelken M: Feasibility of 

a Phase II chemoprevention trial using breast tissue obtained by random FNA. First 

International Conference on Tumor Prevention and Genetics 2000. St. Gallen, 

Switzerland; 17-19 Feb 2000. 

221. Klemp J, Fabian CJ, Brady D, Kimler BF: Incidence of BRCA1/2 mutation carriers in a high 

risk cohort participating in a Phase II (biomarker) chemoprevention trial. First International 

Conference on Tumor Prevention and Genetics 2000. St. Gallen, Switzerland; 17-19 Feb 

2000. 

222. Wang F, Krishnan L, Tawfik O, Ren YF, Kimler BF, Miller RD, Chapman JA, Weed JC: 

Prognostic significance of apoptosis in cancer of the cervix. Abstracts of the 47 th Annual 

Meeting of the Radiation Research Society; 29 Apr - 3 May 2000; Albuquerque, NM; p 74. 

223. Fabian CJ, Kimler BF, Anderson J, Tawfik O, Mayo MS, O’Shaughnessy JA, Albain KS, 

Burak WE Jr, Idhe JK, Ganz PA, Budd GT, Lawrence JA: Phase I biomarker and toxicity 

evaluation of LY353381 (a 3 rd generation selective estrogen receptor modulator, SERM) in 

breast cancer. Proc Am Soc Clin Oncol 19:75, 2000. 

224. Park CH, Kimler BF, Kim WS, Park SH, Yoon S-S, Lee MH, Park K, Jeong HS, Lee SS, 

Lee SJ, Park HK, Park MH, Han SS, Oh W-I, Kim SH, Kim D-W, Rha MY, Ha JE, Park EY, 

Kim M, Kim S, Kim JA, Kim DW: Control of leukemia by extremes of vitamin C (L-ascorbic 

acid) level. Proceedings of the15th International Conference on the Human Functioning, 

Sept.22-24, 2000, Wichita, KS. 

225. Kim WS, Park SH, Yoon S-S, Lee MH, Park MH, Han SS, Lee SJ, Park HK, Kim D-W, Kim 

SH, Oh W-I, Rha MY, Ha JE, Park EY, Kim S, Kimler BF, Park CH: Clinical response in 

acute myeloid leukemia with manipulation of L-ascorbic acid level in vivo to its extremes. 

Am Soc Hematology, 1-5 Dec 2000; San Francisco, CA. 

226. Fabian CJ, Kimler BF, Brady D, Zalles CM, Mayo MS, Masood S, Grizzle WE: Phase II 

chemoprevention trial of DFMO using the random FNA model. Breast Cancer Res 

Treatment 64:48, 2000. 

227. Ellis RJ, Kimler BF, Fabian CJ, Tawfik O, Mehta RS, Kyshtoobayeva A, Fruehauf JP: 

Angiogenesis index (AI) is associated with early recurrence in patients presenting with 

primary breast cancer. Breast Cancer Res Treatment 64:101, 2000. 

228. Kimler BF, Zalles CM, Masood S, Kitchen J, Grizzle WE, Arneson DW, Mayo MS, Fabian 

CJ: Phase II chemoprevention trial of "-difluoromethylornithine (DFMO) in women at high 

risk for breast cancer: surrogate endpoint biomarkers. Proc Am Assoc Cancer Res 

42:826, 2001. 

229. Fabian CJ, Kimler BF, Brady DA, Ferraro JA, Mayo MS, Arneson DW: No detectable 

improvement in clinical parameters or increased side effects in a placebo-controlled phase 

II breast chemoprevention trial of "-difluoromethylornithine (DFMO). Proc Am Assoc 

Cancer Res 42:308, 2001. 

230. Fabian CJ, Kimler BF, Brady D, Ferraro JA, Mayo MS, Arneson DW: Lack of Auditory 

Toxicity in a Phase II breast chemoprevention trial of "-difluoromethylornithine (DFMO). 

Proc Am Soc Clin Oncol 20:33b, 2001. 

231. Kim WA, Lee MH, Chung CW, Kim K, Han SS, Park Q, Sung KW, Kimler BF, Park CH: 

Clinical response in AML with manipulation of L-Ascorbic Acid (LAA) level in vivo to its 

extremes. Experimental Hematology 29(suppl 1):25, 2001. 

232. Fabian CJ, Anderson J, Chamberlain C, Kimler BF, Mayo MS, O'Shaughnessy JA, Lynch 

HT, Johnson KA: Change in serum dehydroepiandrosterone, testosterone, insulin-like 

growth factor-1, and osteocalcin levels with the third generation selective estrogen 

receptor modulator arzoxifene (LY353381HCI). Breast Cancer Res Treatment 69:225, 

2001. 

233. Han S-S, Kim WS, Kim K, Lee MH, Jung CW, Park Q, Sung KW, Kimler BF, Riordan NH, 

Riordan HD, Park CH: L-ascorbic acid (LAA) and arsenic trioxide (As 2 0 3 ) synergistically 

repress constitutive activation of NF-6b and Cox-2 expression in human acute 

promyelocytic leukemia (HL-60) cells. Blood 98:159b, 2001. 

48


234. Park CH, Kim WS, Kim K, Lee MH, Jung CW, Han S-S, Park Q, Sung KW, Kimler BF, 

Riordan NH,Riordan HD: Clinical response achieved in AML by manipulation of L-ascorbic 

acid (LAA) levels. Blood 98:218b-219b, 2001. 

235. Fabian CF, Lukert B, Chamberlain C, Anderson J, Mayo MS, Kimler BF, Johnson KA: 

Effects of arzoxifene, a third generation SERM, on serum osteocalcin levels and bone 

mineral density in pre- and post-menopausal women at increased risk for breast cancer. 

Proc Am Assoc Cancer Res 43:822, 2002. 

236. Zalles, CM, Simonson M, Klemp J, Clark J, Kimler BF, Fabian CJ: Cytomorphology and 

epithelial cell yields in specimens obtained by random periareolar fine needle aspiration 

and ductal lavage of the breast in high risk women. Acta Cytologica 46:988-989, 2002. 

237. Park S, Kim K, Jung CW, Lee MH, Park K, Kim J, Lee J, Riordan NH, Riordan, Kimler BF, 

Park CH: Apoptotic signal transduction as a molecular mechanism for the clinical 

response achieved by L-ascorbic Acid (LAA) in acute myeloid leukemia (AML). Blood 

100:562a, 2002 (Abstract 2210). 

238. Fabian CJ, Clark J, Metheny T, Xue Q, Grizzle WE, Zalles CM, Kimler BF: Proportion of 

benign ductal epithelial cells expressing Ki-67/Mib-1 in random periareolar fine needle 

aspirates from women at high risk for breast cancer. Proc Am Assoc Cancer Res 44:427, 

2003. (Abstract 1878) 

239. Park S, Kim K, Jung CW, Lee MH, Park K, Lee J, Riordan NR, Riordan HD, Kimler BF, 

Park CH: Oxidative stress induced by high dose L-ascorbic acid (LAA) leading to apoptotic 

death of acute myeloid leukemia (AML) cells - a mechanism in support of clinical 

responses. Proc Am Assoc Cancer Res 44:607-608, 2003. (Abstract 2659) 

240. Tawfik OW, Donahue JK, Fan F, Davis M, Persons DL, Connor C, Jewell W, Kimler BF, 

Fabian CF: Comparison of immunohistochemistry (IHC) by automated cellular imaging 

system (ACIS) vs fluorescence in situ hybridization (FISH) in the evaluation of Her-2/neu 

expression in primary breast carcinoma. Proc Am Soc Clin Oncol 22:902, 2003 (abstract 

3626). 

241. Kim K, Park S, Jung CW, Lee MH, Park K, Lee J, Riordan NH, Riordan HD, Kimler BF, 

Park CH: Manipulation of L-ascorbic acid (LAA) to extremes in the treatment of acute 

myeloid leukemia (AML): Clinical responses supported by molecular mechanism. Proc 

Am Soc Clin Oncol 22:609, 2003 (abstract 2448). 

242. Park S, Kim K, Jung CW, Lee MH, Park K, Lee J, Riordan NH, Riordan HD, Kimler BF, 

Park CH: Induction of glutathione synthetic enzymes and glutathione S-transferase as a 

protective mechanism against L-ascorbic acid-induced oxidative stress in AML cells. Exp 

Hematol 31:146, 2003 (abstract 257). 

243. Kimler BF, Preston D, McMillin CH, Dusing R, Zalles CM, Fabian CJ: Evaluation of 

Sestamibi scanning as a predictor of risk of development of breast cancer and as a noninvasive 

biomarker for breast cancer chemoprevention trials. Program of 12th 

International Congress of Radiation Research, p 67, 2003 (abstract 170). 

244. Fabian CJ, Petroff BK, Kimler BF, Clark J, Metheny T, Stecker K, Salunga R, Erlander 

MG: Quantitative RT-PCR to assess change in molecular expression in methanol-formalin 

fixed cytology specimens obtained by random periareolar FNA from women on Phase II 

breast cancer chemoprevention trials. Cancer Epidemiology, Biomarkers & Prevention 

12:1301s, 2003 (abstract A194). 

245. Troch M, Ratliff B, Kimler B, Fabian C, Yee L, Seewaldt V: RAR$ P2 promotor methylation 

in breast random fine needle aspiration: a biologically relevant marker for breast cancer 

chemoprevention. Cancer Epidemiology, Biomarkers & Prevention 12:1334s, 2003 

(abstract C122). 

246. Tawfik O, Fan F, Davis M, Damjanov I, Thomas P, Kimler B: A new semi-automated 

method of grading breast carcinomas based on a multivariant analysis of 527 cases. Mod 

Path 17 (Suppl 1):51A, 2004. (Abstract 201). 

247. Troch MM, Bean G, Scott V, Ratliff B, Kimler BF, Fabian CJ, Zalles CM, Yee L, Seewaldt 

VL: Can RARbeta p2 promoter methylation in breast random periareolar fine-needle 

aspiration serve to risk stratify women at high risk for breast cancer? Proc Am Assoc 

49


Cancer Res 45:307(abstract 1342), 2004. 

248. Fabian CJ, Khan QJ, Clark J, Metheny T, Zalles CM, Kimler BF: Ki-67 expression in 

benign breast ductal cells from random periareolar fine needle aspiration (RPFNA): 

Association with age and atypical cytomorphology.. Proc Am Assoc Cancer Res 

45:307(abstract 1343), 2004. 

249. Kimler BF, Clark J, Metheny T, Zalles CM, Kennedy T, Fabian CJ: COX-2 expression in 

benign breast ductal cells obtained by random periareolar fine needle aspiration (RPFNA) 

of women at high risk for breast cancer. Proc Am Assoc Cancer Res 45:308(abstract 

1345), 2004. 

250. Ratliff BE, Bean G, Marcom PK, Scott JV, Yee L, Kimler BF, Fabian CJ, Zalles CM, Shaw 

H, Seewaldt VL: RARbeta P2 promoter methylation: potential biomarker for use with 

breast random periareolar fine-needle aspiration in breast cancer risk assessment. J Clin 

Oncol 22(Suppl 14S):abstract 1014, 2004. 

251. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS: Breast cancer 

chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third 

generation selective estrogen receptor modulator. J Clin Oncol 22(Suppl 14S):abstract 

1015, 2004. 

252. Petroff BK, Gum SL, Phillips TA, Clark JS, Kimler BF, Fabian CJ: Assessment of risk 

biomarker gene expression by real time reverse transcription-polymerase chain reaction 

using amplified ribonucleic acids from formalin-fixed fine needle aspirates of human breast 

tissue: A preliminary report. Cancer Epidemiol Biomarkers Prev 13:1921s, 2004 (abstract 

C61). 

253. Fabian CJ, Kimler BF, Simonsen S, Metheny T, Zalles CM, Hall M: Reduction in epithelial 

proliferation after six months of letrozole in high risk women on HRT with evidence of 

RPFNA atypia. Breast Cancer Res Treat 88(Suppl 1):S8 (abstract 5), 2004. 

254. Moore C, Bean G, Ratliff B, Kimler B, Faabian C, Zalles C, Seewaldt V: Can RARbeta PE 

promoter methylation in breast random periareolar fine needle aspiration serve to risk 

stratify women at high risk for breast cancer? Breast Cancer Res Treat 88(Suppl 1):S162 

(abstract 4040), 2004. 

255. Bean G, Scott V, Brooke-Ratliff B, Troch MM, Yee L, Seo P, Bowie ML, Marcom PK, Slade 

J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker JC Jr, Moore C, Seewaldt V: 

Methylation of the retinoic acid receptor-beta 2 P2 promoter is an early event in mammary 

carcinogenesis: observations in the laboratory predict risk in a high-risk breast cancer 

cohort. Proc Am Assoc Cancer Res 46:183 (abstract 776), 2005. 

256. Clark JL, Petroff BK, Metheny T, Xue Q, Kimler BF, Fabian CJ: Optimization of 

immunocytochemical assessment of estrogen receptor expression in benign breast 

epithelial cells obtained by random periareolar fine needle aspiration and processed using 

thin layer preparation technology. Proc Am Assoc Cancer Res 46:377 (abstract 1606), 

2005. 

257. Sharma P, Kimler BF, Clark JL, Metheny T, Zalles CM, Hall M, Fabian CJ: ER-a 

expression in benign breast ductal cells obtained from random periareolar fine needle 

aspiration correlates with menopausal status and abnormal cytomorphology. Proc Am 

Assoc Cancer Res 46:377-378 (abstract 1607), 2005. 

258. Petroff BK, Tawfik T, Gum S, Nynca A, Valdez K, Kimler BF, Fabian CJ: Development of 

a rat model of simultaneous mammary and ovarian cancer: expression of putative early 

markers of cancer risk and progression. Proc Am Assoc Cancer Res 46:1429 (abstract 

6075), 2005. 

259. Rider V, Li X, Peterson G, Dawson J, Kimler B, Abdou NI. Differential expression of 

estrogen receptors in females with systemic lupus erythematosus. Ptogram and Abstracts 

of ENDO 2005, The Endocrine Society’s 87th Annual Meeting, San Diego, CA; 4-7 Jun 

2005; p 144 (abstract OR46-5). 

260. Fabian CJ, Kimler BF, Anderson JR, Chamberlain CS, Mayo MS, Khan SA, Dooley WC, 

Krontiras H, Browne D: Comparison of random periareolar fine needle aspiration vs. ductal 

lavage for acquisition of breast tissue in meeting eligibility requirements for a phase II 

50


chemoprevention study. Fourth Annual AACR International Conference on Frontiers in 

Cancer Prevention Research; p 83 (abstract A56), 2005. 

261. Valdez KE, Kimler BF, Fabian CJ, Petroff BK: Optimization of proteomic assessment of 

breast random periareolar fine-needle aspiration specimens from high risk women using 

SELDI-TOF-MS. Fourth Annual AACR International Conference on Frontiers in Cancer 

Prevention Research; p 103-104 (abstract B16), 2005. 

262. Petroff BK, Metheny T, Xue Q, Valdez KE, Kimler BF, Fabian CJ: Repeatability and long 

term stability of Ki-67 immunostaining, cell numbers and cytologic morphology in random 

periareolar fine needle aspiration samples of breast tissue processed as thin layer 

preparations. Fourth Annual AACR International Conference on Frontiers in Cancer 

Prevention Research; p 135-136 (abstract C15), 2005. 

263. Seo PH, Bean GR, Baker JC, Scott JV, Rasheed K, Yee L, Troch MM, Case N, Bowie ML 

Marcom PK, Kimler BF, Zalles CM, Sloane R, Fabian CJ, Seewaldt V: Association of 

RAR$2, ER, BRCA, and p16 promoter methylation with cytologic atypia in random 

periareolar fine needle aspiration (RPFNA) breast tissue of asymptomatic women at high 

risk for breast cancer. Breast Cancer Treat Res (abstract 4022), 2005. 

264. Tawfik O, Davis MK, Clark J, Fan F, Damjanov I, Namiq A, Thomas P, Kimler BF: A newly 

proposed semi-automated method of grading ductal carcinoma in situ of the breast. Mod 

Pathol 19(Suppl 1):43A (abstract 187), 2006. 

265. Ting AY, Xue Q, Tawfik O, Kimler BF, Fabian CJ, Petroff BK: Cancer biomarker 

expression in a preclinical model for chemoprevention of simultaneous breast and ovarian 

cancer. Proc Amer Assoc Cancer Res 47:108 (abstract 697), 2006. 

266. Kimler BF, Fabian CJ, Metheny T, Xue Q, Mayo MS, Khan SA, Dooley WC, Krontiras H, 

Browne D: Comparison of cytomorphology and immunocytochemistry in breast epithelial 

cells obtained by random periareolar fine needle aspiration vs. ductal lavage. Proc Amer 

Assoc Cancer Res 47:141 (abstract 1425), 2006. 

267. Kimler BF, Ursin G, Fabian CJ, Anderson JR, Chamberlain C, Mayo MS, O'Shaughnessy 

JA, Lynch HT, Johnson KA, Browne D: Effect of the third generation selective estrogen 

receptor modulator arzoxifene on mammographic breast density. J Clin Oncol 24(Suppl 

18S):18s (abstract 562), 2006. 

268. Fabian CJ, Kimler BF, Anderson JR, Chamberlain C, Mayo MS, Zalles CM, 

O'Shaughnessy JA, Lynch HT, Johnson KA, Browne D: Phase II breast cancer 

chemoprevention trial of the third generation selective estrogen receptor modulator 

arzoxifene. J Clin Oncol 24(Suppl 18S):49s (abstract 1001), 2006. 

269. Khan QJ, Kimler BF, Smith EJ, O'Dea AP, Sharma P, Fabian CJ: Correlation of 

mammographic breast density with Ki-67 expression in benign breast epithelial cells 

obtained by random periareolar fine needle aspiration of high risk women. J Clin Oncol 

24(Suppl 18S):51s (abstract 1011), 2006. 

270. Sharma P, Kimler BF, Smith EJ, Fabian CJ: Correlation of statin use with breast Random 

Periareolar Fine Needle Aspiration (RPFNA) cytomorphology in high risk postmenopausal 

women. J Clin Oncol 24(Suppl 18S):56s (abstract 1031), 2006. 

271. Tawfik O, Davis M, Kimler BF, Hull S, Fan F, Thomas P, Khan QJ, Sharma P, Connor C, 

Jewell WR, Lai S-M, Fabian CJ: Histopathological and clinical characterization of "triplenegative" 

invasive mammary carcinomas. 5 th International Symposium on Hormonal 

Carcinogenesis; Montpellier, France; 10-13 Sep 2006. 

272. Kubichek GJ, Kimler B, Bell M, Wang F: Changes in breast cavity contours after 

lumpectomy. Int J Radiation Oncol Biol Phys 66:S222 (abstract 2023), 2006. 

273. Kimler BF, Fabian CJ, Metheny T, Xue Q, Cox S, Zalles CM: Cytomorphology and 

proliferation in breast epithelial cells obtained by random periareolar fine needle aspiration 

from obese postmenopausal women at high risk for development of breast cancer. 

Proceedings of the Fifth Annual AACR International Conference on Frontiers in Cancer 

Prevention Research; p 80 (abstract A16), 2006. 

274. Valdez KE, Kimler BF, Fabian CJ, Petroff BK: Proteomic assessment of breast random 

periareolar fine-needle aspiration specimens from high risk women using SELDI-TOF- 

51


MS.Proceedings of the Fifth Annual AACR International Conference on Frontiers in 

Cancer Prevention Research; p 82 (abstract A22), 2006. 

275. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Tamoxifen prevents mammary but not ovarian 

preneoplasia in a preclinical model of simultaneous breast and ovarian cancer 

progression. Proceedings of the Fifth Annual AACR International Conference on Frontiers 

in Cancer Prevention Research; p 93 (abstract A68), 2006. 

276. Bean GR, Baker JC, Tlsty T, Fabian C, Kimler BF, Seewaldt VL: p16 hypermethylation is 

observed as an early event in mammary carcinogenesis. Proceedings of the Fifth Annual 

AACR International Conference on Frontiers in Cancer Prevention Research; p 171 

(abstract B127), 2006. 

277. Chamberlain CS, Schmelze KH, Anderson JR, Khan SA, Dooley WC, Krontiras H, Browne 

D, Kimler BF, Fabian CJ: High risk women report minimal pain rating score with random 

periareolar fine needle aspirations compared to ductal lavage. Breast Cancer Res Treat 

100(Suppl 1):S54-S55 (abstract 1049), 2006. 

278. Kimler BF, Fabian CJ, Anderson JR, Tawfik OW, Mayo MS, O'Shaughnessy JA, Hyams 

DM, Albain KS, Sauter ER, Krontiras H, Budd GT: Breast cancer chemoprevention Phase 

IB evaluation of biomarker modulation by celecoxib, a selective cyclooxygenase 2 

inhibitor. Breast Cancer Res Treat 100(Suppl 1):S58 (abstract 1058), 2006. 

279. Underkoffler D, Bean G, Baker J, Scott V, Wilke L, Troch M, Dong M, Marcom P, Kimler B, 

Fabian C, Zalles C, Broadwater G, Seewaldt V: The frequency of loss of heterozygosity of 

RARb2 in random periareolar fine needle aspiration samples of women at high risk of 

developing breast cancer. Breast Cancer Res Treat 100(Suppl 1):S59-S60 (abstract 

1064), 2006. 

280. Klemp JR, Chamberlain CS, Anderson JR, Sharma P, Khan QJ, Kimler BF, Zalles C, 

Fabian CJ: BRCA1/2 mutation carriers are less likely to exhibit cytomorphologic evidence 

of atypia in benign breast cells obtained by RPFNA. Breast Cancer Res Treat 100(Suppl 

1):S178-S179 (abstract 4022), 2006. 

281. Klemp JR, Stanton AL, Kimler BF, Fabian CJ: Evaluating the effects of chemotherapy on 

cognitive function and quality of life in pre-menopausal women with breast cancer. Breast 

Cancer Res Treat 100(Suppl 1):S238 (abstract 5075), 2006. 

282. Wang X, Kimler BF, Davis MK, Fan F, Thomas P, Tawfik O: A newly proposed semiautomated 

method of grading invasive lobular carcinoma. A unifying concept and 

correlation with prognostic markers and patient survival. Annual Meeting of the United 

States and Canadian Academy of Pathology; San Diego, CA; 24-30 Mar 2007; Abstract 

222. 

283. Hamidpour S, Davis M, Kimler BF, Hull S, Fan F, Khan QJ, Sharma P, Connor C, Lai SM, 

Fabian CJ, Thomas P, Jewell WR, Tawfik O: Histopathological and clinical 

characterization of triple-negative invasive mammary carcinomas. Annual Meeting of the 

United States and Canadian Academy of Pathology; San Diego, CA; 24-30 Mar 2007; 

Abstract 135. 

284. Kimler BF, Fackler MJ, Metheny T, Phillips TA, Sukumar S, Fabian CJ: Consistency of 

quantitative multiplexed - methylation specific PCR (QM-MSP) performed on breast 

epithelial cells acquired by random periareolar fine needle aspiration (RPFNA) of women 

at high risk for development of breast cancer. In: American Association for Cancer 

Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia 

(PA): AACR; 2007. Abstract 1683. 

285. Khan QJ, O'Dea AP, Dusing R, Sharma P, Roling SM, Fabian CJ, Kimler BF: Integrated 

FDG-PET/CT for initial staging of breast cancer. J Clin Oncol 2007 Annual Meeting 

Proceedings Part I 25(Suppl 18S):17s (abstract 558), 2007. 

286. Sharma P, Klemp JR, Kimler BF, Khan QJ, Smith EJ, Fabian CJ: BRCA1 and BRCA2 

germline mutation carriers have a lower breast density compared to high risk women 

without such mutations. J Clin Oncol 2007 Annual Meeting Proceedings Part I 25(Suppl 

18S):65s (abstract 1517), 2007. 

287. Rider V, Li X., Kimler BF, Greenwell C, Abdou NI: Efficacy of faslodex in the treatment of 

52


systemic lupus erythematosus: molecular studies. Lupus 16:202A, 2007. 

288. Gojestani S, Rider V, Kimler BF, Greenwell C, Abdou NI: Estrogen reduces the 

phosphorylation of ERK in systemic lupus erythematosus T cells. Lupus 16:204S, 2007. 

289. Kubicek G, Kimler BF, Reddy EK, Cabrera C, Shnayder Y, Girod D, Dusing R, Tsue T, 

Wang F. PET scans for staging and follow-up for head and neck cancers treated with 

radiotherapy. Radiological Society of North American (RSNA) 2007, Abstract 6001178. 

290. Fabian CJ, Kimler BF, Mayo MS, Zalles CM, Khan SA, Dooley WC, Krontiras H, Browne 

D: Phase II tissue-based biomarker prevention trial of celecoxib in premenopausal women 

at high risk for development of breast cancer. Breast Cancer Res Treat (Suppl 1):, 2007 

(abstract 4040). 

291. Khan QJ, Reddy PS, Kimler BF, Baxa SE, Sharma P, Fabian CJ A prospective study to 

determine the prevalence of hypovitaminosis D in women with early stage breast cancer 

treated with an aromatase inhibitor and the benefit of vitamin D supplementation on 

musculoskeletal symptoms and overall QOL. Breast Cancer Res Treat (Suppl 1):, 2007 

(abstract 6075). 

292. Hamidpour S, Kimler BF, Davis M, Hull S, Fan F, Khan QJ, Thomas P, Tawfik O: A 

comparative histopathological and clinical study of “triple-negative” invasive mammary 

carcinomas in African American and Caucasian women. United States and Canadian 

Academy of Pathology 97th Annual Meeting; 1-7 March 2008; Denver, CO. (Abstract 153). 

293. Liu X, Kimler BF, Davis M, Fan F, Thomas P, Tawfik O: Is measurement of Ki-67 in axillary 

lymph node metastasis of breast cancer useful? United States and Canadian Academy of 

Pathology 97th Annual Meeting; 1-7 March 2008; Denver, CO. (Abstract 188). 

294. Fabian CJ, Kimler BF, Mayo MS, Zalles CM: Phase II biomarker prevention trial of 

celecoxib vs. placebo in women at high risk for development of breast cancer. In: 

Proceedings of the 99th Annual Meeting of the American Association for Cancer 

Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract 

4189. 

295. Kimler BF, Fabian CJ, Roweton J, Zalles CM, Manjeshwar S, Gramling BA, Defreese DC, 

Blaylock L, Jupe ER: Influence of single nucleotide polymorphisms on cytomorphology of 

benign beast epithelial cells acquired by random periareolar fine needle aspiration. In: 

Proceedings of the 99th Annual Meeting of the American Association for Cancer 

Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract 

1916. 

296. Valdez KE, Kimler BF, Fabian CJ, Petroff BK: Expression of putative stem cell marker 

genes in breast epithelial cells from normal and neoplastic breast tissue as measured by 

real-time PCR. In: Proceedings of the 99th Annual Meeting of the American Association 

for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. 

Abstract 2018. 

297. Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa S, O'Dea AP, Fabian CJ: Effect of high 

dose vitamin D on joint pain and fatigue from adjuvant letrozole. J Clin Oncol 26:531s, 

2008 (May 20 Suppl; abstr 9618). 

298. Kubicek GJ, Champ C, Wang F, Kimler BF, Girod D, Reddy E, Keane W, Intenzo C, 

Dusing RW, Machtay M: Role of FDG-PET for staging in head and neck cancer. Int J 

Radiat Oncol Biol Phys 72 (Suppl 1):S99 (abstract 220), 2008. 

299. Kubicek G, Champ C, Wang F, Kimler BF, Fogh S, Girod G, Reddy E, Keane WM, Intenzo 

C, Dusing RW, Machtay M. Value of FDG-PET for staging in head and neck cancer. 

ASTRO Translational Advances in Radiation Oncology and Cancer Imaging Symposium 

2008. 

300. Thatikonda S, Reddy EK, Kimler BF, Wang F: Evaluating the efficacy and toxicity of 

concurrent chemotherapy with accelerated fractionation by concomitant boost (AFX-CB) 

radiation therapy in locally advanced unresectable head and neck squamous cell 

carcinoma patients. Annual Meeting of the Radiological Society of North America; 

Chicago, IL; 1 December 2008; Abstract LL-RO4019-D10. 

301. Fabian CJ, Kimler BF, Phillips T, Zalles CM: Levels of 25-hydroxy-vitamin D in pre- 

53


menopausal women at high risk for development of breast cancer. Cancer Res 

69:(Suppl);(2): 5079, 2009. 

302. Tawfik O, Kimler BF, McGregor DH, Fan F: Variables impacting lymph node assessment 

in colorectal resection specimens removed for adenocarcinoma. Accepted for 

presentation at the United States and Canadian Academy of Pathology’s 98th Annual 

Meeting; Boston, MA; 7-13 March 2009. Abstract 673. 

303. Kimler BF, Metheny T, Hughes J, Roweton J, Zalles CM, Fabian CF: Validation of Ki-67 

as a response biomarker in prevention trials of women at high risk for development of 

breast cancer. Proc 100 th Annual Meeting of the American Association for Cancer 

Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009; pp 723-724 

(Abstract 2993). 

304. Fabian CF, Khan QJ, Sharma P, Baxa S, Metheny T, Zalles CM, Kimler BF: Evaluation of 

Ki-67 measured in benign breast tissue acquired from premenopausal women treated with 

a flaxseed derivative. J Clin Oncol 27:15s (suppl; abst 1507), 2009. 

305. O’Dea AP, Thirunavu M, Nydegger J, Kimler BF, Fabian CF: Low bone density in premenopausal 

women at high risk for breast cancer. J Clin Oncol 27:15s (suppl; abst 1532), 

2009. 

306. Khan QJ, Kimler BF, Sharma P, Reddy PS, Baxa S, Klemp JR, Fabian CJ: Vitamin D 

levels during and after high-dose vitamin D supplementation in women with early-stage 

breast cancer. J Clin Oncol 27(suppl; abst e20561), 2009. 

307. Wang F, Park J, Mitchell MP, Reddy EK, Al-Kassppoles M, Baranda J, Williamson SK, 

Kimler BF: Prognostic value of PET in patients with esophageal cancer. Translational 

Advances in Radiation Oncology and Cancer Imaging Symposium; St. Louis, MO; 11-12 

Sep 2009. 

308. Thatikonda S, Reddy E, Kimler BF, Krishnan L, Williamson SK, Girod DA, Tsue TT, Roy 

M, Wang F: Outcomes of concomitant boost accelerated radiation plus concurrent 

chemotherapy for advanced head and neck carcinomas. Int J Radiat Oncol Biol 75:S406 

(abst 2501), 2009. 

309. Foster EB, Wilson J, Badkul RK, Kimler BF, Reddy EK, Wang F: The influence of 

heterogeneity dose correction and beam energy on planned field margins for thoracic 

tumors. Int J Radiat Oncol Biol 75:S622-S623 (abst 2983), 2009. 

310. Wang F, Thatikonda S, Reddy EK, Williamson SK, Girod DA, Tsue TT, Kimler BF: 

Concurrent chemotherapy and accelerated fractionation with concomitant boost 

radiotherapy for locally advanced head and neck cancer: does disease site matter? 

ASTRO Multidisciplinary Head and Neck Cancer Symposium, 2010; page 63 (#Poster 40). 

311. Fabian CJ, Klemp JR, Kimler BF, Aversman S, Phillips TA, Zalles CM, Sullivan D, Bryan 

Smith B, Donnelly F, Yeh H-W. Effect of successful weight loss program on biomarkers 

for breast cancer in postmenopausal high risk women. J Clin Oncol 28:15s, 2010 (suppl; 

abstr 1522). 

312. Klemp JR, Aversman S, Befort C, Harvey K, Khan QJ, Sharma S, Kimler BF, Phillips T, 

Fabian CJ: Impact of obesity on the effectiveness of aromatase inhibitors (AIs): Can 

breast cancer survivors on AIs lose weight compared to non-AI users? Program and 

Proceedings of the Ninth Annual AACR International Conference on Frontiers in Cancer 

Prevention Research; Philadelphia, PA; 7-10 Nov, 2010. Page 103 (Abstract B4). 

313. Fabian CJ, Kimler BF, Phillips TA, Zalles CM, Klemp JR, Malone LM, Hursting SB: Weight 

loss in postmenopausal women is associated with modulation of serum and tissue based 

risk biomarkers. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium; San 

Antonio, TX; 8-12 Dec 2010. Cancer Res 70 (Suppl):127s (Abstract PD09-04). 

314. Sharma P, Kimler BF, Park YA, Stecklein SR, Petroff BK, Phillips T, Khan QJ, Tawfik OW, 

Jensen RA: Association of BRCA1 promoter methylation in triple-negative breast cancer 

(TNBC) with resistance to standard anthracyline-based adjuvant chemotherapy. J Clin 

Oncol 29: 2011 (suppl; abstr 1123). 

315. Harvey KE, Li S, Carlson SE, Sullivan DK, Klemp JR, Kimler BF, Fabian CJ: Long-chain 

polyunsaturated fatty acid intake and its relationship to long-chain polyunsaturated fatty 

54


acids in serum, red blood cells and breast tissue. Accepted for presentation at the San 

Antonio Breast Cancer Symposium; San Antonio, TX; Dec 2011. 

316. Ward J, Rider V, Abdou NI, Kimler BF: Estradiol differentially regulates Calreticulin: a 

potential link with abnormal calcium signaling in systemic lupus erythematosus T cells? 

Submitted for ASCB meeting, 2011. 

R. Posters or Exhibits 

1. Kimler BF, Leeper DB: The effect of Adriamycin and radiation on G 2 cell survival. 

Conference on Combined Modalities (Chemotherapy-Radiotherapy); Hilton Head Island, 

SC; 15-18 Nov 1978. 

2. Kimler BF: Effect of bleomycin and radiation on G 2 cell progression. Conference on 

Combined Modalities (Chemotherapy-Radiotherapy); Hilton Head Island, SC; 15-18 Nov 

1978. 

3. Kimler BF: Effect of razoxane and radiation on G 2 progression. Conference on Combined 

Modality Cancer Treatment: Radiation Sensitizers and Protectors; Key Biscayne, FL; 3-6 

Oct 1979. 

4. Kimler BF: Effect of razoxane and radiation on cell survival. Conference on Combined 

Modality Cancer Treatment: Radiation Sensitizers and Protectors; Key Biscayne, FL; 3-6 

Oct 1979. 

5. Kimler BF, McDonald T, Abrahams IL: Effect of hyperthermia on the hypoxic 

radiosensitization of mammalian cells by misonidazole. Conference on Combined Modality 

Cancer Treatment: Radiation Sensitizers and Protectors; Key Biscayne, FL; 3-6 Oct 1979. 

6. Kimler BF: Mechanism of action of razoxane-induced division delay. Annual Meeting of the 

Cell Kinetics Society; Lexington, KY; 26-29 Mar 1980. 

7. Kimler BF: Radiation-induced division delay in several cultured mammalian cell lines. 

Annual Meeting of the Cell Kinetics Society; Lexington, KY; 26-29 Mar 1980. 

8. Kimler BF: Interaction of hyperthermia and radiation on the induction of division delay in 

CHO cells. Third International Symposium: Cancer Therapy by Hyperthermia, Drugs, and 

Radiation; Fort Collins, CO; 22-26 Jun 1980. 

9. Kimler BF, Cheng CC, Barnes RE, Barnes ML: Effect of amino-substituted anthraquinones 

on cell cycle kinetics and survival. Annual Meeting of the Cell Kinetics Society; Asilomar, 

CA; 1-4 Mar 1981. 

10. Kimler BF, Henderson SD: Cyclic responses of cultured 9L cells to radiation. 29 th Annual 

Meeting of the Radiation Research Society; Minneapolis, MN; 31 May-4 Jun 1981. 

11. Kimler BF: Interaction of razoxane and radiation in cultured Chinese hamster cells. Annual 

Meeting of the American Society of Therapeutic Radiologists; Miami, FL; 11-16 Oct 1981. 

12. Kimler BF, Czapansky DK, Cheng CC: Correlation between chemical structure of aminosubstituted 

anthraquinones and in vitro biological activity. Annual Meeting of the Cell 

Kinetics Society; Houston, TX; 18-21 Mar 1982. 

13. Kimler BF: Interaction of radiation and amino-substituted anthraquinones on the survival of 

cultured Chinese hamster cells. 30 th Annual Meeting of the Radiation Research Society; 

Salt Lake City, UT; 18-21 Apr 1982. 

14. Kimler BF, Henderson SD, Mansfield CM, Svoboda DJ, Cheng CC: Interaction of 

Dihydroxyanthraquinone (DHAQ, NSC 279836) and radiation on the induction of toxicity in 

rats. 73 rd Annual Meeting of the American Association of Cancer Research; St. Louis, MO; 

28 Apr - 1 May 1982. 

15. Kimler BF, Park CH, Yakar D, Mies RM: Radiation response of human hematopoietic cells 

grown in agar culture. 31 st Annual Meeting of the Radiation Research Society; San 

Antonio, TX; 27 Feb-3 Mar 1983. 

16. Kimler BF: Mechanisms of the interaction between amino-substituted anthraquinones and 

ionizing radiation for the induction of mammalian cell lethality. 7 th International Congress of 

55


Radiation Research; Amsterdam, The Netherlands; 3-8 Jul 1983. 

17. Kimler BF, Park CH, Yakar D, Mies RM: Do human hematopoietic cells (normal and 

leukemic) demonstrate accumulation of and recovery from radiation-induced sublethal 

damage? 11th L.H. Gray Conference: Cellular Repair of Radiation Damage, Mechanisms 

and Modifying Agents; Glasgow, Scotland; 18-22 July 1983. 

18. Kimler BF: Enhancement of radiation-induced lethality by amino-substituted 

anthraquinones in cultured Chinese hamster cells. 11th L.H. Gray Conference: Cellular 

Repair of Radiation Damage, Mechanisms and Modifying Agents; Glasgow, Scotland; 18- 

22 July 1983. 

19. Kimler BF, Cheng CC: Modification of radiation and substituted anthraquinone-induced cell 

lethality by cysteamine and N-ethylmaleimide. Conference on Chemical Modifiers of 

Cancer Treatment; Banff, Canada; 27 Nov - 1 Dec 1983. 

20. Kimler BF, Cox GG, Reddy EK: Interaction of radiation, Dihydroxyanthraquinone, and 

Adriamycin on the induction of acute lethality in mice. Conference on Chemical Modifiers 

of Cancer Treatment; Banff, Canada; 27 Nov - 1 Dec 1983. 

21. Kimler BF, Mansfield CM, Svoboda DJ, Cox GG: Ultrastructural evidence of cardiac 

damage resulting from thoracic irradiation and chemotherapy agents in the rat. 

Conference on Chemical Modifiers of Cancer Treatment; Banff, Canada; 27 Nov - 1 Dec 

1983. 

22. Kimler BF: EFfect of sulfhydryls on potentiation of radiation-induced cell lethality by 

substituted anthraquinones. 32 nd Annual Meeting of the Radiation Research Society 

meeting; Orlando, FL; 26-29 Mar 1984. 

23. Kimler BF, Rethorst RD, Cox GG: Investigation of the interaction of radiation and 

cardiotoxic anticancer agents using a fetal mouse heart organ culture system. 33 rd Annual 

Meeting of the Radiation Research Society; Los Angeles, CA; 8 May 1985. 

24. Norton S, Kimler BF, Chapman AL, Terranova PF: Long-term consequences of low-level 

irradiation of rats in utero. 33 rd Annual Meeting of the Radiation Research Society; Los 

Angeles, CA; 8 May 1985. 

25. Giri SPG, Kimler BF, Giri UP, Cox GG, Reddy EK: The effects of single and fractionated 

irradiation of the trunk in rats. 33 rd Annual Meeting of the Radiation Research Society; Los 

Angeles, CA; 8 May 1985. 


against long-term pulmonary fibrosis in rats. 12th L.H. Gray Conference: Assays of 

Normal-tissue Injury and Their Cellular Interpretations; Manchester, U.K.; 2-5 Sep 1985. 



rats. 12th L.H. Gray Conference: Assays of Normal-tissue Injury and Their Cellular 

Interpretations; Manchester, U.K.; 2-5 Sep 1985. 

28. Kimler BF, Giri PGS, Giri UP, Cox GG, Vats TS: Functional damage induced in rats by 

thoracic irradiation and cancer chemotherapeutic agents. Conference on Chemical 

Modifiers of Cancer Treatment; Clearwater Beach, FL; 20-24 Oct 1985. 

29. Giri SPG, Kimler BF, Giri UP, Cox GG, Vats TS: Potentiation of radiation-induced 

pulmonary fibrosis in rats by cancer chemotherapeutic agents. Conference on Chemical 

Modifiers of Cancer Treatment; Clearwater Beach, FL; 20-24 Oct 1985. 

30. Kimler BF, Held KD: Modification of anthraquinone-induced mammalian cell lethality by 

agents that alter sulfhydryl levels. Conference on Chemical Modifiers of Cancer 

Treatment; Clearwater Beach, FL; 20-24 Oct 1985. 

31. Kimler BF, Held KD: Effect of modification of sulfhydryl levels on the interaction between 

radiation and substituted anthraquinones to produce mammalian cell lethality. Conference 

on Chemical Modifiers of Cancer Treatment; Clearwater Beach, FL; 20-24 Oct 1985. 

32. Wulser MJ, Kimler BF: Mitochondrial activity in cultured mammalian cells treated with 

various cytotoxic agents. Annual Meeting of the Cell Kinetics Society; Santa Fe, NM; 19- 

56


21 Mar 1986. 

33. Kimler BF, Giri PGS, Giri UP, Cox GG: Functional damage induced in rats by various 

schedules of trunk irradiation. 34 th Annual Meeting of the Radiation Research Society ; Las 

Vegas, NV; 13-17 Apr 1986. 

34. Wulser MJ, Kimler BF, Evans RG: Effect of various cytotoxic agents on mitochondrial 

activity in cultured mammalian cells. 34 th Annual Meeting of the Radiation Research 

Society; Las Vegas, NV; 13-17 Apr 1986. 

35. Kimler BF, Wulser MJ: Attempts to utilize a new DNA-specific fluorescent dye, LL585, for 

cell cycle analysis. Association de Cytometrie en Flux meeting; Gif-sur-Yvette, France; 

17-18 Nov 1986. 

36. O'Connor JE, Vargas JL, Kimler BF, Hernandez-Yago J, Grisolia S: Isolated mitochondria 

and flow cytometry. I. Study on the mechanism of Rhodamine-123 uptake by isolated 

mitochondria. Association de Cytometrie en Flux meeting; Gif-sur-Yvette, France; 17-18 

Nov 1986. 

37. O'Connor JE, Kimler BF, Vargas JL, Zaragoza R, Hernandez-Yago J, Grisolia S: Isolated 

mitochondria and flow cytometry. II. Effect of a long-term high-protein diet on rat liver 

mitochondria. Association de Cytometrie en Flux meeting; Gif-sur-Yvette, France; 17-18 

Nov 1986. 

38. O'Connor JE, Kimler BF, Vargas JL, Hernandez-Yago J, Grisolia S: Flow cytometric 

analysis of mammalian mitochondria using Rhodamine-123. Annual Meeting of the Cell 

Kinetics Society; Vancouver, Canada; 25-28 Mar 1987. 

39. Wulser MJ, Kimler BF: Problems with LL585, a new DNA-specific fluorescent dye, for 

mammalian cell analysis. Annual Meeting of the Cell Kinetics Society; Vancouver, 

Canada; 25-28 Mar 1987. 

40. Kimler BF, Park CH, Evans RG: The human bone marrow colony assay as a predictor of 

response. Conference on Prediction of Tumor Treatment Response; Banff, Canada; 21-24 

April 1987. 

41. Kimler BF, Norton S: Correlation of behavioral changes and structural defects in rats 

irradiated in utero. 8 th International Congress of Radiation Research; Edinburgh, Scotland; 

19-25 Jul 1987. 

42. Kimler BF, Wulser MJ, Cox GG: Effect of thiol manipulation on toxicity and therapeutic 

efficacy of combinations of substituted anthraquinones in the murine L1210 leukemia 

model. VIth International Meeting on Chemical Modifiers of Cancer Treatment; Paris, 

France; 21-25 Mar 1988. 

43. Kimler BF, Norton S, Cytacki EP, Rosenthal SJ: Comparison of the effects produced by in 

utero exposure to ionizing radiation versus ultrasound. 36 th Annual Meeting of the 

Radiation Research Society; Philadelphia, PA; 17-21 Apr 1988. 

44. Martin DF, Kimler BF, Evans RG, Morantz RA, Vats TS: Interaction of intracranial 

bleomycin and radiation therapy in the 9L rat brain tumor model. 36 th Annual Meeting of 

the Radiation Research Society; Philadelphia, PA; 17-21 Apr 1988. 

45. Kimler BF, Norton S, Cytacki EP, Rosenthal SJ: Are the effects of fetal rat ultrasound 

exposure on brain development due to heating? Annual Meeting of the North American 

Hyperthermia Group; Seattle, WA; 18-23 Mar 1989. 

46. Kimler BF, McMillan JH, Cox GG, Batnitzky S: Magnetic resonance imaging of rat brain 

tumors using a novel metalloporphyrin contrast agent. 37 th Annual Meeting of the 

Radiation Research Society; Seattle, WA; 18-23 Mar 1989. 

47. Evans RG, Kimler BF: Development of an animal tumor model for intra-operative radiation 

therapy. 37 th Annual Meeting of the Radiation Research Society meeting; Seattle, WA; 18- 

23 Mar 1989. 


neuroblastoma cells. Annual Meeting of the Cell Kinetics Society; Westchester, NY; 29 

Mar -2 Apr 1989. 

57


49. Kimler BF, Norton S, Chrzanowski A: Acute morphological effects of ionizing radiation in 

the developing fetal rat brain. 38 th Annual Meeting of the Radiation Research Society; New 

Orleans, NO; 7-12 Mar 1990. 

50. Kimler BF, Vidal-Pergola GM, Norton S: Recovery from sublethal radiation damage in the 

fetal cerebral cortex of rats: acute morphological effects. 9th International Congress of 

Radiation Research; Toronto, Canada; 7-12 Jul 1991. 

51. Kimler BF, Evans RG, Morantz RA, Batnitzky S: Lack of long-term complications 

subsequent to the use of Fluosol and oxygen as adjuvant to radiation therapy for highgrade 

malignant brain tumors. Ninth International Conference on Brain Tumor Research 

and Therapy; 15-18 Oct 1991; Asilomar, CA. 

52. Fabian CJ, Tranin A, Zeiger S, Zalles C, Kamel S, McKittrick R, Hassanein R, Kimler BF, 

Vergara G: Correlation of aneuploidy, atypical hyperplasia, and overexpressed ER and 

EGFR in random breast aspirates with breast cancer risk estimates based on personal 

and family history in a high risk population. 14th Annual San Antonio Breast Cancer 

Symposium; 6-7 Dec 1991; San Antonio, TX. 

53. Kimler BF, Liu C, Evans RG, Morantz RA: Intra-cranial chemotherapy plus radiation 

therapy in the 9L rat brain tumor model. 40 th Annual Meeting of the Radiation Research 

Society; Salt Lake City, UT; 14-19 Mar 1992. 

54. Li, X, Vidal-Pergola GM, Kimler BF: Cellular effects of radiation in the cerebral cortex of 

rats on gestational days 14-16. Joint Meeting of the Cell Kinetics Society and the 

International Cell Cycle Society; New Orleans, LA; 26-29 Mar 1992. 

55. Fabian CJ, McKittrick R, Zalles C, Kamel S, Tranin A, Zeiger S, Lin F, Kimler BF: Cell 

cycle kinetics in breast aspirates of women at high risk for breast cancer. Joint Meeting of 

the Cell Kinetics Society and the International Cell Cycle Society; New Orleans, LA; 26-29 

Mar 1992. 

56. Liu C, Kimler BF, Evans RG, Morantz: Intracerebral chemotherapy in the 9L rat brain 

tumor model. 83 rd Annual Meeting of the American Association for Cancer Research 

meeting; San Diego, CA; 20-23 May 1992. 

57. Liu C, Kimler BF, Evans RG, Morantz: Immune adjuvants plus chemotherapy or 

radiotherapy in the 9L rat brain tumor model. 83 rd Annual Meeting of the American 

Association for Cancer Research meeting; San Diego, CA; 20-23 May 1992. 

58. Park CH, Kimler BF, Estrov Z, Deisseroth AB, Williams DE, Gillis S: Enhancement by c-kit 

ligand of leukemic colony formation in acute myelogenous leukemia. 83 rd Annual Meeting 

of the American Association for Cancer Research meeting; San Diego, CA; 20-23 May 

1992. 

59. Kamel S, Zeiger S, McKittrick R, Tranin A, Zalles C, Kimler BF, Lin F, Fabian CJ: 

Overexpression of p53 protein in breast aspirates of women at high risk for breast cancer. 

83 rd Annual Meeting of the American Association for Cancer Research meeting; San 

Diego, CA; 20-23 May 1992. 


fractionation on rat postnatal development, behavior, and brain structure: 3 hour interval. 

Tenth International Neurotoxicology Conference; Little Rock, AR; 28 Sep-1 Oct, 1992. 

61. Smalley SR, Kimler BF, Dalziel WC, Mitchell DS, Evans RG: 5-Fluorouracil enhances 

radiation-induced killing of V-79 cells by a variety of mechanisms. Annual Meeting of the 

American Society for Therapeutic Radiology and Oncology; 9-13 Nov 1992; San Diego, 

CA. 

62. Sancho-Tello, M, Terranova PF, Justice WM, Kimler BF: Evaluación por citometría de flujo 

de la regulación de TNF" sobre el crecimiento de células de carcinoma ovárico humano. 

Meeting of Sociedad Iberica de Citometria; 19-21 Nov 1992; Valencia, Spain. 


fractionation on rat postnatal development, behavior, and brain structure: time course of 

recovery. 41 st Annual Meeting of the Radiation Research Society; Dallas, TX; 19-25 Mar 

58


1993. 

64. Kimler BF, Hurwitz A, Peterson SL, Li Y: Paradoxical reversal of therapeutic efficacy of 5- 

fluorouracil by morphine in rodent models of colon cancer in the liver. 84 th Annual Meeting 

of the American Association for Cancer Research; Orlando, FL; 19-22 May 1993. 

65. Kimler BF, Fabian CJ, McKittrick R: Flow cytometric verification of cell cycle recruitment 

by estradiol in women with locally advanced breast cancer. Third Annual Meeting of the 

Iberian Society of Cytometry; 15-18 Nov 1993; Porto, Portugal. 

67. Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SPG, Kimler BF: Retrospective 

ploidy analysis by image and flow cytometry in head and neck cancer. Third Annual 


68. Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SPG, Kimler BF: Comparative 

retrospective dna ploidy analysis by image and flow cytometry in head and neck cancer. 

Annual Meeting of the Cell Kinetics Society; Louisville, KY; 24-27 Mar 1994. 

69. Kimler BF: Analysis of radiation therapy - chemotherapy interactions in the 9L rat brain 

tumor model. 85 th Annual Meeting of the American Association for Cancer Research; San 

Francisco, CA; 10-13 Apr 1994. 

70. Kimler BF, Park CH: Correlation between plating efficiency and radiosensitivity of human 

normal hematopoietic but not leukemic progenitor cells grown in an agar clonogenic 

assay. 43 rd Annual Meeting of the Radiation Research Society; San Jose, CA; 1-6 Apr 

1995. 

71. Kimler BF, Cox GG, Wulser MJ, Peterson SL, Norton S: Dose fractionation of in utero 

irradiation: effect on rat postnatal development, behavior, and brain structure. Tenth 

International Congress of Radiation Research; Würzburg, Germany, 27 Aug - 1 Sep 1995. 

72. Kimler BF, Kamel S, McKittrick R, Zalles C, Zeiger S, Simon C, Fabian CJ: Potential 

biomarkers for prediction of breast cancer risk. The Lovelace Institutes Symposium on 

Mechanisms and Prevention of Environmentally Caused Cancers; Santa Fe, NM; 21-25 

Oct 1995. 

73. Kamel S, Kimler BF, Zeiger S, McKittrick R, Zalles C, Simon C, Fabian CJ: p53 protein 

overexpression predicts premalignant changes in the breast. The Lovelace Institutes 

Symposium on Mechanisms and Prevention of Environmentally Caused Cancers; Santa 

Fe, NM; 21-25 Oct 1995. 

74. Kimler BF, Wulser WJ: Production and removal of radiation-induced damaged cells in the 

fetal rat brain. 44 th Annual Meeting of the Radiation Research Society; Chicago, IL; 14-17 

Apr 1996. 

75. Kimler BF, Morantz RA, Kepes JJ, Evans RG: Long-term survival following radiation 

therapy plus Fluosol and oxygen for high-grade brain tumors. 45 th Annual Meeting of the 

Radiation Research Society, Providence, RI; 3-7 May 1997. 

76. Kimler BF: Radiation-induced cellular changes in the fetal rat brain. 11 th International 

Congress of Radiation Research; Dublin, Ireland; 18-23 July 1999. 

77. Fabian CF, Kimler BF, Brady D, Zalles CM, Zeiger S, Kitchen J, Engelken M: Feasibility of 

a Phase II chemoprevention trial using breast tissue obtained by random FNA. First 

International Conference on Tumor Prevention and genetics 2000. St. Gallen, 

Switzerland; 17-19 Feb 2000. 

78. Wang F, Krishnan L, Tawfik O, Ren YF, Kimler BF, Miller RD, Chapman JA, Weed JC: 

Prognostic significance of apoptosis in cancer of the cervix. 47 th Annual Meeting of the 

Radiation Research Society; 29 Apr - 3 May 2000; Albuquerque, NM. 

79. Fabian CJ, Kimler BF, Anderson J, Tawfik O, Mayo MS, O’Shaughnessy JA, Albain KS, 

Burak WE Jr, Idhe JK, Ganz PA, Budd GT, Lawrence JA: Phase I biomarker and toxicity 

evaluation of LY353381 (a 3 rd generation selective estrogen receptor modulator, SERM) in 

breast cancer. 36 th Annual Meeting of American Society of Clinical Oncology; New 

Orleans, LA; 20-23 May 2000. 

80. Fabian CJ, Kimler BF, Brady D, Zalles CM, Mayo MS, Masood S, Grizzle WE: Phase II 

chemoprevention trial of DFMO using the random FNA model. 23 rd Annual San Antonio 

59


Breast Cancer Symposium; San Antonio, TX; 6-9 Dec 2000. 

81. Ellis RJ, Kimler BF, Fabian CJ, Tawfik O, Mehta RS, Kyshtoobayeva A, Fruehauf JP: 

Angiogenesis index (AI) is associated with early recurrence in patients presenting with 

primary breast cancer. 23 rd Annual San Antonio Breast Cancer Symposium; San 

Antonio, TX; 6-9 Dec 2000. 

82. Fabian CJ, Kimler BF, Brady DA, Ferraro JA, Mayo MS, Arneson DW: No detectable 

improvement in clinical parameters or increased side effects in a placebo-controlled phase 

II breast chemoprevention trial of "-difluoromethylornithine (DFMO). 92 nd Annual Meeting 

of the American Association for Cancer Research; New Orleans, LA; 24-28 Mar 2001. 

83. Kim WA, Lee MH, Chung CW, Kim K, Han SS, Park Q, Sung KW, Kimler BF, Park CH: 

Clinical response in AML with manipulation of L-Ascorbic Acid (LAA) level in vivo to its 

extremes. International Society of Experimental Hematology; Tokyo, Japan; 24-30 Aug 

2001. 

84. Fabian CJ, Anderson J, Chamberlain C, Kimler BF, Mayo MS, O'Shaughnessy JA, Lynch 

HT, Johnson KA: Change in serum dehydroepiandrosterone, testosterone, insulin-like 

growth factor-1, and osteocalcin levels with the third generation selective estrogen 

receptor modulator arzoxifene (LY353381HCI). 24 th San Antonio Breast Cancer 

Symposium; San Antonio, TX; 10-13 Dec 2001. 

85. Fabian CF, Lukert B, Chamberlain C, Anderson J, Mayo MS, Kimler BF, Johnson KA: 

Effects of arzoxifene, a third generation SERM, on serum osteocalcin levels and bone 

mineral density in pre- and post-menopausal women at increased risk for breast cancer. 

93 rd Annual Meeting of the American Association for Cancer Research; San Francisco, 

CA; 6-10 Apr 2002. 

86. Zalles, CM, Simonson M, Klemp J, Clark J, Kimler BF, Fabian CJ: Cytomorphology and 

epithelial cell yields in specimens obtained by random periareolar fine needle aspiration 

and ductal lavage of the breast in high risk women. 50 th Annual Meeting of the American 

Society of Cytopathology; Salt Lake City, UT; 5-9 Nov 2002. 

87. Park S, Kim K, Jung CW, Lee MH, Park K, Kim J, Lee J, ,Riordan NH, Riordan, Kimler BF, 

Park CH: Apoptotic signal transduction as a molecular mechanism for the clinical 

response achieved by L-ascorbic Acid (LAA) in acute myeloid leukemia (AML). 44 th Annual 

Meeting of the American Society of Hematology; Philadelphia, PA; 8 Dec 2002. 

88. Fabian CJ, Clark J, Metheny T, Xue Q, Grizzle WE, Zalles CM, Kimler BF: Proportion of 

benign ductal epithelial cells expressing Ki-67/Mib-1 in random periareolar fine needle 

aspirates from women at high risk for breast cancer. Annual meeting of the American 

Association for Cancer Research; Washington, DC; 11-14 Jul 2003. 

89. Park S, Kim K, Jung CW, Lee MH, Park K, Lee J, Riordan NR, Riordan HD, Kimler BF, 

Park CH: Oxidative stress induced by high dose L-ascorbic acid (LAA) leading to apoptotic 

death of acute myeloid leukemia (AML) cells - a mechanism in support of clinical 

responses. Annual meeting of the American Association for Cancer Research; 

Washington, DC; 11-14 Jul 2003. 

90. Park S, Kim K, Jung CW, Lee MH, Park K, Lee J, Riordan NH, Riordan HD, Kimler BF, 

Park CH: Induction of glutathione synthetic enzymes and glutathione S-transferase as a 

protective mechanism against L-ascorbic acid-induced oxidative stress in AML cells. 32 nd 

Annual Meeting of the International Society for Experimental Hematology; Paris, France; 

5-8 Jul 2003. 

91. Fabian CJ, Petroff BK, Kimler BF, Clark J, Metheny T, Stecker K, Salunga R, Erlander 

MG: Quantitative RT-PCR to assess change in molecular expression in methanol-formalin 

fixed cytology specimens obtained by random periareolar FNA from women on Phase II 

breast cancer chemoprevention trials. Second Annual AACR International Conference: 

Frontiers in Cancer Prevention; Phoenix, AZ; 26-30 October 2003. 

92. Troch M, Ratliff B, Kimler B, Fabian C, Yee L, Seewaldt V: RAR$ P2 promotor methylation 

in breast random fine needle aspiration: a biologically relevant marker for breast cancer 

chemoprevention. Second Annual AACR International Conference: Frontiers in Cancer 

Prevention; Phoenix, AZ; 26-30 October 2003. 

60


93. Tawfik O, Fan F, Davis M, Damjanov I, Thomas P, Kimler B: A new semi-automated 

method of grading breast carcinomas based on a multivariant analysis of 527 cases. 

Annual meeting of United States and Canadian Academy of Pathology; Vancouver, BC; 6- 

12 Mar 2004. 

94. Kimler BF, Clark J, Metheny T, Zalles CM, Kennedy T, Fabian CJ: COX-2 expression in 

benign breast ductal cells obtained by random periareolar fine needle aspiration (RPFNA) 

of women at high risk for breast cancer. Annual Meeting of the American Association for 

Cancer Research; Orlando, FL; 27-31 March 2004. 

95. Fabian CJ, Khan QJ, Clark J, Metheny T, Zalles CM, Kimler BF: Ki-67 expression in 

benign breast ductal cells from random periareolar fine needle aspiration (RPFNA): 

Association with age and atypical cytomorphology.. Annual Meeting of the American 

Association for Cancer Research Annual Meeting; Orlando, FL; 27-31 March 2004. 

96. Troch MM, Bean G, Scott V, Ratliff B, Kimler BF, Fabian CJ, Zalles CM, Yee L, Seewaldt 

VL: Can RARbeta p2 promoter methylation in breast random periareolar fine-needle 

aspiration serve to risk stratify women at high risk for breast cancer? Annual Meeting of 

the American Association for Cancer Research Annual Meeting; Orlando, FL; 27-31 March 

2004. 

97. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS: Breast cancer 

chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third 

generation selective estrogen receptor modulator. Annual Meeting of the American 

Society of Clinical Oncology; New Orleans, LA; 5-8 June 2004. 

98. Ratliff BE, Bean G, Marcom PK, Scott JV, Yee L, Kimler BF, Fabian CJ, Zalles CM, Shaw 

H, Seewaldt VL: RARbeta P2 promoter methylation: potential biomarker for use with 

breast random periareolar fine-needle aspiration in breast cancer risk assessment. 

Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA; 5-8 June 

2004. 

99. Petroff BK, Gum SL, Phillips TA, Clark JS, Kimler BF, Fabian CJ: Assessment of risk 

biomarker gene expression by real time reverse transcription-polymerase chain reaction 

using amplified ribonucleic acids from formalin-fixed fine needle aspirates of human breast 

tissue: A preliminary report. American Association for Cancer Research Frontiers in 

Cancer Prevention Research; Seattle, WA; 16-20 October 2004. 

100. Moore C, Bean G, Ratliff B, Kimler B, Faabian C, Zalles C, Seewaldt V: Can RARbeta PE 

promoter methylation in breast random periareolar fine needle aspiration serve to risk 

stratify women at high risk for breast cancer? 27 th San Antonio Breast Cancer Symposium; 

San Antonio, TX; 8-11 Dec 2004. 

101. Bean G, Scott V, Brooke-Ratliff B, Troch MM, Yee L, Seo P, Bowie ML, Marcom PK, Slade 

J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker JC Jr, Moore C, Seewaldt V: 

Methylation of the retinoic acid receptor-beta 2 P2 promoter is an early event in mammary 

carcinogenesis: observations in the laboratory predict risk in a high-risk breast cancer 

cohort. American Association for Cancer Research Annual Meeting; Anaheim, CA; 16-20 

April 2005. 

102. Clark JL, Petroff BK, Metheny T, Xue Q, Kimler BF, Fabian CJ: Optimization of 

immunocytochemical assessment of estrogen receptor expression in benign breast 

epithelial cells obtained by random periareolar fine needle aspiration and processed using 

thin layer preparation technology. American Association for Cancer Research Annual 

Meeting; Anaheim, CA; 16-20 April 2005. 

103. Petroff BK, Tawfik T, Gum S, Nynca A, Valdez K, Kimler BF, Fabian CJ: Development of 

a rat model of simultaneous mammary and ovarian cancer: expression of putative early 

markers of cancer risk and progression. American Association for Cancer Research 

Annual Meeting; Anaheim, CA; 16-20 April 2005. 

104. Sharma P, Kimler BF, Clark JL, Metheny T, Zalles CM, Hall M, Fabian CJ: ER-a 

expression in benign breast ductal cells obtained from random periareolar fine needle 

aspiration correlates with menopausal status and abnormal cytomorphology. American 

Association for Cancer Research Annual Meeting; Anaheim, CA; 16-20 April 2005. 

61


105. Fabian CJ, Kimler BF, Anderson JR, Chamberlain CS, Mayo MS, Khan SA, Dooley WC, 

Krontiras H, Browne D: Comparison of random periareolar fine needle aspiration vs. ductal 

lavage for acquisition of breast tissue in meeting eligibility requirements for a phase II 

chemoprevention study. American Association for Cancer Research Frontiers in Cancer 

Prevention Research; Baltimore, MD; 31 Oct 2005. 

106. Valdez KE, Kimler BF, Fabian CJ, Petroff BK: Optimization of proteomic assessment of 

breast random periareolar fine-needle aspiration specimens from high risk women using 

SELDI-TOF-MS. American Association for Cancer Research Frontiers in Cancer 

Prevention Research; Baltimore, MD; 1 Nov 2005. 

107. Petroff BK, Metheny T, Xue Q, Valdez KE, Kimler BF, Fabian CJ: Repeatability and long 

term stability of Ki-67 immunostaining, cell numbers and cytologic morphology in random 

periareolar fine needle aspiration samples of breast tissue processed as thin layer 

preparations. American Association for Cancer Research Frontiers in Cancer Prevention 

Research; Baltimore, MD; 2 Nov 2005. 

108. Seo PH, Bean GR, Baker JC, Scott JV, Rasheed K, Yee L, Troch MM, Case N, Bowie ML 

Marcom PK, Kimler BF, Zalles CM, Sloane R, Fabian CJ, Seewaldt V: Association of 

RAR$2, ER, BRCA, and p16 promoter methylation with cytologic atypia in random 

periareolar fine needle aspiration (RPFNA) breast tissue of asymptomatic women at high 

risk for breast cancer. 28 th San Antonio Breast Cancer Symposium; San Antonio, TX; 8- 

11 Dec 2005. 

109. Kimler BF, Fabian CJ, Metheny T, Xue Q, Mayo MS, Khan SA, Dooley WC, Krontiras H, 

Browne D: Comparison of cytomorphology and immunocytochemistry in breast epithelial 

cells obtained by random periareolar fine needle aspiration vs. ductal lavage. Annual 

meeting of American Association for Cancer Research; Washington, D.C. 1-5 Apr 2006. 

110. Ting AY, Xue Q, Tawfik O, Kimler BF, Fabian CJ, Petroff BK: Cancer biomarker 

expression in a preclinical model for chemoprevention of simultaneous breast and ovarian 

cancer. Annual meeting of American Association for Cancer Research; Washington, D.C. 

1-5 Apr 2006. 

111. Kimler BF, Ursin G, Fabian CJ, Anderson JR, Chamberlain C, Mayo MS, O'Shaughnessy 

JA, Lynch HT, Johnson KA, Browne D: Effect of the third generation selective estrogen 

receptor modulator arzoxifene on mammographic breast density. Annual meeting of 

American Society of Clinical Oncology; Atlanta, GA; 2-6 Jun 2006. 

112. Khan QJ, Kimler BF, Smith EJ, O'Dea AP, Sharma P, Fabian CJ: Correlation of 

mammographic breast density with Ki-67 expression in benign breast epithelial cells 

obtained by random periareolar fine needle aspiration of high risk women. Annual meeting 

of American Society of Clinical Oncology; Atlanta, GA; 2-6 Jun 2006. 

113. Sharma P, KImler BF, Smith EJ, Fabian CJ: Correlation of statin use with breast Random 

Periareolar Fine Needle Aspiration (RPFNA) cytomorphology in high risk postmenopausal 

women. Annual meeting of American Society of Clinical Oncology; Atlanta, GA; 2-6 Jun 

2006. 

114. Kubichek GJ, Kimler B, Bell M, Wang F: Changes in breast cavity contours after 

lumpectomy. Annual meeting of the American Society of Therapeutic Radiology and 

Oncology; Philadelphia, PA; 5-9 Nov 2006. 

115. Kimler BF, Fabian CJ, Metheny T, Xue Q, Cox S, Zalles CM: Cytomorphology and 

proliferation in breast epithelial cells obtained by random periareolar fine needle aspiration 

from obese postmenopausal women at high risk for development of breast cancer. Fifth 

Annual AACR International Conference on Frontiers in Cancer Prevention Research; 

Boston, MA; 11-5 Nov 2006. 

116. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Tamoxifen prevents mammary but not ovarian 

preneoplasia in a preclinical model of simultaneous breast and ovarian cancer 

progression.Fifth Annual AACR International Conference on Frontiers in Cancer 

Prevention Research; Boston, MA; 11-5 Nov 2006. 

117. Valdez KE, Kimler BF, Fabian CJ, Petroff BK: Proteomic assessment of breast random 

periareolar fine-needle aspiration specimens from high risk women using SELDI-TOF-MS. 

62


Fifth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 

Boston, MA; 11-5 Nov 2006. 

118. Kimler BF, Fabian CJ, Anderson JR, Tawfik OW, Mayo MS, O'Shaughnessy JA, Hyams 

DM, Albain KS, Sauter ER, Krontiras H, Budd GT: Breast cancer chemoprevention Phase 

IB evaluation of biomarker modulation by celecoxib, a selective cyclooxygenase 2 

inhibitor. San Antonio Breast Cancer Symposium; 14 Dec 2006. 

119. Chamberlain CS, Schmelze KH, Anderson JR, Khan SA, Dooley WC, Krontiras H, Browne 

D, Kimler BF, Fabian CJ: High risk women report minimal pain rating score with random 

periareolar fine needle aspirations compared to ductal lavage San Antonio Breast Cancer 

Symposium; 14 Dec 2006. 

120. Klemp JR, Chamberlain CS, Anderson JR, Sharma P, Khan QJ, Kimler BF, Zalles C, 

Fabian CJ: BRCA1/2 mutation carriers are less likely to exhibit cytomorphologic evidence 

of atypia in benign breast cells obtained by RPFNA. San Antonio Breast Cancer 

Symposium; 15 Dec 2006. 

121. Klemp JR, Stanton AL, Kimler BF, Fabian CJ: Evaluating the effects of chemotherapy on 

cognitive function and quality of life in pre-menopausal women with breast cancer San 

Antonio Breast Cancer Symposium; 16 Dec 2006. 

122. Underkoffler D, Bean G, Baker J, Scott V, Wilke L, Troch M, Dong M, Marcom P, Kimler B, 

Fabian C, Zalles C, Broadwater G, Seewaldt V: The frequency of loss of heterozygosity of 

RARb2 in random periareolar fine needle aspiration samples of women at high risk of 

developing breast cancer. San Antonio Breast Cancer Symposium; 14 Dec 2006. 

123. Kimler BF, Fackler MJ, Metheny T, Phillips TA, Sukumar S, Fabian CJ: Consistency of 

quantitative multiplexed - methylation specific PCR (QM-MSP) performed on breast 

epithelial cells acquired by random periareolar fine needle aspiration (RPFNA) of women 

at high risk for development of breast cancer. Annual Meeting of the American 

Association for Cancer Research; Los Angeles, CA; 14-18- Apr 2007. 

124. Fabian CJ, Kimler BF, Mayo MS, Zalles CM, Khan SA, Dooley WC, Krontiras H, Browne 

D: Phase II tissue-based biomarker prevention trial of celecoxib in premenopausal women 

at high risk for development of breast cancer. San Antonio Breast Cancer Symposium; 15 

Dec 2007. 

125. Khan QJ, Reddy PS, Kimler BF, Baxa SE, Sharma P, Fabian CJ A prospective study to 

determine the prevalence of hypovitaminosis D in women with early stage breast cancer 

treated with an aromatase inhibitor and the benefit of vitamin D supplementation on 

musculoskeletal symptoms and overall QOL. San Antonio Breast Cancer Symposium; 16 

Dec 2007. 

126. Kimler BF, Fabian CJ, Roweton J, Zalles CM, harmila Manjeshwar S, Gramling BA, 

Defreese DC, Blaylock L, Jupe ER: Influence of single nucleotide polymorphisms on 

cytomorphology of benign beast epithelial cells acquired by random periareolar fine needle 

aspiration. Annual Meeting of the American Association for Cancer Research; 14 Apr 

2008. 

127. Valdez KE, Kimler BF, Fabian CJ, Petroff BK: Expression of putative stem cell marker 

genes in breast epithelial cells from normal and neoplastic breast tissue as measured by 

real-time PCR. Annual Meeting of the American Association for Cancer Research; 12-16 

Apr 2008. 

128. Kubicek GJ, Champ C, Wang F, Kimler BF, Girod D, Reddy E, Keane W, Intenzo C, 

Dusing RW, Machtay M: Role of FDG-PET for staging in head and neck cancer. Annual 

Meeting of the American Society for Therapeutic Radiology and Oncology; Boston, MA; 

Sept 2008. 

129. Kubicek G, Champ C, Wang F, Kimler BF, Fogh S, Girod G, Reddy E, Keane WM, Intenzo 

C, Dusing RW, Machtay M. Value of FDG-PET for staging in head and neck cancer. 

ASTRO Translational Advances in Radiation Oncology and Cancer Imaging Symposium; 

Arlington, VA; 17-18 Oct 2008. 

130. Fabian CJ, Kimler BF, Phillips T, Zalles CM: Levels of 25-hydroxy-vitamin D in premenopausal 

women at high risk for development of breast cancer. San Antonio Breast 

63


Cancer Symposium; San Antonio, TX; 11-14 Dec 2008. 

131. Kimler BF, Metheny T, Hughes J, Roweton J, Zalles CM, Fabian CF: Validation of Ki-67 

as a response biomarker in prevention trials of women at high risk for development of 

breast cancer. Annual Meeting of the American Association for Cancer Research; Denver, 

CO; Apr 18-22 2009. 

132. O’Dea AP, Thirunavu M, Nydegger J, Kimler BF, Fabian CF: Low bone density in premenopausal 

women at high risk for breast cancer. Annual Meeting of the American 

Society for Clinical Oncology; Orlando, FL; 29 May - 2 Jun 2009. 

133. Wang F, Park J, Mitchell MP, Reddy EK, Al-Kassppoles M, Baranda J, Williamson SK, 

Kimler BF: Prognostic value of PET in patients with esophageal cancer. Translational 

Advances in Radiation Oncology and Cancer Imaging Symposium; St. Louis, MO; 11-12 

Sep 2009. 

134. Thatikonda S, Reddy E, Kimler BF, Krishnan L, Williamson SK, Girod DA, Tsue TT, Roy 

M, Wang F: Outcomes of concomitant boost accelerated radiation plus concurrent 

chemotherapy for advanced head and neck carcinomas. Presented at ASTRO Annual 

Meeting; Chicago, IL, 1-6 Nov 2009. 

135. Foster EB, Wilson J, Badkul RK, Kimler BF, Reddy EK, Wang F: The influence of 

heterogeneity dose correction and beam energy on planned field margins for thoracic 

tumors. Presented at ASTRO Annual Meeting; Chicago, IL, 1-6 Nov 2009. 

136. Wang F, Thatikonda S, Reddy EK, Williamson SK, Girod DA, Tsue TT, Kimler BF: 

Concurrent chemotherapy and accelerated fractionation with concomitant boost 

radiotherapy for locally advanced head and neck cancer: does disease site matter? 

ASTRO Multidisciplinary Head and Neck Cancer Symposium, Chandler, AZ; 25-27 Feb 

2010; Poster #40. 

137. Fabian CJ, Klemp JR, Kimler BF, Aversman S, Phillips TA, Zalles CM, Sullivan D, Bryan 

Smith B, Donnelly F, Yeh H-W. Effect of successful weight loss program on biomarkers 

for breast cancer in postmenopausal high risk women. ASCO 2010 Annual Meeting; 

Chicago, IL; 4-8 Jun 2010 - Poster Discussion (abstract 1522). 

138. Klemp JR, Aversman S, Befort C, Harvey K, Khan QJ, Sharma S, Kimler BF, Phillips T, 

Fabian CJ: Impact of obesity on the effectiveness of aromatase inhibitors (AIs): Can 

breast cancer survivors on AIs lose weight compared to non-AI users? Submitted for 

presentation at the Ninth Annual AACR International Conference on Frontiers in Cancer 

Prevention Research; Philadelphia, PA; 7-10 Nov, 2010. 

139. Fabian CJ, Kimler BF, Phillips TA, Zalles CM, Klemp JR, Malone LM, Hursting SB: Weight 

loss in postmenopausal women is associated with modulation of serum and tissue based 

risk biomarkers. Poster discussion at the 33rd Annual CTRC-AACR San Antonio Breast 

Cancer Symposium; San Antonio, TX; 8-12 Dec 2010. 

140. Sharma P, Kimler BF, Park YA, Stecklein SR, Petroff BK, Phillips T, Khan QJ, Tawfik OW, 

Jensen RA: Association of BRCA1 promoter methylation in triple-negative breast cancer 

(TNBC) with resistance to standard anthracyline-based adjuvant chemotherapy. ASCO 

2011 Annual Meeting; Chicago, IL; 3-7 Jun 2011 - Poster (abstract 1123). 

141. Harvey KE, Li S, Carlson SE, Sullivan DK, Klemp JR, Kimler BF, Fabian CJ: Long-chain 

polyunsaturated fatty acid intake and its relationship to long-chain polyunsaturated fatty 

acids in serum, red blood cells and breast tissue. Accepted for presentation at the San 

Antonio Breast Cancer Symposium; San Antonio, TX; Dec 2011. 

64


S. Oral Presentations 

1) Scientific papers presented at national and international meetings: 

1. Kimler BF, Powers EL: Effect of inert gases on the radiation sensitivity of Bacillus 

megaterium spores. 20 th Annual Meeting of the Radiation Research Society; Portland, OR; 

1972. 

2. Kimler BF, Powers EL: Effect of water structure on the radiation sensitivity of Bacillus 

megaterium spores. 21 st Annual Meeting of the Radiation Research Society; St. Louis, 

MO; 1973. 

3. Kimler BF, Powers EL: Dosimetry considerations in the radiation biology of bacterial 

spores. Vth International Congress of Radiation Research; Seattle, WA; 1974. 

4. Kimler BF, Sinclair WK, Elkind MM: Sensitization of aerobic and hypoxic Chinese hamster 

cells to X-irradiation by N-ethylmaleimide. 23 rd Annual Meeting of the Radiation Research 

Society; Miami, FL; 1975. 

5. Kimler BF: The effect of Adriamycin on cell cycle progression. 77 th Annual Meeting of the 

American Association of Cancer Research; Toronto, Canada, 1976. 

6. Kimler BF, Schneiderman MH, Leeper DB: The effect of hydroxyurea on radiation-induced 

division delay. 24 th Annual Meeting of the Radiation Research Society; San Francisco, CA; 

1976. 

7. Kimler BF, Schneiderman MH: Screening of cancer chemotherapeutic agents with the 

mitotic selection procedure. 78 th Annual Meeting of the American Association of Cancer 

Research; Denver, CO; 1977. 

8. Kimler BF, Snyder MH, Leeper DB: The effect of caffeine on irradiated CHO cells. 25 th 

Annual Meeting of the Radiation Research Society; San Juan, Puerto Rico; 1977. 

9. Kimler BF, Snyder MH, Leeper DB: Modification of radiation-induced division delay by 

caffeine, dibutyryl c-AMP, and theophylline. 26 th Annual Meeting of the Radiation 

Research Society; Toronto, Canada; 1978. 

10. Kimler BF, Schneiderman MH, Leeper DB: Concentration-dependent blockade in the G 2 

phase by cancer chemotherapeutic agents. Annual Meeting of the Cell Kinetics Society; 

St. Louis, MO; 18 Mar 1978. 

11. Kimler BF, McDonald T, Cheng CC, Podrebarac EG, Mansfield CM: Development and 

testing of new hypoxic cell radoisensitizers. Annual Meeting of the Radiological Society of 

North America; Chicago, IL; 28 Nov-1 Dec 1978. 

12. Kimler BF, McDonald T: Interaction of hyperthermia, radiation, and misonidazole in 

hypoxic mammalian cells. Radiation Therapy Oncology Group (RTOG) Hyperthermia 

Workshop; Chicago, IL; 28 Nov 1978. 

13. Kimler BF, Metzger LJ, McDonald T: Division delay induced by hyperthermia and 

radiation. Radiation Therapy Oncology Group (RTOG) Hyperthermia Workshop; Chicago, 

IL; 28 Nov 1978. 

14. Kimler BF: Interaction of radiation and DHAQ: effect on G 2 progression. Annual Meeting 

of the Cell Kinetics Society; Miami FL; 16-18 Mar 1979. 

15. Kimler BF: Modification of radiation-induced division delay and cell lethality in mammalian 

cells by cancer chemotherapeutic agents. VIth International Congress of Radiation 

Research; Tokyo, Japan; 13-19 May 1979. 

16. Kimler BF, Cheng CC, Hacker MP, Henderson SD, Mansfield CM: 

Dihydroxyanthraquinone: a new cancer chemotherapeutic agent with radiation-potentiating 

properties. Annual Meeting of the Biophysical Society; New Orleans, LA; 1-4 Jun 1980. 

17. Kimler BF: Interaction of radiation and DHAQ: effect on cell survival. 28 th Annual Meeting 

of the Radiation Research Society; New Orlean, LA; 1-5 Jun 1980. 

18. Kimler BF, Henderson SD, Vats TS, Morantz RA: Optimization of therapy in a rat brain 

65


tumor (9L) system. Annual Meeting of the American Society of Therapeutic Radiologists; 

Dallas, TX; 21-25 Oct 1980. 

19. Kimler BF: Comparison of Dihydroxyanthraquinone and Adriamycin: interaction with 

radiation in cultured mammalian cells. Annual Meeting of the American Society of 

Therapeutic Radiologists; Dallas, TX; 21-25 Oct 1980. 

20. Kimler BF: The rat 9L system as a model for brain tumor research. Pediatric Oncology 

Group (POG) Brain Tumor meeting; Atlanta, GA; 29 Feb 1981. 

21. Kimler BF, Henderson SD, Vats TS, Morantz RA: Potentiation of radiation therapy by 

combination chemotherapy in the 9L rat brain tumor. Annual Meeting of the American 

Society of Therapeutic Radiologists; Miami, FL; 11-16 Oct 1981. 

22. Kimler BF: Flow cytometric analysis of cell cycle kinetics in hormone-stimulated breast 

cancer. Breast Committee Working Group, SouthWest Oncology Group meeting; New 

Orleans, LA; 1-3 Sep 1982. 

23. Kimler BF, Mansfield CM, Svoboda DJ, Henderson SD: Comparison of the effects of 

Dihydroxyanthraquinone (DHAQ, NSC 279836) and Adriamycin on the enhancement of 

radiation-induced toxicity in rats. Annual Meeting of the American Society of Therapeutic 

Radiologists; 24-30 Oct 1982; Orlando, FL. 

24. Kimler BF, Fabian C, Park CH: Stimulation of ER+ breast cancer cells prior to 

administration of cell-cycle-specific chemotherapy. Annual Meeting of the Cell Kinetics 

Society; Baltimore, MD; 16-19 Mar 1983. 

25. Kimler BF: Flow cytometry. Symposium on Cytokinetics-Directed Cancer Treatment 

Protocols, SouthWest Oncology Group meeting; Chicago, IL; 14 Sep 1983. 

26. Kimler BF: Modification of the interaction between radiation and dihydroxyanthraquinone 

to produce cytotoxicity in cultured Chinese hamster cells. 84 th Annual Meeting of the 

American Society of Therapeutic Radiologists meeting; Los Angeles, CA; 3-7 Oct 1983. 

27. Kimler BF: The fetal mouse heart organ culture system for pre-clinical in vitro investigation 

of interaction between cardiotoxic agents. Pre-Clinical Therapeutics Workshop, SouthWest 

Oncology Group meeting; Phoenix, AZ; 11-14 Sep 1984. 

28. Kimler BF, Jamieson TW, DeSmet AA, Lindsley HB: Total lymphoid irradiation for 

treatment of experimental collagen-induced arthritis in rats. Annual Meeting of the 

American Society of Therapeutic Radiology and Oncology meeting; Washington, DC; 8-12 

Oct 1984. 

29. Kimler BF, Giri PGS, Giri UP, Cox GG: Potentiation of radiation-induced normal lung 

tissue damage in rats by cancer chemotherapeutic agents. Annual Meeting of the 

American Society of Therapeutic Radiology and Oncology meeting; Washington, DC; 8-12 

Oct 1984. 

30. Kimler BF: Therapeutic efficacy of combinations of anthraquinones in the L1210 murine 

leukemia system. Pre-Clinical Therapeutics Workshop; SouthWest Oncology Group 

meeting; Houston, TX; 6 Mar 1985. 

31. Kimler BF: Intracranial therapy for brain tumors. Pre-Clinical Therapeutics Workshop; 

SouthWest Oncology Group meeting; Detroit, MI; 8 Sep 1985. 

32. Kimler BF, Dean, RD, Spicer J: Investigation of the feasibility of intracranial injection of Tc- 

99m-labelled albumin microspheres for localized treatment of brain tumors. Annual 

Meeting of the American Society for Therapeutic Radiology and Oncology; Miami, FL; 29 

Sep - 4 Oct 1985. 


radiation in the 9L rat brain tumor model. Conference on Interaction of Radiation Therapy 

and Chemotherapy; Williamsburg, VA; 28 Sep - 1 Oct, 1986. 

34. Kimler BF: Spirogermanium for brain tumor therapy: results from pre-clinical studies with 

the 9L rat brain tumor model. Pre-Clinical Therapeutics Workshop, Southwest Oncology 

Group meeting; San Antonio, TX; 2 Mar 1987. 

35. Kimler BF: Correlation between results of an in vitro clonogenic assay for hematopoietic 

66


progenitor cells and patient response. Pre-Clinical Therapeutics Workshop, Southwest 

Oncology Group meeting; Columbus, OH; 15 Sep 1987. 

36. Kimler BF, Norton S: Effects of in utero exposure to ionizing radiation on subsequent 

growth and development in the rat. Annual meeting of the American Society of 

Therapeutic Radiology and Oncology; Boston, MA; 18-23 Oct 1987. 

37. Kimler BF: Fluosol as an adjuvant for brain tumor therapy. Pre-Clinical Therapeutics 

Workshop, SouthWest Oncology Group meeting; New Orleans, LA; 13 Apr 1988. 

38. Kimler BF, Martin DF, Evans RG, Morantz RA, Vats TS: Combination of radiation therapy 

and intracranial bleomycin in the 9L rat brain tumor model. Annual Meeting of the 

American Society of Therapeutic Radiology and Oncology; New Orleans, LA; 9-14 Oct 

1988. 

39. Floreani AF, Kimler BF, Wesselius LJ: Effect of corticosteroid treatment on the 

development of pulmonary changes subsequent to thoracic irradiation in the rat. 92 nd 

Annual Meeting of the American Society of Therapeutic Radiology and Oncology; New 

Orleans, LA; 9-14 Oct 1988. 

40. Kimler BF: Interaction of intracranial bleomycin and radiation therapy in the 9L rat brain 

tumor model. Pre-Clinical Therapeutics Workshop, SouthWest Oncology Group meeting; 

Seattle, WA; 24 Oct 1988. 

41. Kimler BF: Phase I-II trial of Fluosol and radiation therapy for treatment of primary high 

grade brain tumors. Brain Tumor Committee, SouthWest Oncology Group meeting; 

Seattle, WA; 25 Oct 1988. 


neuroblastoma cells. Annual Meeting of the Cell Kinetics Society; Westchester, NY; 29 

Mar -2 Apr 1989. 

43. Kimler BF: A new magnetic resonance contrast agent for brain tumor imaging. Pre-Clinical 

Therapeutics Workshop and Brain Tumor Committee, SouthWest Oncology Group 

meeting; San Antonio, TX; 10-12 Apr 1989. 

44. Evans RG, Kimler BF, Morantz RA, Vats TS, O'Kell V, Lowe N: A Phase I-II study of the 


grade brain tumors. Annual Meeting of the American Society of Therapeutic Radiology and 

Oncology; San Francisco, CA; 1-6 Oct 1989. 

45. O'Connor JE, Matthes M, Costell M, Kimler BF: Effect of oral administration of carnitine on 

spermatogenesis in aging mice. Annual Meeting of the Cell Kinetics Society; St. Louis, 

MO; 28-31 Mar 1990. 

46. Kimler BF: Interaction of intra-operative radiation therapy and cis-platinum in an intraabdominal 

rat tumor model. Pre-Clinical Therapeutic Workshop, SouthWest Oncology 

Group Meeting; Denver, CO; 30 Apr-2 May 1990. 

47. Kimler BF: Fluosol as an adjuvant for radiation therapy of primary malignant brain tumors. 

Pre-Clinical Therapeutics Workshop, SouthWest Oncology Group meeting; Columbus, 

OH; 2 Oct 1990. 

48. Kimler BF, Evans RG, Smalley SR, Gemer LS, Peterson SL: A rat intra-abdominal tumor 

model for investigation of intra-operative radiation therapy. Annual Meeting of the 

American Society of Therapeutic Radiology and Oncology; Miami, FL; 15-19 Oct 1990. 

49. Kimler BF, Vidal-Pergola GM, Norton S: Effect of ionizing radiation on cell cycle kinetics in 

the fetal cerebral cortex of rats. Annual Meeting of the Cell Kinetics Society; Kiawah 

Island, SC; 21-24 Mar 1991. 

50. Kimler BF: Use of a bone marrow hematopoeitic progenitor cell assay for prediction of 

patient response to radiation therapy. Pre-Clinical Therapeutics Workshop, SouthWest 

Oncology Group meeting; Phoenix, AZ; 12 Apr 1991. 

51. Kimler BF, Dalziel WC, Mitchell DS, Smalley SR, Evans RG: Possible mechanisms for the 

enhancement of radiation-induced cell kill by 5-Fluorouracil in V79 cells. Joint Meeting of 

the Cell Kinetics Society and the International Cell Cycle Society; New Orleans, LA; 26-29 

67


Mar 1992. 

52. Kimler BF: Introduction and overview of cytometry. Workshop on DNA/Ploidy Analysis by 

Cytometry, SouthWest Oncology Group meeting; San Antonio, TX; 13 Apr 1992. 

53. Kimler BF, Fabian CJ, Kamel S, McKittrick R, Zalles C: Prediction of breast cancer risk 

based on cytologic characteristic of cells from random breast aspirates. Annual Meeting of 

the Cell Kinetics Society; Richland, WA; 17 Apr 1993. 

54. Kimler BF: Development and use of predictive assays. Pre-Clinical Therapeutics 

Workshop, SouthWest Oncology Group meeting; Denver, CO; 24 Apr 1993. 

55. Kimler BF: Potentiation of radiation therapy by chemotherapy in a rat brain tumor model. 

Pre-Clinical Therapeutics Workshop, SouthWest Oncology Group meeting; Chicago, IL; 9 

Oct 1993. 

56. Kimler BF: Use of tissue biomarkers for prediction of risk of developing breast cancer. 

Pre-Clinical Therapeutics Workshop, SouthWest Oncology Group meeting; Chicago, IL; 9 

Oct 1993. 

57. Kimler BF: Introduction to flow cytometry. Invited presentation at the Third Annual 


58. Kimler BF: Interplay between pyknotic cells and macrophages in the developing rat 

cerebral cortex as a consequence of in utero exposure to radiation. Annual Meeting of the 

Cell Kinetics Society; Louisville, KY; 24-27 Mar 1994. 

59. Kimler BF: Strategies for identification and individualized treatment of hypersensitive 

cancer patients. Pre-Clinical Therapeutics Workshop, SouthWest Oncology Group 

meeting; San Antonio, TX; 15 Oct 1994. 

60. Kimler BF, Sztern MI, Looney GA, Pinson DM, Bauer KD, Hurwitz A: Hypergastrinemia 

due to omeprazole does not alter cell kinetics of carcinogen-induced colon tumors in rats. 

Annual Meeting of the Cell Kinetics Society; Santa Fe, NM; 9-12 Mar 1995. 

61. Kimler BF: Biological basis of apoptosis: initiation, control, detection. Pre-Clinical 

Therapeutics Workshop, SouthWest Oncology Group meeting; New Orleans, LA; 27 Oct 

1995. 

62. Kimler BF: Apoptosis in radiation therapy. Pre-Clinical Therapeutics Workshop, 

SouthWest Oncology Group meeting; New Orleans, LA; 27 Oct 1995. 

63. Kimler BF, Kamel S, McKittrick R, Zalles C, Simon C, Fabian CJ: Prediction of 

development of breast cancer. Annual Meeting of the Cell Proliferation Society; Toledo, 

OH; 28-31 Mar 1996. 

64. Kimler BF: Cytologic characteristics for prediction of risk of developing breast cancer and 

use as surrogate endpoint biomarkers in chemoprevention trials. Pre-Clinical 

Therapeutics Workshop, SouthWest Oncology Group meeting; Chicago, IL; 19 Oct 1996. 

65. Kimler BF, Cox GG, Wulser MJ, Peterson SL, Norton S: Postnatal development and 

behavioral effects of prenatal irradiation. Keynote Speaker, Symposium on The 

Development of the Prenatal Brain and Its Extreme Radiosensitivity, 17th European Winter 

Conference on Brain Research; ARC 2000, France; 8-15 Mar 1997. 

66. Kimler BF: Prenatal irradiation: a major concern for the developing brain. Keynote Lecture 

at the Annual Meeting of the Association for Radiation Research and the 28 th Annual 

Meeting of the European Society for Radiation Research; Oxford, England; 24-26 Sep 

1997. 

67. Kimler BF, Fabian CJ, Zalles CM, Kamel S: Selection of surrogate biomarkers for breast 

cancer chemoprevention trials. Workshop on Cancer Chemoprevention in the Era of 

Genetic Diagnosis; Haifa, Israel; 22-24 June 1998. 

68. Kimler BF, Fabian CJ: Models for phase I/II breast cancer chemoprevention trials. 

Workshop on Cancer Chemoprevention in the Era of Genetic Diagnosis; Haifa, Israel; 22- 

24 June 1998. 

69. Kimler BF: Prevention of early stage breast cancer. European School of Oncology 

Course: Introduction to Cancer Chemoprevention; Haifa, Israel; 25-26 Jun 1998. 

68


70. Kimler BF, Zalles CM, Masood S, Kitchen J, Grizzle WE, Arneson DW, Mayo MS, Fabian 

CJ: Phase II chemoprevention trial of "-difluoromethylornithine (DFMO) in women at high 

risk for breast cancer: surrogate endpoint biomarkers. 92 nd Annual Meeting of the 

American Association for Cancer Research; New Orleans, LA; 28 Mar 2001. 

71. Kimler BF, Preston D, McMillin CH, Dusing R, Zalles CM, Fabian CJ: Evaluation of 

Sestamibi scanning as a predictor of risk of development of breast cancer and as a noninvasive 

biomarker for breast cancer chemoprevention trials. 12th International Congress 

of Radiation Research; Brisbane, Australia; 18 Aug 2003. 

72. Kimler BF: Ki-67: Does it work? Workshop on Stratified Cancer Prevention: Identifying 

Predictive Epithelial Markers for Breast Cancer Risk and Risk Reduction. National Cancer 

Institute, NIH, Bethesda, MD; 5 Sep 2007. 

73. Kimler BF: Breast tissue biomarkers for risk and response assessment. TREC Centers 

Scientific Meeting; Minneapolis, MN; 12 Oct 2007. 

2) Scientific papers presented at local and regional meetings: 

1. Kimler BF: DHAQ: a new antitumor agent and radiopotentiator. Mid-America Radiation 

Research Society meeting; Kansas City, KS; 15 Apr 1980. 

2. Kimler BF, Vats TS, Henderson SD, Morantz RA: Combination of bleomycin and radiation 

therapy for the treatment of brain tumors. Third Annual Pediatric Hematology/Oncology 

Symposium; Overland Park, KS; 7 Apr 1981. 

3. Kimler BF: Bleomycin for intracranial therapy of brain tumors - from the laboratory to the 

clinic. Fifth Annual Pediatric Hematology/Oncology Symposium; Mission, KS; 12 Apr 1983. 

4. Kimler BF, Hacker MP, Cox GG: Protection against dihydroxyanthraquinone-induced 

acute toxicity in mice by Adriamycin. Sixth Annual Pediatric Oncology-Hematology 

Symposium; Kansas City, MO; 12 Apr 1984. 

5. Kimler BF, Rethorst RD, Cox GG: Cardiotoxic effects of radiation and anthraquinones 

investigated in a fetal mouse heart organ culture system. Seventh Annual Pediatric 

Oncology/Hematology Symposium; Kansas City, MO; 11 April 1985. 

6. Kimler BF, Dean, RD, Spicer J: The use of intracranial injection of Tc-99m-labelled 

albumin microspheres for localized treatment of brain tumors. Spring meeting of the 

Missouri River Valley Chapter of the AAPM; Lake of the Ozarks, MO; 17 May 1986. 

7. Kimler BF: A new contrast agent for magnetic resonance imaging of brain tumors. 

Eleventh Annual Pediatric Hematology/Oncology Symposium; Kansas City, MO; 4 Apr 

1989. 

8. Storm S, Oh S, Kimler BF: Squalene as a radioprotector of mice. Annual meeting of the 

Midwest Regional Radiation Research Society; St. Louis, MO; 9-10 Nov 1990. 

3) Invited lectures, workshops, etc. at national postgraduate courses and meetings and at 

other universities. 

1. Interaction of therapeutic modalities on 9L rat brain tumor cells: in vitro and in vivo. Brain 

Tumor Research Center, Department of Neurological Surgery, University of California, 

San Francisco, CA; 6 Mar 1981. 

2. Development of DHAQ - a new cancer chemotherapeutic agent. Department of 

Pharmacology, University of Vermont College of Medicine, Burlington, VT; 1 May 1981. 

3. Development of new hypoxic cell radiosensitizers. Vermont Regional Cancer Center, 

Burlington, VT; 4 May 1981. 

4. DHAQ - a new cancer chemotherapeutic agent with radiation- potentiating properties. 

Department of Therapeutic Radiology, Mary Hitchcock Memorial Hospital, Dartmouth 

Medical School, Hanover, NH; 5 May 1981. 

5. Combination of intracerebral bleomycin and radiation therapy for the treatment of brain 

69


tumors; Department of Therapeutic Radiology, Henry Ford Hospital; Detroit, MI; 1 Feb 

1982. 

6. Laboratory and clinical investigations of lung damage; Department of Radiation Oncology, 

Wayne State University; Detroit, MI; 2 Feb 1982. 

7. Investigations of normal tissue damage induced by cancer therapeutic modalities. 

Department of Biomathematics, M.D. Anderson Hospital, Houston, TX; 17 Mar 1982. 

8. Development of Dihydroxyanthraquinone -- a new cancer chemotherapeutic agent. 

Section of Cancer Biology, Division of Radiation Oncology, Dept of Radiology, Washington 

University School of Medicine; St. Louis, MO; 4 Jun 1982. 

9. The 9L rat brain tumor system as a model for brain tumor research. Department of 

Therapeutic Radiology, Rush-Presbyterian Medical Center; Chicago, IL; 8 Jun 1982. 

10. Normal tissue damage following chemotherapy and thoracic irradiation. Department of 

Radiation Oncology, Medical College of Wisconsin; Milwaukee, WI; 23 Nov 1982. 

11. Methods to monitor therapy-related lung damage in rats and humans. Lung Cancer Study 

Group; Northwestern University Medical School, Chicago, IL; 29 Nov 1982. 

12. Brain tumor therapy research. Department of Radiation Therapy, Mayo Clinic; Rochester, 

MN; 28 Apr 1983. 

13. Quantification of normal tissue damage induced by thoracic irradiation and chemotherapy. 

Department of Radiation Therapy, Mayo Clinic; Rochester, MN; 29 Apr 1983. 

14. Flow cytometry and cell sorting - a new tool for biological investigations. Institute for 

Cytological Investigations; Valencia, Spain; 11 Jul 1983. 

15. Interactions between substituted anthraquinones and ionizing radiation in cultured 

mammalian cells. Imperial Cancer Research Fund Laboratory; London, England; 15 Jul 

1983. 

16. Possible mechanisms for the interaction of ionizing radiation and substituted 

anthraquinones. Department of Radiation Therapy, University of Texas Medical Branch at 

Galveston; Galveston, TX; 20 Sep 1983. 

17. Response of human hematopoietic cells to ionizing radiation - rationale for fractionated 

radiation therapy prior to bone marrow transplantation. Research Seminar Series, M.D. 

Anderson Hospital; Houston, TX; 22 Sep 1983. 

18. Observations on the combination of radiation and dihydroxyanthraquinone, a new 

anticancer agent. Division of Oncology, Department of Medicine, University of Texas 

Health Science Center at San Antonio; San Antonio, TX; 23 Sep 1983. 

19. Interactions of radiation and substituted anthraquinone in cultured mammalian cells. 

Donner Laboratory Seminar, Biology and Medicine Division, Lawrence Berkeley 

Laboratory; Berkeley, CA; 10 Oct 1983. 

20. Radiation-drug interactions for a new cancer chemotherapeutic agent, dihydroxyanthraquinone. 

Radiation Oncology Research Laboratory, Department of Radiation Oncology, 

University of California at San Francisco; San Francisco, CA; 11 Oct 1983. 

21. Normal tissue damage induced by radiation and cancer chemotherapeutic agents. 

Department of Radiation Therapy and Nuclear Medicine, Thomas Jefferson University 

Hospital; Philadelphia, PA; 18 Apr 1984. 

22. Thiols in radiation biology; effect of NEM and the age response. Armed Forces 

Radiobiology Research Institute; Bethesda, MD; 12 Oct 1984. 

23. Flow cytometry applications to radiation biology. Armed Forces Radiobiology Research 

Institute; Bethesda, MD; 12 Oct 1984. 

24. Application of flow cytometry for cytological research. Institute for Cytological 

Investigations; Valencia, Spain; 26 Oct 1984. 

25. Basics of radiation biology: Discussion of risks to the laboratory worker. Institute for 

Cytological Investigations; Valencia, Spain; 30 Oct 1984. 

26. The 9L rat brain tumor system as a model for brain tumor therapy research. Oncology 

Grand Rounds, St. Jude Children's Research Hospital, Memphis, TN; 25 Jan 1985. 

70


27. Efecto protector de las antraciclines contra una toxicidad inducida en el raton por 

antraquinones. Instituto de Investigaciones Citologicas; Valencia, Spain; 14 Feb 1986. 

28. Use of a rat brain tumor model for the development of new therapeutic approaches to the 

treatment of brain tumors. Instituto de Investigaciones Citologicas; Valencia, Spain; 27 Jun 

1986. 

29. Culture techniques for human tumor stem cells. Lecture for the XII Curso de Cultivos de 

Tejidos, Instituto de Investigaciones Citologicas; Valencia, Spain; 24 Jul 1986. 

30. Oncologic applications of flow cytometry. Commercial exhibit and symposium for 

Izasa/Coulter, Inc.; Madrid, Spain; 20 Nov 1986. 

31. Interactions of ionizing radiation and amino-substituted anthraquinones in cultured 

mammalian cells. Instituto de Investigaciones Citologicas; Valencia, Spain; 4 Jun 1987. 

32. Effects of exposure to physical agents in utero on rat growth and development. Instituto de 

Investigaciones Citologicas; Valencia, Spain; 11 Dec 1987. 

33. Combined modality therapy approaches to the treatment of brain tumors. University of 

Nebraska Medical Center, Omaha, NE; 8 Apr 1988. 

34. Interesting interactions of anthraquinones in the murine L1210 leukemia model. University 

of Nebraska Medical Center, Omaha, NE; 8 Apr 1988. 

35. Pre-clinical research in brain tumor therapy. Symposium on "Innovations in Pediatric Brain 

Tumor Therapy"; Kansas City, MO; 12 May 1989. 

36. Development of Fluosol as an adjunct for radiation therapy of brain tumors: Laboratory 

and clinical data. Instituto de Investigaciones Citologicas, Valencia, Spain; 25 Sep 1989. 

37. Cytometric analysis of metabolic alterations in mammalian cells. International Workshop 

on Flow and Image Cytometry; Porto, Portugal; 21 Feb 1991. 

38. Structural and functional brain damage subsequent to in utero exposure to ionizing 

radiation. Department of Anatomy, Tulane Medical School, New Orleans, LA; 5 Feb 1992. 

39. Cytometry for breast cancer: prediction, diagnosis, and treatment. Invited presentation at 

the Meeting of Sociedad Iberia de Citometria; 19 Nov 1992; Valencia, Spain. 

40. Cytometric evaluation of cellular drug resistance. Invited presentation at the Meeting of 

Sociedad Iberica de Citometria; 20 Nov 1992; Valencia, Spain. 

41. Advances in oncology research: From the laboratory to the clinic. Oncology Grand 

Rounds, Texas Tech University Health Sciences Center; Lubbock, TX; 8 Sep 1993. 

42. Introduction to uses of flow cytometry in biology and medicine. Department of Pathology, 

University of Magdeburg; Magdeburg, Germany; 24 Jan 1994. 

43. Structural and functional brain damage in rats subsequent to in utero exposure to ionizing 

radiation. Department of Radiation Oncology, University of Magdeburg; Magdeburg, 

Germany; 25 Jan 1994. 

44. Advances in oncology research: from the laboratory to the clinic. Department of Medicine, 

University of Magdeburg; Magdeburg, Germany; 27 Jan 1994. 

45. Introduction to applications of flow cytometry in biology and medicine. Midwest Research 

Institute, Kansas City, MO; 24 Feb 1994. 

46. Use of cytometric techniques for breast cancer prediction, diagnosis, and treatment. 

Department of Hematology/Oncology, University of California - Davis Cancer Center, 

Sacramento, CA; 14 Apr 1994. 

47. Advances in oncology research: from the laboratory to the clinic. Department of 

Hematology/Oncology, University of California - Davis Cancer Center, Sacramento, CA; 

15 Apr 1994. 

48. Radiation and chemotherapy sensitive patients: Genetics and cancer therapy. Lecture at 

Armed Forces Institute of Pathology Course on Radiation and Chemotherapy Injury, 

Vienna, VA; 21-23 May 1994. 

49. Ionizing radiation sensitive patients: genetics and cancer therapy. Lecture at Armed 

Forces Institute of Pathology Course on Radiation and Chemotherapy Injury: Etiology, 

Treatment, Diagnosis, and Genetics; Vienna, VA; 7-9 Sep 1996. 

71


50. Agent-specific biomarkers. Strategy Session on Breast Cancer Prevention Clinical Trials 

To Be Conducted by CCOP Research Bases. Division of Cancer Prevention and Control, 

National Cancer Institute; Rockville, MD; 16 Sep 1996. 

51. Production and removal of radiation-induced damaged cells in the fetal rat brain.. Instituto 

de Investigaciones Citologicas; Valencia, Spain; 17 Mar 1997. 

52. Development of chemopreventive agents against breast cancer. University of Missouri- 

Kansas City School of Pharmacy Sixth Annual Research Day. Invited Guest Speaker. 

Kansas City, MO; 16 Apr 1999. 

53. The treatment of genetically sensitive patients with radiation and chemotherapy. 

Department of Radiation Oncology, Samsung Medical Center, Seoul, Korea; 2 Mar 2001. 

54. Cancer chemoprevention: breast cancer as a model. Medical Grand Rounds, Samsung 

Medical Center, Seoul, Korea; 7 Mar 2001. 

55. Celecoxib as a potential breast cancer preventive agent. Workshop and Conference on 

COX-2 – Specific Inhibition in Cancer Treatment and Prevention; Palm Beach, FL; 29 Nov 

- 2 Dec 2001. 

56. Development of chemoprevention against breast cancer. Life Sciences Research 

Seminar, Kansas City VA Medical Center, Kansas City, MO; 18 Feb 2004. 

57. Prevention update. Post San Antonio Breast Oncology Symposium, Duke University 

Medical Center, Pinehurst, NC; 4 Mar 2005. 

58. Breast-tissue sampling for risk assessment and prevention. 2006 President's Day Breast 

Cancer Challenge; Ridgedale, MO; 19 February 2006. 

59. New Advocate Reviewer Training Program; Susan G. Komen Breast Cancer Foundation; 

Dallas, TX; 2-3 Oct 2006. 

60. Update on Komen Promise Grant: Flaxseed lignan as a prevention strategy for pre - 

menopausal women at high risk for development of breast cancer. Breast Cancer 

Challenge; Ridgedale, MO; 30 July 2011. 

4) Invited lectures at local and regional courses and meetings. 

1. Hypoxic cell radiosensitizers: radiation biology and pharmacology. Pharmacology 

Seminar, KUMC; 23 Sept 1980. 

2. Development and screening of new cancer chemotherapeutic agents. Sigma Xi Lecture, 

KUMC. 20 Nov 1980. 

3. Flow cytometry. Sigma Xi Lecture, KUMC; 29 Oct 1981. 

4. Methods to monitor therapy-related lung damage. Department of Anatomy, KUMC; 27 Jan 

1983. 

5. Ultrastructural evidence of damage resulting from thoracic irradiation and cancer 

chemotherapy agents in the rat. Central States Electron Microscopy Society meeting; 

Kansas City, KS; 27 May 1983. 

6. Investigations with human tumor cells. Heart of America Association of Cytotechnologists 

meeting; Kansas City, MO; 2 Jun 1984. 

7. Interaction of anthraquinones and anthracyclines in the mouse. Environmental Health 

Seminar, Department of Pharmacology, Toxicology, and Therapeutics, KUMC; 19 Feb 

1987. 

8. Flow cytometry as a preparative and analytical procedure to study sub-populations of cells 

and organelles. Special seminar sponsored by the International Center for Cell Biology, 

KUMC; 31 Mar 1987. 

9. Interactions of ionizing radiation and amino-substituted anthraquinones in cultured 

mammalian cells. Kansas Cancer Research Conference; KUMC; 9-10 Apr 1987. 

10. Biology of hyperthermia. Hyperthermia Symposium, KUMC Tumor Conference; 16 May 

1987. 

11. Experimental approaches to improve radiation therapy for the treatment of malignant brain 

72


tumors. Department of Pharmacology, Toxicology, and Therapeutics, KUMC; 6 Dec 1988. 

12. Taking Bleomycin from the laboratory to the clinic for treatment of brain tumors. Faculty 

Research Seminar for the Summer Research Training Program for Medical Students, 

KUMC; 7 Jun 1989. 

13. Fetal effects of prenatal radiation. Department of Radiation Oncology, KUMC; 17 Jan 

1990. 

14. Taking Fluosol from the laboratory to the clinic for treatment of brain tumors. Faculty 

Research Seminar for the Summer Research Training Program for Medical Students, 

KUMC; 9 Jul 1990. 

15. Radiation-induced carcinogenesis. Oncology Conference, Department of Radiation 

Oncology, KUMC; 29 Aug 1990. 

16. Risk factors in fetal brain development. Saturday Seminar Series, Science Pioneers; 

Kansas City, MO; 27 Oct 1990. 

17. Effects of ionizing radiation on the fetal rat brain. Faculty Research Seminar for the 

Summer Research Training Program for Medical Students, KUMC; 26 Jun 1991. 

18. Radiation carcinogenesis. Environmental and Occupational Health Center Seminar; 

KUMC; 10 Oct 1991. 

19. Flow cytometry for breast cancer. Radiation Oncology Core Curriculum Lecture Series; 

KUMC; 18 Jun 1992. 

20. Radiation zaps fetal rat brains. Faculty Research Seminar for the Summer Research 

Training Program for Medical Students, KUMC; 8 Jul 1992. 

21. Hyperthermia for treatment of breast cancer. Radiation Oncology Teaching Conference, 

KUMC; 17 Sep 1992. 

22. Structural and functional damage induced by irradiation of the developing rat brain. 

Physiology Department, KUMC; 5 Oct 1992. 

23. Preclinical investigations in brain tumor therapy. Radiation Oncology Teaching 

Conference, KUMC; 21 Oct 1992. 

24. Manipulation of cancer drug pharmacokinetics by morphine and other agents. KUMC 

Cancer Center Research Roundtable; 27 Apr 1993. 

25. Lectures delivered at a Course on Clinical Applications of Flow Cytometry; University of 

Valenica, Valencia, Spain; 28 Jun - 2 Jul 1993. 

26. Predictive assays for cancer therapy. Faculty Research Seminar for the Summer 

Research Training Program for Medical Students, KUMC; 28 Jul 1993. 

27. Effects of ionizing radiation on developing fetal rat brain. Faculty Research Seminar for 

the Summer Research Training Program for Medical Students, KUMC; 21 Jun 1995. 

28. Structural and functional brain damage subsequent to in utero exposure to ionizing 

radiation. Department of Physiology, KUMC; 8 Jan 1996. 

29. Applications of flow cytometry in biology and medicine. Research Roundtable Seminar, 

Kansas Cancer Institute, KUMC; 19 Nov 1996. 

30. Flow cytometry in breast cancer. Radiation Oncology Teaching Lecture, KUMC; 14 Dec 

1996. 

31. Radiation biology. Radiation Oncology Workshop for Radiation Inspectors; KUMC; 27 

Aug 1998. 

32. The treatment of genetically sensitive patients with radiation and chemotherapy. RT 

Career Education Conference, Kansas City, MO; 11 Sep 1999. 

33. Radiobiology. Plastic Surgery Grand Rounds, KUMC; 15 Jun 2000. 

34. Predictive assays for radiation therapy. RT Career Education Conference, Kansas City, 

MO; 9 Sep 2000. 

35. Random periareolar fine needle aspiration for prediction of breast cancer and development 

of chemopreventive agents. Heart of America Association of Cytotechnologists meeting; 

Kansas City, MO; 27 Sep 2003. 

36. Investigational new drug filing. Clinical Trials Educational Lecture Series, KUMC; 19 Feb 

73


2004. 

37. Cancer in the Omics Era. Science Pioneers Saturday Science Seminar; Kansas City, MO; 

20 Jan 2007. 

38. Writing Workshop: How to write a great review. School of Medicine, KUMC; 21 Mar 2007. 

39. The radiobiological bases for the radiation response of brain tumors. Meeting of the 

Missouri River Valley Chapter of the American Association of Physicists in Medicine; 

Kansas City, KS; 6 October 2007. 

74


T. Miscellaneous (films, educational tapes, syllabi, software packages, and courses 

developed) 

1. Syllabus on Radiation Biology, as part of the Nuclear Medicine Science Syllabus 

developed by The Society of Nuclear Medicine, 1982. 

2. International Workshop on Flow and Image Cytometry; Porto, Portugal; 18 Feb-1 Mar 

1991. 

3. Course on Clinical Applications of Flow Cytometry; University of Valencia, Valencia, Spain; 

28 Jun - 2 Jul 1993. 


24 - 28 Oct 1994. 


18 - 22 Dec 1995. 

6. Course on Cytometric Analysis of Cell Proliferation and Apoptosis; University of Valencia, 

Valencia, Spain; 22 - 26 Jul 1996. 

7. Course on Use of Flow Cytometry for Studies of Cell Metabolism; University of Valencia, 

Valencia, Spain; 3 - 7 Nov 1997. 

75

Curriculum Vitae - University of Kansas Medical Center

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?